text
stringlengths 102
112k
| url
stringlengths 37
240
| crawl_date
timestamp[us, tz=UTC]date 2024-01-04 00:15:18
2024-01-31 23:10:45
| exclusion_reason
stringclasses 1
value |
|---|---|---|---|
The rise in service activities, along with increased digital marketing services and the success of the work-from-home trend, is enabling the Zacks Advertising and Marketing industry to counter the prevailing revenue softness.
Customer-centric approaches to business, digital strategies and technology investments are helping Publicis Groupe S.A. (PUBGY - Free Report) , Omnicom Group Inc. (OMC - Free Report) and WPP plc (WPP - Free Report) to sail through the current testing times.
About the Industry
The Zacks Advertising and Marketing industry comprises companies that offer an extensive range of services, including advertising, branding, content marketing, digital/direct marketing, digital transformation, financial/corporate business-to-business advertising, graphic arts/digital imaging, healthcare marketing and communications and in-store design services. Prominent players from the industry include Interpublic and Omnicom. The pandemic has changed the way industry players have conducted business and delivered services so far. Currently, the industry’s key focus is on channelizing money and efforts toward media formats and devices. To position themselves suitably in the post-pandemic era, service providers are increasing their efforts toward formulating strategic initiatives and identifying sources of demand.
What's Shaping the Future of the Industry?
Economic Recovery: The sector is a major beneficiary of the broader economy and service activities. According to the Bureau of Economic Analysis, GDP grew at an annual rate of 2.5% in 2023 compared with 1.9% growth in 2022. Economic activities in the non-manufacturing sector are in good shape. The Services PMI measured by the Institute for Supply Management has stayed above the 50% mark for the past 12 months, indicating continued expansion.
Reviving Demand: The industry is mature, with demand for services remaining stable over time. Revenues, income and cash flows are anticipated to gradually reach pre-pandemic levels, aiding most industry players in paying out stable dividends.
Digital Marketing Gathering Steam: Digital media consumption has shot up, with consumers spending more time on various media platforms and video-streaming services. Thus, agencies offering digital marketing services stand to gain, as these firms are better positioned to address the rapid change in customer preference.
Zacks Industry Rank Indicates Bright Near-Term Prospects
The Zacks Advertising and Marketing industry, housed within the broader Zacks Business Services sector, currently carries a Zacks Industry Rank #53. This rank places it in the top 21% of more than 250 Zacks industries.
The group’s Zacks Industry Rank, which is the average of the Zacks Rank of all the member stocks, indicates solid near-term growth prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one.
Before we present a few stocks that you may want to consider for your portfolio, let’s take a look at the industry’s recent stock market performance and current valuation:
Industry's Price Performance
Over the past year, the Zacks Advertising and Marketing industry has fallen while the S&P 500 composite and the broader sector witnessed growth. The industry has declined 5.9% against the S&P 500 composite’s growth of 22.9%. The broader sector has gained 15% in the said time frame.
One-Year Price Performance
Industry's Current Valuation
On the basis of the forward 12-month price-to-earnings (P/E) ratio, which is commonly used for valuing advertising and marketing stocks, the industry is currently trading at 10.57X compared with the S&P 500’s 20.47X and the sector’s 20.05X.
Over the past five years, the industry has traded as high as 16.98X and as low as 7.74X, with the median being 11.24X, as the charts below show.
Price to Forward 12 Months P/E Ratio
3 Advertising Stocks to Consider
Here, we have presented three stocks that are well-positioned for near-term growth:
Omnicom: The company is a provider of advertising, marketing and corporate communications services. Consistency and diversity of operations and focus on delivering consumer-centric strategic business solutions ensure the long-term profitability for Omnicom. It has divested underperforming and non-core businesses and reorganized them to meet clients’ ever-transforming needs.
The Zacks Consensus Estimate for the company’s 2024 EPS has been revised 0.8% over the past 60 days. It currently carries a Zacks Rank #2 (Buy). Shares of Omnicom have gained 22% in the past three months.
Price and Consensus: OMC
Publicis: The company is a provider of marketing, communications and digital business transformation services. It is witnessing strength across regions, especially in the United States and Europe, driven by strong momentum in account wins.
The Zacks Consensus Estimate for the company’s 2023 EPS increased 2% over the past 60 days. Shares of Publicis have gained 30.4% in the past three months. The company currently carries a Zacks Rank #2.
Price and Consensus: PUBGY
WPP plc: This provider of communications, experience, commerce and technology services has gained 15.3% in the past three months. WPP continues to win creative and media assignments from leading global organizations. Its net new business performance remains in good shape.
The Zacks Consensus Estimate for the company’s 2024 EPS has increased 2% over the past 60 days. The company currently carries a Zacks Rank #2.
Price and Consensus: WPP
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Omnicom Group Inc. (OMC) - free report >>
|
https://www.zacks.com/commentary/2217176/3-advertising-marketing-stocks-to-watch-from-a-booming-industry?-marketing-stocks-to-watch-from-a-booming-industry
| 2024-01-30T02:38:43Z
|
blocked_url
|
Several stocks from a variety of sectors are standing out after beating earnings expectations last Friday. Following their favorable quarterly results now appears to be a good time to buy as earnings estimate revisions are likely to trend higher in the following weeks.
This could very well lead to a nice amount of upside in these stocks and here are three to consider right now.
Booz Allen Hamilton (BAH - Free Report)
We’ll start with Booz Allen Hamilton as the management and technology solutions provider was added to the Zacks Rank #1 (Strong Buy) list after posting strong results for its fiscal third quarter last Friday.
Providing cyber expertise, analytics, engineering, and digital solutions to the United States and international governments it's noteworthy that Booz Allen’s Zacks Government Services Industry is in the top 1% of over 250 Zacks industries. Correlating with such Q3 earnings of $1.41 per share surpassed the Zacks Consensus of $1.13 a share by 25% and soared 32% from $1.07 a share in the prior-year quarter.
Image Source: Zacks Investment Research
Booz Allen was also able to beat top line estimates by 1.54% with Q3 sales at $2.56 billion. Third quarter sales rose 13% year over year and Booz Allen raised its full-year 2024 outlook. The company now sees revenue growth at 14-15% this year compared to previous forecast of 11-14%. Booz Allen now forecasts adjusted earnings at $5.25-$5.40 per share versus previous guidance of $4.95-$5.10 a share.
In addition to this Booz Allen raised its quarterly dividend by 8% to $0.51 a share and has now boosted its yield seven times in the last five years. Notably, Booz Allen’s total return over the last year is a very stellar +56% when including dividends and BAH shares hit 52-week highs of $147.52 last Friday.
Image Source: Zacks Investment Research
ColgatePalmolive (CL - Free Report)
Consumer staples giant Colgate-Palmolive looks attractive following its Q4 results and currently sports a Zacks Rank #2 (Buy). The home care consumer products company and oral hygiene titan posted Q4 earnings of $0.87 a share which beat expectations by 2%. Fourth quarter earnings jumped 13% YoY with sales of $4.95 billion beating estimates by 1% and rising 7% from $4.62 billion in the comparative quarter.
Furthermore, Colgate has now surpassed earnings expectations in each of its last four quarterly reports with its Latin America and Europe region sales propelling the company of late. Latin America and Europe net sales were up 18% and 10% respectively during Q4. Colgate’s stock is up a respectable +15% over the last year after hitting 52-week highs of $84 a share today. Plus, Colgate’s 2.32% annual dividend yield should keep investors locked in as macroeconomic conditions have improved significantly.
Image Source: Zacks Investment Research
Gentex (GNTX - Free Report)
Lastly, Gentex sports a Zacks Rank #2 (Buy) with the automotive original equipment manufacturer posting very reassuring Q4 results. As a provider of automatic-dimming rear-view mirrors and electronics, Gentex’s Q4 earnings of $0.50 a share topped the Zacks Consensus by 13% with sales of $589.13 million coming in 5% better than expected.
Year over year Q4 EPS climbed 37% from $0.37 a share in the comparitive quarter with quartelry sales expanding 19%. Gentex has exceeded earnings expectations in each of its last four quarterly reports posting an impressive average earnings surprise of 12.2%. Quieting fears of a potential negative impact from the UAW strikes, Gentex stock is now up +18% in the last year and is hovering near its 52-week highs of $34.33 a share seen last August. Gentex also offers a modest 1.42% annual dividend yield.
Image Source: Zacks Investment Research
Bottom Line
Booz Allen Hamilton, Colgate-Palmolive, and Gentex have started to reconfirm their growth expectations with many analysts raising their price targets for these stocks after stong quarterly results making now an ideal time to buy.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Colgate-Palmolive Company (CL) - free report >>
Booz Allen Hamilton Holding Corporation (BAH) - free report >>
|
https://www.zacks.com/commentary/2217425/3-standout-stocks-to-buy-after-earnings
| 2024-01-30T02:38:50Z
|
blocked_url
|
It’s a highly critical week for earnings, with several mega-cap technology companies slated to reveal quarterly results. The strength of these mega-cap names has been admired by all, with many expecting positive results to keep overall market momentum flowing.
Perhaps the most popular of the bunch, market leader Apple (AAPL - Free Report) will reveal quarterly results on February 1st after the market’s close. The company has been on a solid earnings streak as of late, exceeding our consensus earnings and revenue expectations in three consecutive quarters.
Shares got a nice boost following its latest set of results, sparking a strong rally.
Image Source: Zacks Investment Research
How do expectations stack up heading into the release? Let’s take a quick look at headline estimates and a few key other metrics to keep an eye on within the release.
Headline Figures
Analysts have been bullish regarding the bottom line, with the $2.09 Zacks Consensus EPS Estimate up a modest 1.5% since November and suggesting growth of roughly 11% year-over-year.
Image Source: Zacks Investment Research
Revenue expectations have been revised modestly lower, as the $117 billion quarterly sales estimate has been taken 1.4% lower over the same period.
Image Source: Zacks Investment Research
Key Metrics
Apple’s services portfolio has also been a great source of growth over the last several years. It includes Apple Music, Apple TV+, Apple Arcade, Apple Pay, and more.
For the quarter, we expect the company to post $23.3 billion in revenue from Services, nicely above the year-ago mark of $20.7 billion, reflecting 12.5% growth. Apple has consistently positively surprised on this metric as of late, as we can see below.
Image Source: Zacks Investment Research
As expected, iPhone revenue will also be a big focus, particularly as the company continues to face competition in other markets. For the quarter, we expect Apple to post $68.6 billion in iPhone revenue, suggesting an increase of roughly 4% year-over-year.
iPhone results have been primarily mixed as of late, with the company falling short of consensus expectations in back-to-back releases.
Image Source: Zacks Investment Research
Valuation
Shares are trading at a premium relative to historical levels, with the current 28.4X forward 12-month earnings multiple sitting above the 25.2X five-year median. The forward 12-month price-to-sales ratio sits at 7.4X, near five-year highs and above the 6.0X five-year median.
Still, investors have had little issue forking up the premium given the company’s dominant stance, as reflected by the share performance.
Image Source: Zacks Investment Research
Bottom Line
We’ve got a loaded slate of earnings this week, with beloved Apple (AAPL - Free Report) a part of the reporting docket. Earnings estimates have been taken higher whereas revenue expectations have fallen modestly, with both items expected to be higher than the year-ago period.
Investors will closely watch the company’s Services results as well as iPhone sales, two key growth drivers for Apple. Heading into the release, the stock is presently a Zacks Rank #3 (Hold).
|
https://www.zacks.com/commentary/2217427/apple-q1-earnings-key-metrics-to-watch
| 2024-01-30T02:38:56Z
|
blocked_url
|
For investors seeking momentum, Alerian MLP ETF (AMLP - Free Report) is probably on radar. The fund just hit a 52-week high and is up 25.4% from its 52-week low price of $35.68/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed:
AMLP in Focus
The underlying Alerian MLP Infrastructure Index is capped, float-adjusted, capitalization-weighted composite of energy infrastructure Master Limited Partnerships that earn the majority of their cash flow from the transportation, storage, and processing of energy commodities. The expense ratio of the ETF is 0.85%.
Why the Move?
The Master Limited Partnerships (MLPs) corner of the broad energy space has been an area to watch lately, given the rise in oil prices. MLPs represent an attractive investment option for income-focused investors as these pay out substantially all of their income to investors on a regular basis.
These have relatively consistent and predictable cash flows, making them safer and less risky than the other plays in the broader energy space. In addition to high yields and the potential for capital appreciation, MLPs also have lower volatility and provide diversification benefits to the portfolio.
More Gains Ahead?
The momentum in AMLP remains strong, given a positive weighted alpha of 13.10. There is definitely still some promise for investors who want to ride on this surging ETF.
|
https://www.zacks.com/stock/news/2216863/mlp-etf-amlp-hits-new-52-week-high
| 2024-01-30T02:39:02Z
|
blocked_url
|
If you've been stuck searching for Mutual Fund Equity Report funds, consider Thrivent Large Cap Value Fund S (TLVIX - Free Report) as a possibility. TLVIX possesses a Zacks Mutual Fund Rank of 1 (Strong Buy), which is based on various forecasting factors like size, cost, and past performance.
History of Fund/Manager
TLVIX finds itself in the Thrivent family, based out of Appleton, WI. The Thrivent Large Cap Value Fund S made its debut in December of 1997 and TLVIX has managed to accumulate roughly $1.88 billion in assets, as of the most recently available information. The fund's current manager, Kurt Lauber, has been in charge of the fund since March of 2013.
Performance
Obviously, what investors are looking for in these funds is strong performance relative to their peers. This fund has delivered a 5-year annualized total return of 13.09%, and it sits in the top third among its category peers. But if you are looking for a shorter time frame, it is also worth looking at its 3-year annualized total return of 12.49%, which places it in the top third during this time-frame.
It is important to note that the product's returns may not reflect all its expenses. Any fees not reflected would lower the returns. Total returns do not reflect the fund's [%] sale charge. If sales charges were included, total returns would have been lower.
When looking at a fund's performance, it is also important to note the standard deviation of the returns. The lower the standard deviation, the less volatility the fund experiences. Compared to the category average of 15.54%, the standard deviation of TLVIX over the past three years is 17.22%. The fund's standard deviation over the past 5 years is 19.72% compared to the category average of 17.26%. This makes the fund more volatile than its peers over the past half-decade.
Risk Factors
The fund has a 5-year beta of 0.98, so investors should note that it is hypothetically as volatile as the market at large. Alpha is an additional metric to take into consideration, since it represents a portfolio's performance on a risk-adjusted basis relative to a benchmark, which in this case, is the S&P 500. The fund has produced a negative alpha over the past 5 years of -1.69, which shows that managers in this portfolio find it difficult to pick securities that generate better-than-benchmark returns.
Holdings
Investigating the equity holdings of a mutual fund is also a valuable exercise. This can show us how the manager is applying their stated methodology, as well as if there are any inherent biases in their approach. For this particular fund, the focus is largely on equities that are traded in the United States.
Currently, this mutual fund is holding 89.21% in stocks, with an average market capitalization of $181.58 billion. The fund has the heaviest exposure to the following market sectors:
- Finance
- Technology
Expenses
For investors, taking a closer look at cost-related metrics is key, since costs are increasingly important for mutual fund investing. Competition is heating up in this space, and a lower cost product will likely outperform its otherwise identical counterpart, all things being equal. In terms of fees, TLVIX is a no load fund. It has an expense ratio of 0.56% compared to the category average of 0.94%. From a cost perspective, TLVIX is actually cheaper than its peers.
This fund requires a minimum initial investment of $2,000, and each subsequent investment should be at least $50.
Fees charged by investment advisors have not been taken into considiration. Returns would be less if those were included.
Bottom Line
Overall, Thrivent Large Cap Value Fund S ( TLVIX ) has a high Zacks Mutual Fund rank, and in conjunction with its comparatively strong performance, average downside risk, and lower fees, this fund looks like a good potential choice for investors right now.
For additional information on the Mutual Fund Equity Report area of the mutual fund world, make sure to check out www.zacks.com/funds/mutual-funds. There, you can see more about the ranking process, and dive even deeper into TLVIX too for additional information. Zacks provides a full suite of tools to help you analyze your portfolio - both funds and stocks - in the most efficient way possible.
|
https://www.zacks.com/stock/news/2216865/is-thrivent-large-cap-value-fund-s-tlvix-a-strong-mutual-fund-pick-right-now?
| 2024-01-30T02:39:08Z
|
blocked_url
|
If you have been looking for Mutual Fund Equity Report funds, a place to start could be Parnassus Mid-Cap Investor (PARMX - Free Report) . PARMX possesses a Zacks Mutual Fund Rank of 1 (Strong Buy), which is based on various forecasting factors like size, cost, and past performance.
History of Fund/Manager
PARMX finds itself in the Parnassus family, based out of San Francisco, CA. The Parnassus Mid-Cap Investor made its debut in April of 2005 and PARMX has managed to accumulate roughly $1.48 billion in assets, as of the most recently available information. The fund's current manager is a team of investment professionals.
Performance
Of course, investors look for strong performance in funds. PARMX has a 5-year annualized total return of 8.76% and is in the bottom third among its category peers. But if you are looking for a shorter time frame, it is also worth looking at its 3-year annualized total return of 0.95%, which places it in the bottom third during this time-frame.
It is important to note that the product's returns may not reflect all its expenses. Any fees not reflected would lower the returns. Total returns do not reflect the fund's [%] sale charge. If sales charges were included, total returns would have been lower.
When looking at a fund's performance, it is also important to note the standard deviation of the returns. The lower the standard deviation, the less volatility the fund experiences. PARMX's standard deviation over the past three years is 18.67% compared to the category average of 16.76%. Over the past 5 years, the standard deviation of the fund is 19.38% compared to the category average of 18.54%. This makes the fund more volatile than its peers over the past half-decade.
Risk Factors
Investors should note that the fund has a 5-year beta of 0.99, so it is likely going to be as volatile as the market at large. Alpha is an additional metric to take into consideration, since it represents a portfolio's performance on a risk-adjusted basis relative to a benchmark, which in this case, is the S&P 500. Over the past 5 years, the fund has a negative alpha of -5.66. This means that managers in this portfolio find it difficult to pick securities that generate better-than-benchmark returns.
Expenses
Costs are increasingly important for mutual fund investing, and particularly as competition heats up in this market. And all things being equal, a lower cost product will outperform its otherwise identical counterpart, so taking a closer look at these metrics is key for investors. In terms of fees, PARMX is a no load fund. It has an expense ratio of 0.96% compared to the category average of 0.94%. PARMX is actually more expensive than its peers when you consider factors like cost.
This fund requires a minimum initial investment of $2,000, and each subsequent investment should be at least $50.
Fees charged by investment advisors have not been taken into considiration. Returns would be less if those were included.
Bottom Line
Overall, even with its comparatively weak performance, average downside risk, and higher fees, Parnassus Mid-Cap Investor ( PARMX ) has a high Zacks Mutual Fund rank, and therefore looks a good potential choice for investors right now.
Don't stop here for your research on Mutual Fund Equity Report funds. We also have plenty more on our site in order to help you find the best possible fund for your portfolio. Make sure to check out www.zacks.com/funds/mutual-funds for more information about the world of funds, and feel free to compare PARMX to its peers as well for additional information. Zacks provides a full suite of tools to help you analyze your portfolio - both funds and stocks - in the most efficient way possible.
|
https://www.zacks.com/stock/news/2216866/is-parnassus-mid-cap-investor-parmx-a-strong-mutual-fund-pick-right-now?
| 2024-01-30T02:39:15Z
|
blocked_url
|
Any investors hoping to find a Mutual Fund Equity Report fund could think about starting with Fidelity Asset Manager 50% (FASMX - Free Report) . FASMX carries a Zacks Mutual Fund Rank of 2 (Buy), which is based on various forecasting factors like size, cost, and past performance.
History of Fund/Manager
FASMX finds itself in the Fidelity family, based out of Boston, MA. Fidelity Asset Manager 50% debuted in December of 1988. Since then, FASMX has accumulated assets of about $7.29 billion, according to the most recently available information. The fund is currently managed by Avishek Hazrachoudhury who has been in charge of the fund since April of 2018.
Performance
Of course, investors look for strong performance in funds. FASMX has a 5-year annualized total return of 7.47% and is in the bottom third among its category peers. But if you are looking for a shorter time frame, it is also worth looking at its 3-year annualized total return of 1.84%, which places it in the bottom third during this time-frame.
It is important to note that the product's returns may not reflect all its expenses. Any fees not reflected would lower the returns. Total returns do not reflect the fund's [%] sale charge. If sales charges were included, total returns would have been lower.
When looking at a fund's performance, it is also important to note the standard deviation of the returns. The lower the standard deviation, the less volatility the fund experiences. The standard deviation of FASMX over the past three years is 11.06% compared to the category average of 13.93%. Over the past 5 years, the standard deviation of the fund is 11.48% compared to the category average of 14.96%. This makes the fund less volatile than its peers over the past half-decade.
Risk Factors
Investors should not forget about beta, an important way to measure a mutual fund's risk compared to the market as a whole. FASMX has a 5-year beta of 0.59, which means it is likely to be less volatile than the market average. Because alpha represents a portfolio's performance on a risk-adjusted basis relative to a benchmark, which is the S&P 500 in this case, one should pay attention to this metric as well. With a negative alpha of -2.54, managers in this portfolio find it difficult to pick securities that generate better-than-benchmark returns.
Expenses
As competition heats up in the mutual fund market, costs become increasingly important. Compared to its otherwise identical counterpart, a low-cost product will be an outperformer, all other things being equal. Thus, taking a closer look at cost-related metrics is vital for investors. In terms of fees, FASMX is a no load fund. It has an expense ratio of 0.61% compared to the category average of 0.94%. FASMX is actually cheaper than its peers when you consider factors like cost.
Investors need to be aware that with this product, the minimum initial investment is $0; each subsequent investment has no minimum amount.
Fees charged by investment advisors have not been taken into considiration. Returns would be less if those were included.
Bottom Line
Overall, Fidelity Asset Manager 50% ( FASMX ) has a high Zacks Mutual Fund rank, and in conjunction with its comparatively weak performance, average downside risk, and lower fees, Fidelity Asset Manager 50% ( FASMX ) looks like a great potential choice for investors right now.
This could just be the start of your research on FASMXin the Mutual Fund Equity Report category. Consider going to www.zacks.com/funds/mutual-funds for additional information about this fund, and all the others that we rank as well for additional information. Want to learn even more? We have a full suite of tools on stocks that you can use to find the best choices for your portfolio too, no matter what kind of investor you are.
|
https://www.zacks.com/stock/news/2216867/is-fidelity-asset-manager-50-fasmx-a-strong-mutual-fund-pick-right-now?
| 2024-01-30T02:39:21Z
|
blocked_url
|
There are plenty of choices in the Mutual Fund Equity Report category, but where should you start your research? Well, one fund that may not be worth investigating is Brown Capital Management Small Company Investor (BCSIX - Free Report) . BCSIX bears a Zacks Mutual Fund Rank of 5 (Strong Sell), which is based on various forecasting factors like size, cost, and past performance.
History of Fund/Manager
BCSIX finds itself in the Brown Capital Management family, based out of Rocky Mount, NC. Brown Capital Management Small Company Investor made its debut in July of 1992, and since then, BCSIX has accumulated about $715.96 million in assets, per the most up-to-date date available. The fund's current manager is a team of investment professionals.
Performance
Of course, investors look for strong performance in funds. This fund carries a 5-year annualized total return of 5.85%, and it sits in the bottom third among its category peers. If you're interested in shorter time frames, do not dismiss looking at the fund's 3 -year annualized total return of -10.88%, which places it in the bottom third during this time-frame.
It is important to note that the product's returns may not reflect all its expenses. Any fees not reflected would lower the returns. Total returns do not reflect the fund's [%] sale charge. If sales charges were included, total returns would have been lower.
When looking at a fund's performance, it is also important to note the standard deviation of the returns. The lower the standard deviation, the less volatility the fund experiences. BCSIX's standard deviation over the past three years is 22.55% compared to the category average of 18.06%. Over the past 5 years, the standard deviation of the fund is 23.83% compared to the category average of 19.75%. This makes the fund more volatile than its peers over the past half-decade.
Risk Factors
The fund has a 5-year beta of 1.04, so investors should note that it is hypothetically more volatile than the market at large. Because alpha represents a portfolio's performance on a risk-adjusted basis relative to a benchmark, which is the S&P 500 in this case, one should pay attention to this metric as well. Over the past 5 years, the fund has a negative alpha of -8.08. This means that managers in this portfolio find it difficult to pick securities that generate better-than-benchmark returns.
Expenses
As competition heats up in the mutual fund market, costs become increasingly important. Compared to its otherwise identical counterpart, a low-cost product will be an outperformer, all other things being equal. Thus, taking a closer look at cost-related metrics is vital for investors. In terms of fees, BCSIX is a no load fund. It has an expense ratio of 1.29% compared to the category average of 1.08%. So, BCSIX is actually more expensive than its peers from a cost perspective.
While the minimum initial investment for the product is $5,000, investors should also note that each subsequent investment needs to be at least $500.
Fees charged by investment advisors have not been taken into considiration. Returns would be less if those were included.
Bottom Line
Overall, Brown Capital Management Small Company Investor ( BCSIX ) has a low Zacks Mutual Fund rank, and in conjunction with its comparatively weak performance, average downside risk, and higher fees, Brown Capital Management Small Company Investor ( BCSIX ) looks like a somewhat weak choice for investors right now.
Want even more information about BCSIX? Then go over to Zacks.com and check out our mutual fund comparison tool, and all of the other great features that we have to help you with your mutual fund analysis for additional information. Zacks provides a full suite of tools to help you analyze your portfolio - both funds and stocks - in the most efficient way possible.
|
https://www.zacks.com/stock/news/2216868/is-brown-capital-management-small-company-investor-bcsix-a-strong-mutual-fund-pick-right-now?
| 2024-01-30T02:39:28Z
|
blocked_url
|
Mutual Fund Equity Report fund seekers should consider taking a look at MFS Growth Fund A (MFEGX - Free Report) . MFEGX carries a Zacks Mutual Fund Rank of 1 (Strong Buy), which is based on various forecasting factors like size, cost, and past performance.
History of Fund/Manager
MFS is based in Boston, MA, and is the manager of MFEGX. Since MFS Growth Fund A made its debut in December of 1986, MFEGX has garnered more than $8.32 billion in assets. The fund is currently managed by Eric B. Fischman who has been in charge of the fund since April of 2002.
Performance
Of course, investors look for strong performance in funds. This fund has delivered a 5-year annualized total return of 15.71%, and it sits in the middle third among its category peers. Investors who prefer analyzing shorter time frames should look at its 3-year annualized total return of 4.78%, which places it in the middle third during this time-frame.
It is important to note that the product's returns may not reflect all its expenses. Any fees not reflected would lower the returns. Total returns do not reflect the fund's [%] sale charge. If sales charges were included, total returns would have been lower.
When looking at a fund's performance, it is also important to note the standard deviation of the returns. The lower the standard deviation, the less volatility the fund experiences. MFEGX's standard deviation over the past three years is 20.08% compared to the category average of 15.01%. Looking at the past 5 years, the fund's standard deviation is 19.56% compared to the category average of 16.01%. This makes the fund more volatile than its peers over the past half-decade.
Risk Factors
The fund has a 5-year beta of 1, so investors should note that it is hypothetically as volatile as the market at large. Alpha is an additional metric to take into consideration, since it represents a portfolio's performance on a risk-adjusted basis relative to a benchmark, which in this case, is the S&P 500. The fund has produced a positive alpha over the past 5 years of 0.29, which shows that managers in this portfolio are skilled in picking securities that generate better-than-benchmark returns.
Holdings
Investigating the equity holdings of a mutual fund is also a valuable exercise. This can show us how the manager is applying their stated methodology, as well as if there are any inherent biases in their approach. For this particular fund, the focus is primarily on equities that are traded in the United States.
As of the last filing date, the mutual fund has 81.89% of its assets in stocks, and these companies have an average market capitalization of $563.02 billion. Turnover is 36%, which means this fund makes fewer trades than its comparable peers.
Expenses
For investors, taking a closer look at cost-related metrics is key, since costs are increasingly important for mutual fund investing. Competition is heating up in this space, and a lower cost product will likely outperform its otherwise identical counterpart, all things being equal. In terms of fees, MFEGX is a load fund. It has an expense ratio of 0.85% compared to the category average of 0.96%. From a cost perspective, MFEGX is actually cheaper than its peers.
Investors should also note that the minimum initial investment for the product is $1,000 and that each subsequent investment needs to be at $50
Fees charged by investment advisors have not been taken into considiration. Returns would be less if those were included.
Bottom Line
Overall, MFS Growth Fund A ( MFEGX ) has a high Zacks Mutual Fund rank, and in conjunction with its comparatively similar performance, average downside risk, and lower fees, this fund looks like a great potential choice for investors right now.
For additional information on this product, or to compare it to other mutual funds in the Mutual Fund Equity Report, make sure to go to www.zacks.com/funds/mutual-funds for additional information. Want to learn even more? We have a full suite of tools on stocks that you can use to find the best choices for your portfolio too, no matter what kind of investor you are.
|
https://www.zacks.com/stock/news/2216869/is-mfs-growth-fund-a-mfegx-a-strong-mutual-fund-pick-right-now?
| 2024-01-30T02:39:34Z
|
blocked_url
|
Provident Financial (PROV - Free Report) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 19.23%. A quarter ago, it was expected that this holding company for Provident Savings Bank would post earnings of $0.28 per share when it actually produced earnings of $0.25, delivering a surprise of -10.71%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Provident Financial
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Provident Financial shares have added about 17.3% since the beginning of the year versus the S&P 500's gain of 2.5%.
What's Next for Provident Financial?
While Provident Financial has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Provident Financial: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.26 on $10.05 million in revenues for the coming quarter and $1.05 on $40.03 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Financial - Savings and Loan is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, New York Community Bancorp (NYCB - Free Report) , has yet to report results for the quarter ended December 2023. The results are expected to be released on January 31.
This bank holding company is expected to post quarterly earnings of $0.29 per share in its upcoming report, which represents a year-over-year change of +16%. The consensus EPS estimate for the quarter has been revised 4.8% lower over the last 30 days to the current level.
New York Community Bancorp's revenues are expected to be $935.9 million, up 62.2% from the year-ago quarter.
|
https://www.zacks.com/stock/news/2216874/provident-financial-prov-surpasses-q2-earnings-estimates
| 2024-01-30T02:39:40Z
|
blocked_url
|
DXC Technology (DXC - Free Report) is slated to report third-quarter fiscal 2024 results on Feb 1.
For the third quarter of fiscal 2024, the company anticipates revenues between $3.32 billion and $3.37 billion. The Zacks Consensus Estimate for fiscal third-quarter revenues stands at $3.36 billion, indicating a year-over-year decline of 5.8%.
DXC anticipates non-GAAP earnings between 75 cents and 80 cents per share. The consensus mark for earnings is pegged at 77 per share, suggesting a 19% year-over-year decrease.
The company’s earnings outpaced estimates twice in the trailing four quarters while matching on one occasion and missing once, with an average surprise of -1.8%.
Let’s see how things are shaping up for this announcement.
Factors to Consider
DXC’s third-quarter performance is likely to have been negatively impacted by softening IT spending as organizations are pushing back their investments in big and expensive technology products amid the ongoing macroeconomic and geopolitical issues.
Moreover, a weak traditional business is likely to have weighed on the to-be-reported quarter's performance. However, sequential revenue stabilization is expected to have continued.
The negative impacts of the aforementioned factors are likely to have been partially offset by DXC’s strength in the digital business and partnerships, which have been helping it expand in the cloud computing space.
The company expects third-quarter organic revenues to decline in the 4-5% range, considering the weaker demand environment amid the ongoing challenging macroeconomic situation. Our estimate suggests that DXC’s total organic revenues are likely to have dropped 4.8% in the to-be-reported quarter.
The year-over-year expected organic revenue decline is mainly due to an anticipated weak performance in DXC’s Global Infrastructure Services (“GIS”) as well as the Global Business Services (“GBS”) segment.
The GIS segment’s third-quarter performance is likely to have been negatively impacted by weakness in the IT Outsourcing and Modern Workplace areas, which are parts of this division.
Our estimate for the GIS segment’s third-quarter revenues is pegged at $1.68 billion, indicating a year-over-year decline of 8.7% on an organic basis. Meanwhile, our estimate of $1.67 billion for the GBS segment’s revenues suggests a year-over-year organic decline of 0.7%.
Furthermore, revenue shortfall is likely to have weighed on third-quarter margins. DXC projects the adjusted EBIT margin in the range of 7%-7.5% in the fiscal third quarter.
Additionally, DXC’s cost-saving initiatives and lower interest expenses are likely to have partially offset the negative impact of revenue shortfall on bottom-line results. Apart from the abovementioned factors, a reduction in shares outstanding on the company’s aggressive share repurchase initiative is likely to have boosted the EPS.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for DXC this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. However, that’s not the case here.
Though DXC currently carries a Zacks Rank of 3, it has an Earnings ESP of -2.14%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With the Favorable Combination
Per our model, Fabrinet (FN - Free Report) , Apple (AAPL - Free Report) and Meta Platforms (META - Free Report) have the right combination of elements to post an earnings beat in their upcoming releases.
Fabrinet carries a Zacks Rank #2 and has an Earnings ESP of +2.13%. The company is scheduled to report second-quarter fiscal 2024 results on Feb 5. Its earnings beat the Zacks Consensus Estimate in the preceding four quarters, with the average surprise being 3.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Fabrinet’s second-quarter earnings stands at $2.04 per share, indicating a year-over-year improvement of 7.4%. It is estimated to report revenues of $699.8 million, which suggests an increase of approximately 4.7% from the year-ago quarter.
Apple is slated to report first-quarter fiscal 2024 results on Feb 1. The company has a Zacks Rank #3 and an Earnings ESP of +1.96% at present. Apple’s earnings beat the Zacks Consensus Estimate thrice in the trailing four quarters while missing on one occasion, the average surprise being 3.5%.
The Zacks Consensus Estimate for first-quarter earnings is pegged at $2.09 per share, suggesting an increase of 11.2% from the year-ago quarter’s earnings of $1.88. Apple’s quarterly revenues are estimated to improve marginally to $117.62 billion from $117.15 billion in the year-ago quarter.
Meta carries a Zacks Rank #2 and has an Earnings ESP of +0.51%. The company is scheduled to report fourth-quarter 2023 results on Feb 1. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 27.5%.
The Zacks Consensus Estimate for Meta’s fourth-quarter earnings is pegged at $4.84 per share, indicating a year-over-year increase of 61.3%. The consensus mark for revenues stands at $38.93 billion, calling for a year-over-year rise of 21%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Apple Inc. (AAPL) - free report >>
Fabrinet (FN) - free report >>
|
https://www.zacks.com/stock/news/2216878/dxc-technology-dxc-to-report-q3-earnings-what-to-expect?
| 2024-01-30T02:39:47Z
|
blocked_url
|
Investors are always looking for stocks that are poised to beat at earnings season and HCA Healthcare, Inc. (HCA - Free Report) , may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because HCA Healthcare is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for HCA in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at $5.37 per share for HCA, compared to a broader Zacks Consensus Estimate of $5.05 per share. This suggests that analysts have very recently bumped up their estimates for HCA, giving the stock a Zacks Earnings ESP of +6.39% heading into earnings season.
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that HCA has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 (Strong Buy)Rank stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for HCA Healthcare, and that a beat might be in the cards for the upcoming report.
|
https://www.zacks.com/stock/news/2216879/is-a-surprise-coming-for-hca-healthcare-hca-this-earnings-season?
| 2024-01-30T02:39:53Z
|
blocked_url
|
Wall Street was upbeat last week. The S&P 500 managed to secure a weekly win after setting a new record on Thursday. The S&P 500 added 1.1% last week, the Dow Jones inched up 0.7% and the Nasdaq Composite added about 0.9%. This suggests resilience in the market, although uncertainties loom.
The tech-heavy Nasdaq Composite experienced a decline of nearly 0.4% on Friday, largely driven by Intel's disappointing first-quarter outlook. This setback has tempered some of the optimism generated by AI-related stocks that have been instrumental in pushing the market to record highs. Intel's shares took a huge hit, with its peers AMD and Nvidia also feeling the impact.
Inflation Gauge Indicates Moderation
The release of the PCE (Personal Consumption Expenditures) index for December provided further evidence of moderating inflation. The "Core" PCE, the Federal Reserve's preferred inflation measure, dropped below 3% on an annual basis, marking the slowest growth rate since March 2021.
This data, coupled with a stronger-than-expected initial estimate of fourth-quarter U.S. GDP, suggests the possibility of a "soft landing" for the US economy. The U.S. economy exhibited a robust performance in the fourth quarter of 2023, with the real Gross Domestic Product (GDP) expanding at an annualized rate of 3.3%. This growth exceeded market expectations of 2% and followed a 4.9% increase in the third quarter (read: U.S. GDP Growth Beats Expectations in Q4: ETFs to Benefit).
Earnings Reports Offer Insights
Investors also closely examined the latest batch of earnings reports. Colgate-Palmolive (CL - Free Report) stood out with robust fourth-quarter results attributed to its Latin American consumer markets. In contrast, Visa (V) delivered a cautious revenue growth forecast, raising concerns about a slowdown in U.S. payments volume growth, which could signal an impending economic downturn.
Meanwhile, Netflix (NFLX - Free Report) logged its best weekly performance in more than a year due to a better-than-expected earnings report. Tesla (TSLA - Free Report) , the electric vehicle (EV) manufacturer, released its Q4 earnings report on Jan 24, after the market closed, which missed estimates and led to a decline in its stock price. The company also provided a pessimistic outlook for full-year production in 2024.
ETFs in Focus
Against this backdrop, below we highlight a few winning inverse/leveraged ETFs of last week.
GraniteShares 2x Short TSLA Daily ETF (TSDD - Free Report) ) – Up 29.1%
The GraniteShares 1.5x Short TSLA Daily ETF seeks daily investment results, before fees and expenses, of -1.5 times the daily percentage change of the common stock of Tesla Inc.The expense ratio of the fun is 1.50%. Tesla lost 13.7% last week due to weak earnings report and guidance(read: Tesla Slumps on Q4 Earnings Miss and Soft Outlook: ETFs in Focus).
AdvisorShares MSOS 2x Daily ETF (MSOX - Free Report) ) – Up 16.9%
The AdvisorShares MSOS 2x Daily ETF seeks daily investment results that correspond to two times the return of AdvisorShares Pure US Cannabis ETF. The expense ratio of the fun is 1.13%. Cannabis stocks and ETFs have surged over the past few months since the Department of Health and Human Services asked the DEA to review its classification of cannabis. Earlier this month, a group of 12 state attorneys general sent a letter to the DEA supporting the reclassification (read: Cannabis ETFs: What's Behind the Latest Surge).
MicroSectors U.S. Big Oil Index 3X Leveraged ETN (NRGU - Free Report) ) – Up 16.8%
The MicroSectors U.S. Big Oil Index 3X Leveraged ETNs provide levered exposure to the Solactive MicroSectors U.S. Big Oil Index. U.S. crude oil topped $78 in best week since September on upbeat U.S. growth and China stimulus.
GraniteShares 2x Long BABA Daily ETF (BABX - Free Report) ) – Up 13.1%
The GraniteShares 1.75x Long BABA Daily ETF seeks daily investment results, before fees and expenses, of 1.75 times the daily percentage change of the common stock of Alibaba Group Holding Limited. The expense ratio of the fun is 1.15%. Alibaba stock price increased 6% last week.
Direxion Daily FTSE China Bull 3X Shares (YINN - Free Report) – Up 11.6%
The Direxion Daily FTSE China Bull 3X Shares seeks daily investment results, before fees and expenses, of 300% of the performance of the FTSE China 50 Index. The People’s Bank of China surprised investors on Wednesday by revealing a bigger-than-expected RRR cut weeks in advance, providing markets with a much-needed boost. China’s central bank also revealed broad plans to guide money into sectors of national importance to boost the faltering economy this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Netflix, Inc. (NFLX) - free report >>
Colgate-Palmolive Company (CL) - free report >>
Tesla, Inc. (TSLA) - free report >>
Direxion Daily FTSE China Bull 3X Shares (YINN) - free report >>
MicroSectors U.S. Big Oil Index 3X Leveraged ETN (NRGU) - free report >>
AdvisorShares MSOS 2x Daily ETF (MSOX) - free report >>
|
https://www.zacks.com/stock/news/2216892/best-inverseleveraged-etfs-of-last-week
| 2024-01-30T02:39:59Z
|
blocked_url
|
PTC Inc (PTC - Free Report) is slated to report first-quarter fiscal 2024 results on Jan 31.
The Zacks Consensus Estimate for revenues is pegged at $538.6 million, suggesting growth of 15.6% from a year ago. The consensus estimate for earnings is pegged at 98 cents per share, indicating a decline of 1% from the prior year.
The company has a trailing four-quarter earnings surprise of 2.43%, on average.
Factors to Consider
Strength in the industrial Internet of Things solutions, and healthy demand for product lifecycle management (“PLM”) and computer-aided design (“CAD”) solutions are expected to have contributed to PTC’s fiscal first-quarter top line. A strong uptick in demand for Creo+ and Windchill platforms and is likely to have acted as a tailwind.
Increasing demand for products, especially digital transformation and software-as-a-service or SaaS, across all segments and regions is expected to have driven PTC’s revenue performance in the to-be-reported quarter. Continued momentum in Onshape and Arena will further assist the company in the SaaS transition.
Subscription-centric model and disciplined operational management are likely to have favored its overall performance. The Zacks Consensus Estimate for recurring revenues is pegged at $495 million, implying an 18.7% rise from a year ago.
Synergies from the recent buyouts of ServiceMax and Codebeamer are likely to have aided the company's performance. Codebeamer is aiding PTC in significantly strengthening its position in the Application Lifestyle Management or ALM market.
For the fiscal first quarter, PTC expects ARR to be between $1.995 billion and $2.010 billion. Cash from operations is projected to be $185 million and free cash flow is forecast to be $180 million.
However, volatility in foreign exchange rates and a challenging global macroeconomic environment are expected to have weighed on the company’s performance. Also, increasing research and development costs to fend off competition are likely to have acted as headwinds.
What Our Model Says
Our proven model predicts an earnings beat for PTC this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.
PTC has an Earnings ESP of +2.12% and a Zacks Rank #2. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Other Stocks to Consider
Here are a few stocks that you may want to consider, as our model shows that these, too, have the right combination of elements to post an earnings beat this quarter.
Apple (AAPL - Free Report) has an Earnings ESP of +1.96% and carries a Zacks Rank #3 at present. Apple is scheduled to release first-quarter fiscal 2024 results on Feb 1.
The Zacks Consensus Estimate for Apple’s to-be-reported quarter’s earnings and revenues is pegged at $2.09 per share and $117.6 billion, respectively. Shares of AAPL have gained 34.6% in the past year.
Fortive Corporation (FTV - Free Report) has an Earnings ESP of +0.64% and presently carries a Zacks Rank #2. FTV is slated to release quarterly numbers on Jan 31. You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for FTV’s to-be-reported quarter’s revenues and earnings is pegged at $1.57 billion and 93 cents per share, respectively. Shares of FTV have rallied 11.7% in the past year.
Roper Technologies (ROP - Free Report) has an Earnings ESP of +1.69% and a Zacks Rank #2 at present. ROP will release results on Jan 31.
The Zacks Consensus Estimate for Roper Technologies’ to-be-reported quarter’s earnings and revenues is pegged at $4.33 per share and $1.58 billion, respectively. Shares of ROP have gained 29.8% in the past year.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Apple Inc. (AAPL) - free report >>
Roper Technologies, Inc. (ROP) - free report >>
|
https://www.zacks.com/stock/news/2216902/ptc-set-to-report-q1-earnings-heres-what-you-should-know
| 2024-01-30T02:40:05Z
|
blocked_url
|
Americans are spending lavishly, driven by a rise in personal income and waning fears of a recession as inflation continues to ease. Although personal consumption expenditure (PCE), an important gauge for the Fed, increased marginally in December, people are a lot more confident that the economy will make a softer landing, which is lifting their confidence.
The Commerce Department said on Jan 26 that consumer spending increased 0.7% in December, higher than the consensus estimate of 0.5%. Also, personal income rose 0.3% in December, in line with expectations.
Easing inflation has once again lifted consumer sentiment, which is making them spend more freely as the Federal Reserve has indicated at ending its monetary tightening campaign after raising interest rates by 525 basis points since March 2022.
The Commerce Department also said that PCE inflation increased 0.2% in December from November’s unrevised decline of 0.1%. Core PCE, which excludes the volatile food and energy prices, also rose 0.2% in December, up from November’s increase of 0.1%.
However, year over year, PCE inflation increased 2.6%, while core PCE increased 2.9%, the smallest increase since March 2021.
The marginal month-over-month rise in inflation is not likely to impact the Federal Reserve’s decision much as it gears up to go for rate cuts in 2024. Investors are expecting the Federal Reserve to go for at least three 25-basis point rate cuts this year.
Lower interest rates bode well for the broader economy and allow consumers to spend more freely as they will have more purchasing power. Given this situation, investing in consumer discretionary stocks seems prudent.
Our Choices
We have narrowed our search to five consumer discretionary stocks namely Royal Caribbean Cruises Ltd. (RCL - Free Report) , Netflix, Inc. (NFLX - Free Report) , OneSpaWorld Holdings (OSW - Free Report) , Pearson plc (PSO - Free Report) and Electronic Arts Inc. (EA - Free Report) that have strong potential for 2024. These stocks have seen positive earnings estimate revisions in the last 60 days. Each of our picks carries a Zacks Rank #1 (Strong Buy) or 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Royal Caribbean Cruises Ltd. owns and operates three global brands — Royal Caribbean International, Celebrity Cruises and Azamara Club Cruises. Additionally, RCL has a 50% investment in a joint venture with TUI AG, which operates the brand TUI Cruises. Royal Caribbean Cruises' brands primarily serve the contemporary, premium and deluxe segments of the cruise vacation industry, which also includes the budget and luxury segments.
Royal Caribbean Cruises' expected earnings growth rate for the current year is 188.4%. The Zacks Consensus Estimate for current-year earnings has improved 0.6% over the past 60 days. RCL currently sports a Zacks Rank #1.
Netflix, Inc. is considered a pioneer in the streaming space. NFLX has been spending aggressively on building its portfolio of original shows. This is helping Netflix sustain its leading position despite the launch of new services like Disney+ and Apple TV+, as well as existing services like Amazon Prime Video.
Netflix’s expected earnings growth rate for the current year is 40.1%. The Zacks Consensus Estimate for current-year earnings has improved 5.8% over the past 60 days. Netflix presently sports a Zacks Rank #1.
OneSpaWorld Holdings is a provider and innovator in the fields of wellness, beauty, rejuvenation and transformation on cruise ships and land. OSW’s service includes traditional and alternative massage, body and skincare treatment options, ayurvedic treatments, comprehensive hair and nail services, fitness, acupuncture, herbal medicine, pain management, and medi-spa.
OneSpaWorld Holdings’ expected earnings growth rate for the current year is 139.3%. The Zacks Consensus Estimate for current-year earnings has improved 3.1% over the past 60 days. OSW carries a Zacks Rank #2 at present.
Pearson plc is a global media conglomerate. PSO publishes books, periodicals, reports and screen-based services for professional communities worldwide under brand names that include the Financial Times, Pitman Publishing and Churchill Livingstone.
Pearson’s expected earnings growth rate for the current year is 28.1%. The Zacks Consensus Estimate for current-year earnings has improved 2.5% over the past 60 days. PSO presently has a Zacks Rank #2.
Electronic Arts Inc., popularly known as EA, is a leading developer, marketer, publisher and distributor of digital interactive entertainment, including games, extra content and services. EA’s portfolio includes wholly owned games like Apex Legends, Battlefield, and The Sims or licensed from others, including Madden NFL, Star Wars and others.
Electronic Arts’expected earnings growth rate for the current year is 28.8%. The Zacks Consensus Estimate for the current-year earnings has improved 3.5% over the past 60 days. EA presently carries a Zacks Rank #2.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Netflix, Inc. (NFLX) - free report >>
Royal Caribbean Cruises Ltd. (RCL) - free report >>
Pearson, PLC (PSO) - free report >>
|
https://www.zacks.com/stock/news/2216903/5-stocks-to-buy-on-steady-rise-in-personal-spending-income
| 2024-01-30T02:40:12Z
|
blocked_url
|
The fourth-quarter 2023 earnings season for the auto sector kicked off last week. Two S&P 500 sector companies — Tesla (TSLA - Free Report) and PACCAR (PCAR - Free Report) — reported their quarterly numbers.
Tesla delivered a disappointing fourth-quarter 2023 show, missing both earnings and revenue estimates. This marked the second earnings miss in a row for the electric vehicle (EV) behemoth, following 10 straight quarters of beat. The company also cautioned that its vehicle volume growth rate for 2024 is expected to be noticeably lower than in 2023.
PACCAR not just pulled off a comprehensive beat but also witnessed year-over-year growth in the top and bottom lines. The trucking giant achieved record revenues and net income in 2023.
U.S. legacy automaker Ford (F - Free Report) is recalling around 1.9 million explorer SUVs to fix trim pieces. Ford’s crosstown rival General Motors (GM - Free Report) and Japan-based Honda's groundbreaking joint venture in Michigan is to begin hydrogen fuel cell production, promising innovative and sustainable transportation solutions. Also, GM is making a $1.4 billion investment in Brazil, spearheading the nation's electric vehicle transition. Truck transmission manufacturer Allison Transmission (ALSN - Free Report) joined forces with Oshkosh Corp. for the supply of e-axles for electric refuse vehicles. It also partnered with SANY for mining transmission solutions.
While PCAR sports a Zacks Rank #1 (Strong Buy), GM and ALSN currently carry a Zacks Rank #2 (Buy) each. TSLA and F are currently #3 Ranked (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.
Last Week’s Top Stories
Tesla’s fourth-quarter earnings per share of 71 cents missed the Zacks Consensus Estimate of 75 cents and also declined from the year-ago figure of $1.19. Total revenues of $25.17 billion also lagged the consensus mark of $25.94 billion but inched up 3% year over year. Automotive gross profit came in at $4.06 billion. Automotive gross margin came in at 18.8%, down from 25.9% reported in fourth-quarter 2022 but topped our forecast of 18.4%. This can be attributed to lower-than-expected cost of automotive sales. The metric came in at 17.5 billion, below our projection of 18.3 billion. Tesla’s operating margin declined 964 basis points year over year to 7.6% in the quarter under discussion and also lagged our estimate of 7.9%.
Tesla had cash/cash equivalents/investments of $29,094 million as of Dec 31, 2023. Long-term debt and finance leases, net of the current portion, totaled $2,857 million. Net cash provided by operating activities amounted to $4,370 million in fourth-quarter 2023. Capital expenditure totaled $2,306 million in the quarter under review. Tesla generated a free cash flow of $2,064 million during the reported quarter, which rose from $1,420 million generated in the year-ago period.
PACCAR recorded earnings of $2.70 per share for fourth-quarter 2023, which surged 53.4% from the year-ago figure. The bottom line surpassed the Zacks Consensus Estimate of $2.20 per share. Consolidated revenues (including trucks and financial services) came in at $9,076.6 million, up from $8,129.5 million in the corresponding quarter of 2022. Sales from Trucks, Parts and Others were $8,591.8 million, which surpassed the Zacks Consensus Estimate of $8,190 million.
Revenues from the Trucks segment totaled $6,968.7 million in the fourth quarter. Global truck deliveries came in at 51,100 units. The segment’s pre-tax income was $996.4 million. Revenues from the Parts segment totaled $1,610.3 million in the reported quarter. The segment’s pre-tax income came in at $432.4 million. Revenues of the Financial Services segment came in at $484.8 million. Other sales amounted to $12.8 million. PACCAR’s cash and marketable debt securities amounted to $8,659.3 million as of Dec 31, 2023. Capex and R&D expenses for 2024 are envisioned in the band of $700-$750 million and $460-$500 million, respectively.
Ford is recalling approximately 1.9 million Explorer SUVs due to a loose piece of trim that could unhitch and create a road hazard for other drivers. Per the company, clips that attach the trim to the exterior of the vehicle are not properly engaged due to improper assembly or repair, causing the A-pillar trim to become loose or fully detach. The recall covers Explorer SUVs from model years 2011-2019. Per the National Highway Traffic Safety Administration, the detached trim piece could become a road hazard for other drivers, increasing the risk of a crash.
Ford is not aware of any accidents or injuries related to the issue. It received more than 14,000 warranty reports related to detached or missing A-pillar trim parts. Per Maria Buczkowski, Ford’s spokesperson, only 5% of recalled Explorers are affected by the issue. She urged owners to contact their dealership for an inspection when the parts become available. Inspections and essential replacements will be done free of cost. Ford expects to notify owners via letters in March.
General Motors and Honda are poised to revolutionize the automotive industry with the commencement of commercial production at their hydrogen fuel cell facility in Michigan. The joint venture, Fuel Cell System Manufacturing LLC (FCSM), is the first large-scale manufacturing facility dedicated to fuel cell systems. With a sprawling 70,000-square-foot space in Brownstown, MI, FCSM is set to lead the charge in advancing hydrogen fuel cell technology. The partnership seeks to expand hydrogen fuel cell applications beyond automobiles, including rail, aircraft, commercial vehicles, and stationary power stations. With a focus on innovation and sustainability, GM and Honda are ushering in a new era of hydrogen technology, driving forward the development of cleaner and more efficient transportation solutions.
In another development, General Motors is injecting $1.4 billion into Brazil's electric vehicle sector by 2028, aligning with president Luiz Inacio Lula da Silva's push for automotive investment. This investment, part of a broader transformation, aims to renew vehicle offerings, develop technologies and modernize factories. GM's move follows Brazil's new automotive guidelines and dovetails with the "Mover" program for green mobility, emphasizing decarbonization and innovation. The commitment underscores GM's focus on sustainable mobility, transitioning toward an all-electric future.
Allison has been chosen by Oshkosh to supply e-axles for North America's pioneering fully integrated, zero-emission electric refuse collection vehicle. The Allison eGen Power 100S has been integrated into the McNeilus Volterra ZSL electric refuse vehicle, tailored to minimize environmental impact and noise pollution in communities worldwide. Recognizing the efficiency advantage of the eGen Power 100S architecture in heavy stop-start refuse applications, Oshkosh plans to deploy two eGen Power 100S e-axles in tandem configuration per vehicle, ensuring extended range, cleaner air and quieter operation. The development marks Allison's debut in refuse collection applications and positions it to meet the growing demand for electric vehicles while delivering sustainable solutions for waste management.
In other news, Allisonforged a strategic partnership with SANY, a leading global heavy equipment manufacturer in the mining and construction sectors. The collaboration positions Allison as a key supplier of transmissions for SANY's lineup of mining vehicles, including the next-generation SANY SKT105 wide body mining dump truck, rigid dump trucks and articulated dump trucks. Per the terms of the agreement, Allison will supply its family of Off Road Series and Wide Body Dump Series transmissions for integration into SANY's fleet of mining vehicles.
Price Performance
The following table shows the price movement of some of the major auto players over the last week and six-month period.
Image Source: Zacks Investment Research
What’s Next in the Auto Space?
Industry watchers will keep a tab on U.S. vehicle sales for the month of January. Investors are also awaiting the quarterly releases of auto companies like General Motors, Group 1 and Oshkosh that are slated to report this week.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Ford Motor Company (F) - free report >>
PACCAR Inc. (PCAR) - free report >>
General Motors Company (GM) - free report >>
|
https://www.zacks.com/stock/news/2216905/auto-roundup-tslas-q4-earnings-miss-gms-14b-ev-investment-in-brazil-more?-more
| 2024-01-30T02:40:18Z
|
blocked_url
|
We expect Amgen (AMGN - Free Report) to beat expectations when it reports fourth-quarter and full-year 2023 results on Feb 6, after market close. In the last reported quarter, the company delivered an earnings surprise of 6.67%.
Factors to Consider
Amgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Prolia and Blincyto, among others. However, the prices of most products are expected to have declined.
The Zacks Consensus Estimate for Prolia, Repatha, Evenity and Blincyto sales is pegged at $1.05 billion, $428.0 million, $319.0 million and $227.0 million, respectively.
Our estimates for Prolia, Repatha, Evenity and Blincyto sales are pegged at $1.03 billion, $426.5 million, 318.2 million and $223.2 million, respectively.
In addition, higher volumes of newer drugs like Tezspire and Tavneos are expected to have contributed to top-line growth driven by new patient volume growth. Sales of both Tezspire and Tavneos improved sequentially in the third quarter, a trend expected to have continued in the fourth quarter. Like the previous two quarters, Tezspire volumes are likely to have benefitted from the launch of a self-administered, pre-filled, single-use pen formulation of the drug in the first quarter, improving patient convenience and accessibility and also providing more flexibility in treatment options.
Our estimates for Tezspire and Tavneos are pegged at $177.1 million and $47.0 million, respectively.
However, lower revenues from oncology biosimilars (Kanjinti and Mvasi) and legacy established products are expected to have hurt the top line. In addition, in the first three quarters of 2023, sales of Otezla in the United States were hurt by free drug programs launched by new competitors and lower pricing.
On the third-quarter conference call, Amgen had said that it is seeing reduced impact of the free drug programs. Amgen is also making investments to educate physicians about the benefits of Otezla for appropriate patients and has increased the Otezla sales force by 20%. It remains to be seen if these initiatives led to any improvement in sales of Otezla.
The Zacks Consensus Estimate for Otezla is $618.0 million, while our estimate is $606.4 million.
For Enbrel, improved payer coverage led to an increase in new patients, boosting volume growth in the last two quarters. The positive trend is expected to have continued in the fourth quarter. However, lower pricing is expected to have hurt sales of this legacy established product. The Zacks Consensus Estimate as well as our model estimate for Enbrel is $1.06 billion.
In October 2023, Amgen closed the previously announced acquisition of Horizon Therapeutics for $27.8 billion. The addition of Horizon Therapeutics has added several rare disease drugs like Tepezza, Krystexxa and Uplizna to Amgen’s portfolio. Amgen's fourth-quarter results will include sales of all these drugs.
Adjusted EPS in the fourth quarter is expected to be lower than the third quarter due to increased investments in pipeline candidates like maridebart cafraglutide, olpasiran and AMG 193. In addition, the recognition of interest expense related to Horizon financing will also hurt earnings per share in the fourth quarter.
Earnings Surprise History
This large biotech’s performance has been strong, with earnings beating estimates in all the trailing four quarters. The company delivered a four-quarter earnings surprise of 6.04%, on average.
Amgen’s stock has risen 23.9% in the past year against a decrease of 14.1% for the industry.
Image Source: Zacks Investment Research
Earnings Whispers
Our proven model predicts an earnings beat for Amgen in the to-be-reported quarter. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely positive surprise. This is the case here, as elaborated below.
Earnings ESP: Amgen’s Earnings ESP is +1.01% as the Most Accurate Estimate of $4.74 is higher than the Zacks Consensus Estimate of $4.68. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Amgen has a Zacks Rank #3.
Other Stocks to Consider
Here are some large drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Novartis (NVS - Free Report) has an Earnings ESP of +3.39% and a Zacks Rank #3.
Novartis’ stock has risen 19.5% in the past year. Novartis topped earnings estimates in the last four quarters. NVS delivered a four-quarter earnings surprise of 6.99%, on average. Novartis is scheduled to release its fourth-quarter results on Jan 31.
AstraZeneca (AZN - Free Report) has an Earnings ESP of +3.17% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
AstraZeneca’s stock has risen 1.9% in the past year. AstraZeneca beat earnings estimates in the last four quarters. AZN has a four-quarter earnings surprise of 8.30%, on average. AstraZeneca is scheduled to release its fourth-quarter results on Feb 8.
Sanofi (SNY - Free Report) has an Earnings ESP of +13.01% and a Zacks Rank #3.
Sanofi’s stock has risen 3.2% in the past year. Sanofi beat earnings estimates in three of the last four quarters while missing in one. SNY has a four-quarter earnings surprise of 2.88%, on average. Sanofi is scheduled to release its fourth-quarter results on Feb 1.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
AstraZeneca PLC (AZN) - free report >>
|
https://www.zacks.com/stock/news/2216908/can-amgen-amgn-keep-the-beat-streak-alive-in-q4-earnings?
| 2024-01-30T02:40:24Z
|
blocked_url
|
Investors are always looking for stocks that are poised to beat at earnings season and Marathon Petroleum Corporation (MPC - Free Report) , may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Marathon Petroleum is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for MPC in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at $2.42 per share for MPC, compared to a broader Zacks Consensus Estimate of $2.36 per share. This suggests that analysts have very recently bumped up their estimates for MPC, giving the stock a Zacks Earnings ESP of +2.21% heading into earnings season.
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that MPC has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Marathon Petroleum, and that a beat might be in the cards for the upcoming report.
|
https://www.zacks.com/stock/news/2216909/should-you-buy-marathon-petroleum-mpc-ahead-of-earnings?
| 2024-01-30T02:40:30Z
|
blocked_url
|
Pfizer (PFE - Free Report) has been relying on its newly launched and newly acquired products to improve its sales performance amid a decline in revenues from its COVID-19 products.
Pfizer records direct sales and alliance revenues from its partner, BioNTech (BNTX - Free Report) , for the COVID-19 vaccine, Comirnaty, and product revenues from its oral antiviral pill for COVID, Paxlovid.
Investors will be keen to know the sales numbers of Pfizer’s several newly launched drugs like Abrysvo, Velsipity, Penbraya, Zavzpret as well as newly acquired products like Nurtec and Oxbryta on the fourth-quarter conference call.
Pfizer’s RSV vaccine, Abrysvo, was approved and launched to help protect older adults, as well as infants through maternal immunization in the United States as well as EU in 2023. In October 2023, the FDA approved its once-daily pill called Velsipity (etrasimod) to treat moderately-to-severely active ulcerative colitis (UC) as well as its pentavalent meningococcal vaccine, Penbraya. In August, the FDA approved Elrexfio (elranatamab), a BCMA-CD3-targeted bispecific antibody for relapsed/refractory multiple myeloma. In June, the FDA approved Litfulo (ritlecitinib), its JAK3 inhibitor for treating severe alopecia areata and Ngenla, a long-acting once-weekly treatment for pediatric growth hormone deficiency.
Litfulo was approved in Europe in September 2023, Elrexfio in December while etrasimod (for UC) and pentavalent meningococcal vaccines are under review in the EU. Ngenla is already approved in EU and some other countries like Japan. Pfizer’s CGRP receptor antagonist, Zavzpret/zavegepant nasal spray, for the acute treatment of migraine was approved in 2022.
Pfizer’s stock has declined 36.9% in the past year against an increase of 19.8% for the industry.
Image Source: Zacks Investment Research
Sales of Abrysvo, which was launched in 2023, were above management’s expectations in the third quarter, driven by strong demand as well as some stocking benefits. It remains to be seen how the vaccine contributed to the top line in the fourth quarter. Our model estimate for Abrysvo for the fourth quarter is $510 million.
Sales of Nurtec ODT/Vydura and Oxbryta improved sequentially in the third quarter, a trend expected to have continued in the fourth quarter. Nurtec ODT/Vydura was added to Pfizer’s portfolio with the acquisition of most of Biohaven in 2022. Oxbryta was added with the October 2022 acquisition of Global Blood Therapeutics. Our model estimates for Nurtec and Oxbryta are $246 million and $94.5 million, respectively. The Zacks Consensus Estimate for Nurtec and Oxbryta for the fourth quarter is $251 million and $96.0 million, respectively.
The December 2023 acquisition of Seagen added a class of antibody-drug conjugates or ADCs, Adcetris, Padcev, Tukysa and Tivdak to Pfizer’s portfolio. Antibody-drug conjugates are being considered a disruptive innovation in the pharmaceutical industry as these will allow better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors. Though the contribution of these four drugs to Pfizer’s top line is expected to have been minimal in the fourth quarter of 2023 (as the Seagen acquisition was closed on Dec 14), investors will still keep a tab on the sales performance of these drugs in the quarter.
Overall, though sales from BioNTech partnered Comirnaty and Paxlovid are expected to have declined due to lower demand, some key non-COVID products like Vyndaqel/Vyndamax and Prevnar family of vaccines, newly acquired products like Nurtec ODT/Vydura and Oxbryta and new product launches are likely to have provided some top-line support in the fourth quarter.
The Zacks Consensus Estimate for the Prevnar family of vaccines is $1.89 billion, while our model estimates the same to be $1.76 billion.
The Zacks Consensus Estimate for sales of Vyndaqel/Vyndamax is $945.0 million, while our model estimates the same to be $921.0 million.
Zacks Rank and Stocks to Consider
Pfizer has a Zacks Rank #5 (Strong Sell) currently.
Some better-ranked large drugmakers worth considering are Regeneron Pharmaceuticals (REGN - Free Report) and Novo Nordisk (NVO - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Regeneron’s 2024 earnings have risen from $41.60 per share to $44.28 per share. Regeneron’s stock has surged 27.6% in the past year.
Regeneron beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 12.34%.
Estimates for Novo Nordisk’s 2024 earnings per share have increased from $3.15 to $3.32 over the past 60 days. NVO’s stock has surged 55.5% in the past year.
Earnings of Novo Nordisk beat estimates in two of the last four quarters, missed in one and matched estimates in one, delivering an earnings surprise of 0.58% on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Regeneron Pharmaceuticals, Inc. (REGN) - free report >>
Pfizer Inc. (PFE) - free report >>
|
https://www.zacks.com/stock/news/2216911/will-new-drugs-drive-pfizer-pfe-sales-in-q4-earnings?
| 2024-01-30T02:40:36Z
|
blocked_url
|
Chevron Corporation (CVX - Free Report) is set to release fourth-quarter results on Feb 2. The current Zacks Consensus Estimate for the to-be-reported quarter is a profit of $3.31 per share on revenues of $52.6 billion.
Let’s delve into the factors that might have influenced the American energy biggie’s performance in the December quarter. But it’s worth taking a look at Chevron’s previous-quarter performance first.
Highlights of Q3 Earnings & Surprise History
In the last reported quarter, the San Ramon, CA-based integrated player missed the consensus mark due to weak results in its downstream segment. Chevron had reported adjusted earnings per share of $3.05, below the Zacks Consensus Estimate of $3.68. However, revenues of $54.1 billion had come in $81 million above the consensus mark on higher liquids production.
CVX beat the Zacks Consensus Estimate for earnings in two of the last four quarters and missed in the other two, resulting in an earnings surprise of (2.2%), on average. This is depicted in the graph below:
Factors to Consider
Chevron is expected to have benefited from an uptick in oil and gas production, primarily reflecting robust output in the showpiece Permian Basin region. As a matter of fact, for the to-be-reported quarter, the Zacks Consensus Estimate for total volume is pegged at 3,231 thousand oil-equivalent barrels per day (MBOE/d), indicating a rise from the prior-year quarter’s output of 3,011 MBOE/d.
A dip in costs might have buoyed CVX’s profit and margins even further. In the third quarter of 2023, the company’s purchased oil and products cost decreased by 16.6% from the year-ago period to $32.3. The decline is most likely to have continued in the fourth quarter on the back of Chevron’s prudent expense management policies.
However, as a counter to its production gains, Chevron is expected to have been weighed down by the drop in hydrocarbon realizations. According to the U.S. Energy Information Administration, in October, November and December 2022, the average monthly WTI crude price was $87.55, $84.37 and $76.44 per barrel, respectively. Average prices were $85.64 in October, $77.69 in November and $71.90 in December, i.e., weaker year over year.
The news is even more bearish on the natural gas front. In Q4 of 2022, U.S. Henry Hub average natural gas prices were $5.66 per MMBtu in October, $5.45 in November and $5.53 in December. The fuel traded at $2.98, $2.71 and $2.53 per MMBtu in October, November and December, respectively. In other words, natural gas traded noticeably lower in all three months.
On a further bearish note, a relatively weaker macro backdrop is expected to have impacted Chevron’s refined product sales, which is estimated to have declined 1.2% year over year to 2,645 thousand barrels per day.
What Does Our Model Say?
The proven Zacks model does not conclusively show that Chevron is likely to beat estimates in the fourth quarter. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of beating estimates. But that’s not the case here.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, for this company is -0.77%.
Zacks Rank: CVX currently carries a Zacks Rank #3.
Stocks to Consider
While an earnings beat looks uncertain for Chevron, here are some firms from the energy space that you may want to consider on the basis of our model:
MPLX LP (MPLX - Free Report) has an Earnings ESP of +4.65% and a Zacks Rank #3. The firm is scheduled to release earnings on Jan 30.
You can see the complete list of today’s Zacks #1 Rank stocks here.
MPLX beat the Zacks Consensus Estimate for earnings in two of the last four quarters and missed in the other two. It has a trailing four-quarter earnings surprise of 1.5%, on average. Valued at around $38 billion, MPLX has gained 9.3% in a year.
ExxonMobil (XOM - Free Report) has an Earnings ESP of +0.47% and a Zacks Rank #3. The firm is scheduled to release earnings on Feb 2.
ExxonMobil beat the Zacks Consensus Estimate for earnings in two of the last four quarters and missed in the other two. It has a trailing four-quarter earnings surprise of 0.6%, on average. Valued at around $408.2 billion, XOM has lost 9.3% in a year.
Plains All American Pipeline, L.P. (PAA - Free Report) has an Earnings ESP of +6.12% and a Zacks Rank #3. The firm is scheduled to release earnings on Feb 9.
Plains All American Pipeline beat the Zacks Consensus Estimate for earnings in three of the last four quarters and missed in the other. It has a trailing four-quarter earnings surprise of 18.3%, on average. Valued at around $11.4 billion, PAA has gained 31.3% in a year.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Chevron Corporation (CVX) - free report >>
Exxon Mobil Corporation (XOM) - free report >>
|
https://www.zacks.com/stock/news/2216912/chevron-cvx-q4-earnings-coming-up-heres-how-it-will-fare
| 2024-01-30T02:40:43Z
|
blocked_url
|
U.S. stock markets continue to show momentum in January after some initial hiccups following an astonishing 2023. Month to date, the Dow, the S&P 500, and the Nasdaq Composite are up 1.1%, 2.5% and 3%, respectively. Before last week, the S&P 500 and the Nasdaq Composite had completed a six-day winning streak. The Dow and the S&P 500 are currently trading at their historic high levels.
Robust Economic Data for Q4 2023
The Department of Commerce reported that the U.S. economy grew at 3.3% in fourth-quarter 2023, well above the consensus estimate of 2%. The U.S. GDP rose 2.5% in 2023 compared with 1.9% in 2022. At the beginning of 2023, the consensus estimate for full-year GDP was 2%.
The headline personal consumption expenditure (PCE) price index rose 2.7% year over year in third-quarter 2023 compared with 5.1% a year ago. The core PCE price Index (excluding volatile food and energy items) increased 3.2% annually in the same period compared with 5.9% a year ago. The metric is the Fed’s most favored inflation gauge.
In the last quarter, personal consumption expenditures increased 2.8%. The chain-weighted price index rose 1.5% in the third quarter, down from 3.3% in the previous period and below the consensus estimate of 2.5%.
Solid Economic Data for December
The Department of Commerce reported that the headline PCE price Index for December rose 0.2% month over month and 2.6% annually. The core PCE inflation in December increased 0.2% month over month and 2.9% annually.
The annual rate of increase in December was the slowest since March 2021. The consensus estimate was 0.2% and 3%, respectively. In November, core PCE inflation increased 3.2% year over year.
Personal spending in December increased 0.7% month over month, beating the consensus estimate of 0.5%. November’s data was revised upward to 0.4% from 0.2% reported earlier. Personal income increased 0.3% in December compared with 0.4% in November. The personal savings rate fell to 3.7% for the month from 4.1% in November.
An Ideal Situation
A strong U.S. economy along with a steadily dwindling inflation rate, put an end to the fear of a near-term recession and restored hope among market participants that the Fed is likely to achieve the much-hyped soft landing of the economy.
Since July 2023, the central bank has stopped hiking interest rate hike, which is currently in the range of 5.25-5.5%. In its December FOMC meeting, the Fed indicated possible rate cuts of 25 basis points for three times in 2024.
The CME FedWatch tool currently shows a 47.7% probability that the central bank will initiate the first rate cut. The interest rate future tool is also showing the possibility of five rate cuts of 25 basis points in 2024.
At this stage, it should be prudent to invest in U.S. corporate behemoths (market capital > $40 billion) with a favorable Zacks Rank. These companies have a robust business model, a solid financial position and globally acclaimed brand value.
Our Top Picks
We have narrowed our search to five such stocks that have strong potential for 2024. These stocks have seen positive earnings estimate revisions in the last 30 days. Finally, each of our picks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The chart below shows the price performance of our five picks in the past three months.
Image Source: Zacks Investment Research
Netflix Inc. (NFLX - Free Report) added 13.12 million paid subscribers globally in fourth-quarter 2023, with a rise of 1% in average revenue per subscription. NFLX attributed the robust top-line growth to its paid subscription-sharing offering (part of its password-sharing crackdown), recent price changes and the strength of its business in general.
NFLX is expected to continue dominating the streaming space, courtesy of its diversified content portfolio, which is attributable to heavy investments in the production and distribution of localized and foreign-language content.
Netflix has an expected revenue and earnings growth rate of 14.3% and 40.1%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 4.9% over the last seven days.
Arista Networks Inc. (ANET - Free Report) develops markets and sells cloud networking solutions in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. ANET benefits from the expanding cloud networking market, driven by strong demand for scalable infrastructure. The company recently joined the Microsoft Intelligent Security Association.
Arista Networks continues to gain from solid momentum and diversification across its top verticals and product lines. It is well-poised for growth in the data-driven cloud-networking business, with proactive platforms and predictive operations. ANET introduced an enterprise-grade Software-as-a-Service offering for its flagship CloudVision platform.
Arista Networks has an expected revenue and earnings growth rate of 11.5% and 10.1%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.3% over the last 30 days.
Regeneron Pharmaceuticals Inc. (REGN - Free Report) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. REGN’s products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity.
REGN also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics, Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma, Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults, REGEN-COV for COVID-19, and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals has an expected revenue and earnings growth rate of 5.9% and 4.5%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 1.9% over the last 30 days.
The Progressive Corp. (PGR - Free Report) continues to gain on higher premiums, given its compelling product portfolio, leadership position and strength in both Vehicle and Property businesses. Focus on becoming a one-stop insurance destination, catering to customers opting for a combination of home and auto insurance, augurs well for PGR.
Policies in force and retention ratio should remain healthy for PGR. Competitive pricing to retain current customers and address customer needs with new offerings should continue to drive policy life expectancy.
The Progressive has an expected revenue and earnings growth rate of 12.6% and 19.3%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.54% over the last seven days.
The Bank of New York Mellon Corp. (BK - Free Report) has been benefiting from higher rates and a rise in assets under management (AUM) balance. BK’s global expansion efforts, robust AUM balance, digitization of operations and solid balance sheet will likely keep aiding revenues.
The high interest rate environment will likely keep on aiding net interest revenues, while rising funding costs will exert some pressure on BK in the near term. BK’s business transformation plan will bolster market share, leading to higher profit margins.
The Bank of New York Mellon has an expected revenue and earnings growth rate of 0.8% and 2.2%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 4.2% over the last 30 days.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Regeneron Pharmaceuticals, Inc. (REGN) - free report >>
The Bank of New York Mellon Corporation (BK) - free report >>
Netflix, Inc. (NFLX) - free report >>
|
https://www.zacks.com/stock/news/2216913/5-us-corporate-giants-to-buy-on-solid-economic-data
| 2024-01-30T02:40:49Z
|
blocked_url
|
Cencora (COR - Free Report) is scheduled to release first-quarter fiscal 2024 results on Jan 31, before the opening bell.
In the last reported quarter, the company delivered an earnings surprise of 2.51%. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 3.88%.
Please note that Cencora was formerly known as AmerisourceBergen, which changed its name and ticker symbol to Cencora and COR, respectively, effective Aug 30.
Q1 Estimates
The Zacks Consensus Estimate for revenues is pegged at $68.81 billion, indicating an improvement of 9.5% from that reported in the prior-year quarter. The same for earnings is pinned at $2.85 per share, implying growth of 5.2% from the year-ago quarter’s reported number.
Factors to Note
Sustained strong growth in specialty product sales, coupled with broad-based solid performance and utilization trends across the portfolio in the U.S. Healthcare Solutions segment, might have favored COR’s fiscal first-quarter performance. High demand for recently-approved GLP-1 drugs for diabetes and/or weight loss is likely to have boosted growth. Moreover, the new distribution center in California will continue to support its scale of supply.
The commercial COVID-19 treatments recorded lower sales in the past two quarters. This trend is likely to have continued in the soon-to-be-reported quarter. Revenues from the U.S. Healthcare Solutions segment are expected to grow 7-10% in fiscal 2024. This may be reflected in the fiscal first-quarter results as well. Our model expects first-quarter revenues for this segment to be $61.2 billion.
Operating income at the aforementioned segment is anticipated to grow 4-7% in fiscal 2024. This is likely to be reflected in the fiscal first-quarter results. Our model predicts the segment’s adjusted operating income to be $610.5 million.
Apart from this, the International Healthcare Solutions segment’s World Courier unit is expected to have exhibited solid performance in the quarter under review. In fact, the unit’s impressive track record as an international leader in specialty logistics has enabled Cencora to serve customers globally. The company was able to do so despite a challenging COVID-induced environment and additional operational challenges. The addition of PharmaLex in 2023 is also likely to bring additional revenues.
Per the fiscal 2024 guidance, operating income at the International Healthcare Solutions segment is estimated to grow 1-4%. This is likely to be reflected in the upcoming quarterly results. Our model expects the segment’s adjusted operating income and revenues to be $164.6 million and $6.9 billion, respectively.
Although revenues and operating income are likely to be on the higher side, gross margin is likely to get hurt during the soon-to-be-reported quarter due to higher volumes of low-margin GLP-1 products, coupled with lower volumes of high-margin government-owned COVID treatments.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Cencora this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate is 0.00% for COR at present. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #2 at present.
Stocks Worth a Look
Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this reporting cycle.
Dentsply Sirona (XRAY - Free Report) has an Earnings ESP of +6.43% and a Zacks Rank of 3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The stock has fallen 5.2% in the past year. XRAY’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 20.65%.
Merit Medical Systems (MMSI - Free Report) has an Earnings ESP of +3.68% and a Zacks Rank of 2 at present.
The stock has risen 15% in the past year. MMSI’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 14.41%.
AMN Healthcare Services (AMN - Free Report) has an Earnings ESP of +3.42% and a Zacks Rank of 3 at present.
The stock has fallen 22.3% in the past year. COO’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 12.66%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
DENTSPLY SIRONA Inc. (XRAY) - free report >>
Merit Medical Systems, Inc. (MMSI) - free report >>
|
https://www.zacks.com/stock/news/2216914/cencora-cor-to-report-q1-earnings-whats-in-the-cards?
| 2024-01-30T02:40:55Z
|
blocked_url
|
Stryker Corporation (SYK - Free Report) is scheduled to release fourth-quarter 2023 results on Jan 30, after market close. In the last reported quarter, the company delivered an earnings surprise of 0.82%.
Q4 Estimates
The Zacks Consensus Estimate for earnings is pegged at $3.27 per share, indicating an increase of 9% year over year.
The consensus mark for revenues is pinned at $5.6 billion, implying growth of 7.7% from the prior-year quarter’s reported figure.
Factors to Note
Stryker's MedSurg and Neurotechnology segment witnessed substantial sales growth on the back of robust performance of subsegments in the third quarter. Strong performances in Australia, Europe and emerging markets also boosted revenues. This trend is likely to have continued in the fourth quarter.
Growth across Orthopaedics & Spine’s Hip, Knee, and Trauma and Extremities subsegments might have favored the segment's performance on the back of continued procedural growth, strong uptake of the Insignia Hip Stem and the recent launch of Q Guidance Navigation System.
Stryker witnessed both domestic and international growth (in Japan, Korea and emerging markets) in the first nine months of 2023. It is committed to the sustained expansion of Mako, reflecting robust demand for this differentiated robotic technology. This heightened demand is likely to have contributed to the Orthopaedics & Spine segment's performance in the soon-to-be-reported quarter. However, variability in the hospital environment might have offset some of the gains.
The company’s prospects in 2023 seem promising on the back of strong customer demand for its existing as well as new products. However, ongoing hospital staffing pressure and foreign currency movements are likely to have hurt its sales growth.
Procedural volumes in China might have reflected recovery owing to the removal of lockdown restrictions across major cities in the country. However, the current inflationary pressure is likely to have hurt SYK’s net margin, thereby limiting its growth.
Stryker is working toward alleviating the rising inflationary pressure. It is also taking several cost-cutting initiatives, including restructuring plans. Although these steps might have helped boost the company’s growth, they are also likely to drive expenses in the upcoming quarters. However, the company continues to recognize improved pricing in the past couple of quarters. This is likely to have benefited sales in the fourth quarter as well.
SYK continued its full launch of the 1788 camera system in September that witnessed strong demand. The fourth quarter will be a full quarter, following the launch of the camera system. The strong initial uptake is likely to have continued in the soon-to-be-reported quarter, thereby driving additional revenues.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Stryker this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate is 0.00% for SYK at present. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #2 at present.
Stocks Worth a Look
Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this reporting cycle.
Dentsply Sirona (XRAY - Free Report) has an Earnings ESP of +6.43% and a Zacks Rank of 3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The stock has fallen 5.2% in the past year. XRAY’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 20.65%.
Merit Medical Systems (MMSI - Free Report) has an Earnings ESP of +3.68% and a Zacks Rank of 2 at present.
The stock has risen 15% in the past year. MMSI’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 14.41%.
AMN Healthcare Services (AMN - Free Report) has an Earnings ESP of +3.42% and a Zacks Rank of 3 at present.
The stock has fallen 22.3% in the past year. COO’s earnings beat estimates in the last reported quarter. It has a trailing four-quarter average earnings surprise of 12.66%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Stryker Corporation (SYK) - free report >>
DENTSPLY SIRONA Inc. (XRAY) - free report >>
|
https://www.zacks.com/stock/news/2216915/stryker-syk-to-report-q4-earnings-whats-in-the-cards?
| 2024-01-30T02:41:02Z
|
blocked_url
|
Energy Transfer (ET - Free Report) announced that its board of directors has approved a 0.8% increase in its quarterly cash distribution rate. The new distribution rate will be 31.5 cents per unit compared with the previous quarter’s 31.25 cents, payable on Feb 20, 2024, to unitholders of record as of Feb 7, 2024.
This increase resulted in an annualized distribution of $1.26 per unit compared with the previous level of $1.25.
Can Energy Transfer Sustain Distribution Hikes?
Energy Transfer owns and operates a diversified portfolio of energy assets in the United States. The firm benefits from its portfolio of assets with geographic diversity. Its multiple segments generate high-quality and balanced earnings. The partnership's Lake Charles LNG Terminal provides it with a strong foothold in the global LNG business and further boosts its performance.
The majority of the firm’s segment margins are fee-based and, therefore, have limited commodity price sensitivity. In November 2023, Energy Transfer completed its previously announced merger with Crestwood Equity Partners LP.
As a result of the acquisition, the firm now owns and operates more than 125,000 miles of pipelines and related assets in all the major U.S. producing regions, further enhancing its leadership position in the midstream sector. The transaction is immediately accretive to distributable cash flow per unit for Energy Transfer, and adds significant cash flows from firm and long-term contracts.
Energy Transfer has the potential to expand and improve even more, which suggests that management will have sufficient funds to continue with its unitholder-friendly activities in the future.
Oil & Gas Companies Paying Dividends
The oil and gas midstream companies generally earn a steady income through long-term transportation and storage contracts with customers. The stability of performance allows these companies to share profits with shareholders.
In the past few months, some other oil and gas companies like ONEOK, Inc. (OKE - Free Report) , Cheniere Energy, Inc. (LNG - Free Report) and Delek Logistics Partners, LP (DKL - Free Report) have also raised their quarterly dividend and distribution rates by 3.7%, 10% and 1%, respectively.
The Zacks Consensus Estimate for ONEOK’s 2024 earnings is pegged at $4.85 per share, implying a year-over-year decrease of 11.9%. OKE’s current dividend yield is 5.42%.
The Zacks Consensus Estimate for Cheniere Energy’s 2024 earnings is pegged at $10.04 per share, implying a year-over-year decrease of 74.7%. LNG’s current dividend yield is 1.04%.
The Zacks Consensus Estimate for Delek Logistics Partners’ 2024 earnings is pegged at $3.64 per unit, implying a year-over-year increase of 12.4%. The firm reported an earnings surprise of 2.6% in the last quarter.
Price Performance
In the past three months, Energy Transfer’s units have risen 10% compared with the industry’s growth of 6.7%.
Image Source: Zacks Investment Research
Zacks Rank
Energy Transfer currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
ONEOK, Inc. (OKE) - free report >>
Cheniere Energy, Inc. (LNG) - free report >>
|
https://www.zacks.com/stock/news/2216917/energy-transfer-et-raises-quarterly-distribution-rate-by-08
| 2024-01-30T02:41:08Z
|
blocked_url
|
The three mostly followed indexes ended last week positively, hovering near record highs despite a cautious approach by investors. The Dow Jones Industrial Average, the S&P 500, and the tech-heavy Nasdaq Composite gained 0.3%, 0.8%, and 0.6%, respectively.
Several data releases during the week kept investors speculating about the Federal Reserve’s latest policy decision to be revealed this week. The ‘advance’ fourth-quarter GDP showed a 3.3% annualized increase compared to the consensus estimate of 2%. Initial jobless claims rose by 25,000 to 214,000 for the week ending January 20, 2023. Inflation has come down more rapidly than expected and is currently at the lowest levels in the past three years. However, the unexpectedly strong economic growth could lead the Fed to take more time to begin rate cuts.
Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market.
As usual, Zacks Research guided investors over the past three months with its time-tested methodologies. Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action.
Here are some of our key achievements:
Rolls-Royce and LiveRamp Surge Following Zacks Rank Upgrade
Shares of Rolls-Royce Holdings plc (RYCEY - Free Report) have gained 27.8% (versus the S&P 500’s 8.4% increase) since it was upgraded to a Zacks Rank #2 (Buy) on November 20.
Another stock, LiveRamp Holdings, Inc. (RAMP - Free Report) , which was upgraded to a Zacks Rank #1 (Strong Buy) on November 21, has returned 17% (versus the S&P 500’s 7.6% increase) since then.
Zacks Rank, our short-term rating system, has earnings estimate revisions at its core. Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
A hypothetical portfolio of Zacks Rank #1 (Strong Buy) stocks returned +20.63% in 2023 vs. +24.83% for the S&P 500 index and +15% for the equal-weight S&P 500 index. The portfolio of Zacks Rank #1 stocks is an equal-weight portfolio, while the S&P 500 index is a market-cap-weighted index that has been notably distorted by the concentrated performance of mega-cap stocks in 2023.
We are not trying to cherry-pick here. But since this Zacks Model portfolio, consisting of Zacks Rank #1 stocks, is an equal-weight portfolio, the equal-weight S&P 500 index is the appropriate benchmark for comparison. Looked at this way, this portfolio has handily outperformed the index.
The Zacks Model Portfolio - consisting of Zacks Rank #1 stocks – has outperformed the S&P index by more than 13 percentage points since 1988 (Through January 1st, 2024, the Zacks # 1 Rank stocks generated an annualized return of +24.18% since 1988 vs. +10.88% for the S&P 500 index).You can see the complete list of today’s Zacks Rank #1 stocks here >>>
Check Rolls-Royce’s historical EPS and Sales here>>>
Check LiveRamp’s historical EPS and Sales here>>>
Image Source: Zacks Investment Research
Zacks Recommendation Upgrades Hibbett and AvidXchange Higher
Shares of Hibbett, Inc. (HIBB - Free Report) and AvidXchange Holdings, Inc. (AVDX - Free Report) have advanced 14.5% (versus the S&P 500’s 7.3% rise) and 11.4% (versus the S&P 500’s 7.6% rise) since their Zacks Recommendation was upgraded to Outperform on November 24 and November 21, respectively.
While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions.
The Zacks Recommendation classifies stocks into three groups — Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model.
To access our research reports with Zacks Recommendations for the 1100+ stocks we cover, click here>>>
Zacks Focus List Stocks Uber Technologies, Block Shoot Up
Shares of Uber Technologies, Inc. (UBER - Free Report) , which belongs to the Zacks Focus List, have gained 37.2% over the past 12 weeks. The stock was added to the Focus List on August 16, 2019. Another Focus-List holding, Block, Inc. (SQ - Free Report) , which was added to the portfolio on March 28, 2017, has returned 33.5% over the past 12 weeks. The S&P 500 has advanced 12.1% over this period.
The 50-stock Zacks Focus List model portfolio returned +21.72% in 2023 (through November 30) vs. +20.79% for the S&P 500 index and +6.32% for the equal-weight S&P 500 index. In 2022, the portfolio produced -15.2% vs. the S&P 500 index’s -17.96%.
Since 2004, the Focus List portfolio has produced an annualized return of +11.07% through November 30, 2023. This compares to a +9.49% annualized return for the S&P 500 index in the same time period.
On a rolling one-, three- and five-year annualized basis, the Zacks Focus List returned +13.49%, +9.21%, and +14.05% vs. +13.82%, +9.74% and +12.51% for the S&P 500 index, respectively.
Unlock all of our powerful research, tools and analysis, including the Focus List, Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. Gain full access now >>
Zacks ECAP Stocks Costco Wholesale and Thermo Fisher Scientific Make Significant Gains
Costco Wholesale Corporation (COST - Free Report) , a component of our Earnings Certain Admiral Portfolio (ECAP), has jumped 22.5% over the past 12 weeks. Thermo Fisher Scientific Inc. (TMO - Free Report) has followed Costco Wholesale with 20.4% returns.
The Zacks Earnings Certain Admiral Portfolio (ECAP), which consists of 30 concentrated, ultra-defensive, long-term Buy and Hold stocks, returned +12.17% in 2023 vs. +26.28% for the S&P 500 index. The portfolio returned -4.7% in 2022 vs. the S&P 500 index’s -17.96%.
With little to no turnover and annual rebalance periodicity, the ECAP seeks to minimize capital loss by holding shares of companies whose earnings streams exhibit a proven 20+ year track record of surviving recessionary periods with minimal impact on aggregate earnings growth relative to the overall S&P 500.
The ECAP and many other model portfolios are available as part of Zacks Advisor Tools, a cloud-based solution to access Zacks award-winning stock, mutual fund and ETF research. Click here to schedule a demo.
Zacks ECDP Stocks The Home Depot and Intercontinental Exchange Outperform Peers
The Home Depot, Inc. (HD - Free Report) , which is part of our Earnings Certain Dividend Portfolio (ECDP), has returned 20.2% over the past 12 weeks. Another ECDP stock, Intercontinental Exchange, Inc. (ICE - Free Report) , has climbed 17.9% over the same time frame. Of course, the inclination of investors toward quality dividend stocks to secure an income stream amid heightened market volatility contributed to this performance.
Check The Home Depot’s dividend history here>>>
Check Intercontinental Exchange’s dividend history here>>>
With an extremely low Beta and a history of minimum earnings variability over the last 20+ years, this 25-stock portfolio helps significantly mitigate risk.
The Zacks Earnings Certain Dividend Portfolio (ECDP) returned -0.9% in 2023 vs. +26.28% for the S&P 500 index) and +8.11% for the Dividend Aristocrats ETF (NOBL). The portfolio returned -2.3% in 2022 vs. -17.96% for the S&P 500 index and -8.34% for NOBL.
Click here to access this portfolio on Zacks Advisor Tools.
Zacks Top 10 Stocks — e.l.f. Beauty Delivers Solid Returns
e.l.f. Beauty, Inc. (ELF - Free Report) , from the Zacks Top 10 Stocks for 2024, has jumped 8.9% since the list was released on January 2 compared to a 2.6% increase for the S&P 500 Index.
The Top 10 portfolio returned +25.15% in 2023 vs. +26.28% for the S&P 500 index. Since 2012, the Top 10 portfolio has produced a cumulative return of +1060.9% through the end of 2023 vs. +360.1% for the S&P 500 index.
On a rolling one-, three- and five-year annualized basis, the Zacks Top 10 portfolio returned +25.15%, +14.13%, and +29.3% vs. +26.28%, +10.23% and +15.61% for the S&P 500 index, respectively.
Since 2012, the Zacks Top 10 portfolio has returned an annualized return of +22.67% through the end of 2023 vs. +13.56% for the S&P 500 index.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Intercontinental Exchange Inc. (ICE) - free report >>
Thermo Fisher Scientific Inc. (TMO) - free report >>
The Home Depot, Inc. (HD) - free report >>
Costco Wholesale Corporation (COST) - free report >>
Hibbett, Inc. (HIBB) - free report >>
Rolls-Royce Holdings PLC (RYCEY) - free report >>
Block, Inc. (SQ) - free report >>
ProShares S&P 500 Dividend Aristocrats ETF (NOBL) - free report >>
e.l.f. Beauty (ELF) - free report >>
AvidXchange Holdings, Inc. (AVDX) - free report >>
|
https://www.zacks.com/stock/news/2216918/beat-the-market-the-zacks-way-rolls-royce-costco-elf-beauty-in-focus
| 2024-01-30T02:41:14Z
|
blocked_url
|
Dover Corporation (DOV - Free Report) will release fourth-quarter 2023 results on Feb 1, before the opening bell.
Q3 Results
In the last reported quarter, Dover’s earnings were in line with the Zacks Consensus Estimate, while sales missed the same. DOV reported a year-over-year improvement in its bottom line, whereas the top line remained flat year over year. The company has a trailing four-quarter negative surprise of 1.69%, on average.
Q4 Estimates
The Zacks Consensus Estimate for DOV’s fourth-quarter 2023 earnings per share is pegged at $2.45, suggesting growth of 13.4% from the prior-year quarter’s reported level. The same for total revenues is pinned at $2.18 billion, indicating an increase of 1.9% from the prior-year quarter’s reported figure.
Price Performance
Dover’s shares have gained 6.2% in the past year compared with industry’s growth of 16.6%.
Image Source: Zacks Investment Research
Factors at Play
DOV has been witnessing robust bookings and order backlogs across its segments on strong demand and shipment levels, which are likely to have benefited its fourth-quarter performance. Gains from the recent acquisitions are also likely to have contributed to Dover’s performance in the to-be-reported quarter.
The company’s margins have been gaining from a strong volume, an improved price-cost spread and tight cost controls for a while, offsetting the negative impacts of supply-chain constraints, input inflation and production disruptions. These are likely to have driven DOV’s profitability in the quarter under review.
Segmental Estimates
In the Engineered Products segment, the demand for engineered products, vehicle service and industrial automation has been strong, which is expected to get reflected in the December-end quarter top-line results. We expect organic sales growth of 12.3% for the quarter. Improved price-cost dynamics and volume are likely to have offset input shortages. However, our model predicts currency translation to have an unfavorable impact of 1.3% on the segment’s sales.
The Zacks Consensus Estimate for the segment’s fourth-quarter 2023 revenues is pegged at $583 million, suggesting growth of 11.1% from the prior-year quarter’s reading. The consensus estimate for the segment’s adjusted EBITDA is pegged at $124.1 million.
The Clean Energy and Fueling Solutions segment is likely to have gained from growth in below-ground, fuel transport, vehicle wash and industrial gasses in the quarter under review. However, it is expected to have been slightly hampered by subdued demand for above-ground fueling due to customer construction delays in Europe/Asia. The Zacks Consensus Estimate for the segment’s revenues is pegged at $456 million for the quarter to be reported, suggesting a decline of 1.2% from the year-earlier actual.
The consensus estimate for the segment’s adjusted EBITDA is pegged at $97.2 million. We expect unfavorable impacts of currency translation to weigh 1.3% year over year on the segment’s results.
The Imaging & Identification segment's results are expected to reflect strong demand for marking and coding printers and spares, as well as continued strength in consumables. The Zacks Consensus Estimate for the segment’s revenues is pinned at $279 million, suggesting a decrease from the $292 million reported in the prior-year quarter. The Zacks Consensus Estimate for the segment’s adjusted EBITDA is pegged at $75.4 million. We expect organic sales of the segment to fall 1.6% year over year in the quarter.
Robust demand for industrial pumps and polymer processing activity is likely to have aided the Pumps & Process Solutions segment’s fourth-quarter performance. Our model predicts year-over-year growth of 0.1% for the segment’s organic sales. We expect currency translation to have a year-over-year negative impact of 1.2% in the quarter.
The Zacks Consensus Estimate for the segment’s revenues is pegged at $422 million, suggesting growth of 1% from the prior-year quarter’s reported figure. The consensus mark for the segment’s fourth-quarter adjusted EBITDA is pegged at $116.3 million.
In the Climate and Sustainability Technologies segment, strong order rates in the food retail business and large backlogs are likely to have aided the segment’s fourth-quarter performance. Margins are likely to have gained on higher volumes. However, higher costs and impacts of currency translations are likely to have partially offset the tailwind. We anticipate the segment’s organic sales to fall 0.3% year over year in the to-be-reported quarter. Our model predicts currency translation to have a year-over-year negative impact of 0.4% on the segment’s top line.
The Zacks Consensus Estimate for the segment’s quarterly revenues is pegged at $439 million, implying a 0.6% fall from the year-earlier reported figure. The consensus estimate for the segment’s adjusted EBITDA is pegged at $68.8 million.
Here’s What Zacks Model Predicts
Our proven model doesn’t conclusively predict an earnings beat for Dover this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here, as you can see below.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Dover has an Earnings ESP of -1.98%.
Zacks Rank: Dover currently carries a Zacks Rank # 3.
Stocks That Warrant a Look
Here are some companies with the right combination of elements to post an earnings beat in their upcoming releases.
Kubota Corporation (KUBTY - Free Report) , scheduled to release earnings on Feb 13, has an Earnings ESP of +2.64%.
The Zacks Consensus Estimate for KUBTY’s earnings for the fourth quarter is pegged at 72 cents per share. It currently flaunts a Zacks Rank of 1. The consensus estimate for the quarterly earnings has moved 7% north in the past 60 days. It has an average trailing four-quarter earnings surprise of 31.2%.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Reliance Steel & Aluminum Co. (RS - Free Report) , set to release earnings on Feb 15, has an Earnings ESP of +3.35% and a Zacks Rank of 2 at present.
The Zacks Consensus Estimate for RS’ fourth-quarter earnings is pegged at $3.88 per share. Earnings estimates have been unchanged in the past 60 days. The company has an average trailing four-quarter earnings surprise of 10.6%.
Ingersoll Rand Inc. (IR - Free Report) , scheduled to release earnings on Feb 15, currently has an Earnings ESP of +0.98% and a Zacks Rank of 3.
The consensus estimate for Ingersoll Rand’s earnings for the fourth quarter is pegged at 76 cents per share. Earnings estimates have been unchanged in the past 60 days. It has an average trailing four-quarter earnings surprise of 16.1%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Dover Corporation (DOV) - free report >>
Reliance Steel & Aluminum Co. (RS) - free report >>
|
https://www.zacks.com/stock/news/2216919/dover-dov-to-report-q4-earnings-whats-in-the-offing?
| 2024-01-30T02:41:20Z
|
blocked_url
|
How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries.
FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks.
What if you'd invested in Meta Platforms (META - Free Report) ten years ago? It may not have been easy to hold on to META for all that time, but if you did, how much would your investment be worth today?
Meta Platforms' Business In-Depth
With that in mind, let's take a look at Meta Platforms' main business drivers.
Meta Platforms is the world’s largest social media platform. The company’s portfolio offering evolved from a single Facebook app to multiple apps like photo and video sharing app Instagram and WhatsApp messaging app owing to acquisitions. Along with in-house developed Messenger, these apps now form Meta’s family of products used by almost 3.96 billion people on a monthly basis as of Sep 30, 2023.
Newly introduced metric, which is the family daily active people (DAP) that measures daily users of its family of products, was 3.14 billion, as of Sep 30.
Meta uses metrics like daily active users (DAUs) and monthly active users (MAUs) to measure Facebook’s user base. As of Sep 30, 2023, DAUs and MAUs were 2.085 billion and 3.049 billion, respectively.
Headquartered in Menlo Park, CA, Meta generated revenues worth $116.61 billion in 2022. Advertisement accounted for 97.5% of revenues. Marketers buy ads that can appear on multiple platforms including Meta, Instagram, Messenger and third-party applications and websites.
Meta, thanks to its huge user base gained a significant market share in the advertising space wherein it faces tough competition from Google, Twitter, Amazon and Snapchat-parent Snap.
Meta also faces significant competition from the likes of Apple (messaging), YouTube (advertising and video), Bytedance (social media) and Tencent (messaging and social media).
Meta core app enables people to connect, share, discover and communicate with one other on mobile devices and personal computers. User engagement on core Meta platform is fostered by News Feed that displays an algorithmically-ranked series of stories and advertisements customized for each user.
Instagram is a community for sharing photos, videos and messages, enabling people to discover interests that they care about. People can express themselves through photos, videos and private messaging via Instagram Feed and Stories.
Messenger helps people to connect with friends, family, groups and businesses across platforms and devices. WhatsApp is a simple, reliable and secure messaging application, used by people and businesses around the world to communicate in a private way.
Meta also offers virtual reality (VR) products through its Oculus division.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Meta Platforms, if you bought shares a decade ago, you're likely feeling really good about your investment today.
A $1000 investment made in January 2014 would be worth $7,238.57, or a gain of 623.86%, as of January 29, 2024, according to our calculations. This return excludes dividends but includes price appreciation.
In comparison, the S&P 500 gained 173.19% and the price of gold went up 52.70% over the same time frame.
Looking ahead, analysts are expecting more upside for META.
Meta is benefiting from steady user growth across all regions, particularly Asia Pacific. Increased engagement for its offerings like Instagram, WhatsApp, Messenger and Facebook has been a major growth driver. The company is leveraging AI to recommend Reels content, which is driving traffic on Instagram and Facebook. Its innovative portfolio, which includes Threads, Reels and Llama 2, is likely to aid prospects. We expect revenues to witness a CAGR of 12.7% between 2022 and 2025. Advertising revenues are expected to witness a CAGR of 13% per our model estimate. However, challenging macroeconomic conditions remain a headwind for Meta’s advertising revenues, along with targeting and measurement headwinds due to Apple’s iOS changes. Slow monetization of Reels, along with mounting operating losses at Reality Labs, are concerns.
Shares have gained 11.35% over the past four weeks and there have been 4 higher earnings estimate revisions for fiscal 2023 compared to none lower. The consensus estimate has moved up as well.
|
https://www.zacks.com/stock/news/2216921/heres-how-much-a-1000-investment-in-meta-platforms-made-10-years-ago-would-be-worth-today
| 2024-01-30T02:41:26Z
|
blocked_url
|
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Cadence Design Systems (CDNS - Free Report) ten years ago? It may not have been easy to hold on to CDNS for all that time, but if you did, how much would your investment be worth today?
Cadence Design Systems' Business In-Depth
With that in mind, let's take a look at Cadence Design Systems' main business drivers.
Based in San Jose, CA, Cadence Design Systems Inc is a leader in electronic system design space. The company’s Intelligent System Design strategy aids users to transform design concepts into reality by offering computational software, hardware and IP.
Cadence’s core electronic design automation (EDA) software and services enable engineers to develop different types of ICs. Its design IP’s are directly integrated into the ICs.
Cadence reported revenues of $3.562 billion in 2022.
The major product lines are as follows:
Functional verification products (26% of total 2022 revenues) comprise four primary verification engines – JasperGold formal verification platform, Xcelium parallel simulation platform, Palladium Enterprise Emulation Platform and Protium FPGA-Based Prototyping Platform.
Digital IC Design and Signoff (28%) offerings include Genus Synthesis solution, Joules RTL power and Modus software solution. Innovus implementation system is the company’s physical implementation offering. The company’s signoff offerings include the Tempus Timing Signoff Solution, Voltus Power Integrity Solution, Quantus Extraction Solution and Pegasus Physical Verification System.
Custom IC Design and Simulation (22%) includes the Virtuoso custom design platform, Virtuoso Advanced Node, and the Virtuoso RF Solution. The Spectre Simulation Platform offers large-scale verification simulation.
Systems Design & Analysis segment (12%) offers Allegro system interconnect design platform, Fidelity CFD Software and OrCAD solution. The Allegro System Design Platform aids users in carrying out PCB authoring and implementation, PCB library design management and collaboration, signal and power integrity analysis, IC package and system-in-package design.
Under the IP segment (12%), Cadence offers Tensilica digital signal processors (DSPs), vertically targeted subsystems for AI, audio/voice, baseband and vision/imaging applications, controllers and physical interfaces (PHYs) for standard protocols and analog IP.
In 2022, the company derived 44.3% of revenues from United States, while the balance 55.7% came from its international operations.
Bottom Line
While anyone can invest, building a lucrative investment portfolio takes research, patience, and a little bit of risk. If you had invested in Cadence Design Systems ten years ago, you're probably feeling pretty good about your investment today.
According to our calculations, a $1000 investment made in January 2014 would be worth $20,531.78, or a 1,953.18% gain, as of January 29, 2024. Investors should keep in mind that this return excludes dividends but includes price appreciation.
The S&P 500 rose 173.19% and the price of gold increased 52.70% over the same time frame in comparison.
Looking ahead, analysts are expecting more upside for CDNS.
Cadence’s performance is being driven by strength across all segments due to higher customer demand. Accelerated design activity owing to transformative generational trends such as generative AI, hyperscale computing, 5G and autonomous driving is likely to boost the top line going ahead. Management noted that comprehensive JedAI Generative AI platform is witnessing continued momentum, with sales of its GenAI solutions having nearly tripled in the last year. Frequent new product launches and strategic collaborations bode well. Cadence has increased revenue guidance for 2023 to $4.06-$4.1 billion compared with the previous view of $4.05-$4.09 billion. We expect the metric to be $4.08 billion. However, higher research & development costs, stiff competition and weakness prevailing over global macroeconomic conditions remain concerning.
The stock is up 6.74% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 1 higher, for fiscal 2023. The consensus estimate has moved up as well.
|
https://www.zacks.com/stock/news/2216922/heres-how-much-a-1000-investment-in-cadence-design-systems-made-10-years-ago-would-be-worth-today
| 2024-01-30T02:41:32Z
|
blocked_url
|
Equinor ASA, (EQNR - Free Report) the Norwegian state-owned energy giant, awarded a two-year life cycle simulator project to Kongsberg Digital, a fellow Norwegian digital solutions provider, for a gas field located in the North Sea off the coast of Norway. The aim is to boost operational efficiency, enhance training programs and ensure the simulator-based engineering achieves the highest level of fidelity.
The agreement with Equinor, valued at over NOK 25 million (almost $2.4 million), involves the reconstruction of the Sleipner life cycle simulators using Kongsberg Digital's K-Spice and LedaFlow simulation technologies. Kongsberg Digital anticipates that this project will significantly increase the simulation capabilities of the Sleipner area in the North Sea.
Shane McArdle, CEO of Kongsberg Digital, expressed appreciation for the collaboration with Equinor on the Sleipner life cycle simulator project, emphasizing the company’s dedication to delivering comprehensive, trustworthy and reliable digital solutions to the energy sector.
The development of three simulators — Engineering Study Simulator, Engineering Test Simulator and Operator Training Simulator — utilizing K-Spice and LedaFlow simulation technologies aims to provide a comprehensive life cycle simulator engineering and training tool environment for multidisciplinary operation and engineering teams. Additionally, these simulators will replicate the processes of all wells, pipelines, and offshore production facilities for three distinct assets of the Sleipner installations — the processing, drilling, and living quarter platform (Sleipner A), the unmanned production platform (Sleipner B), and the processing and CO2 removal platform (Sleipner T). The project will involve utilizing K-Spice Power to model the power grid.
The Sleipner life cycle simulator project is slated to begin in the first quarter of 2024, with an estimated completion by the end of 2025. This two-year project is anticipated to develop a dynamic simulator model incorporating topside process simulation models using K-Spice and multiphase flow models of production wells and flowlines using the LedaFlow software.
McArdle expressed confidence that the Sleipner asset will experience significant advantages in operational efficiency, troubleshooting analysis and training opportunities through the utilization of Kongsberg’s technologies.
Zacks Rank & Key Picks
Equinor currently carries a Zack Rank #3 (Hold).
Some better-ranked stocks in the energy sector are Sunoco LP (SUN - Free Report) , Oceaneering International, Inc. (OII - Free Report) and Enbridge Inc. (ENB - Free Report) . While both Sunoco and Oceaneering International sport a Zacks Rank #1 (Strong Buy), Enbridge carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Sunoco is among the biggest motor fuel distributors in the U.S. wholesale market in terms of volumes. By distributing more than 10 fuel brands via 10,000 convenience stores under long-term distribution contracts, the partnership will continue to generate stable cash flow.
SUN’s earnings beat estimates in two of the trailing four quarters and missed twice, delivering an average surprise of 28.33%.
Oceaneering International is a leading provider of integrated technology solutions, active at all phases of the offshore oilfield lifecycle. Its strong relationship with high-quality customers provides revenue visibility and business certainty. OII is well-positioned to supply equipment for deep-water projects.
Enbridge has an extensive oil and liquid pipeline system that spreads across 17,809 miles. A significant portion of the midstream operator’s earnings is generated from transportation operations, driven by a string of long-term contracts. ENB anticipates substantial cash flows from the recently completed midstream projects.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Sunoco LP (SUN) - free report >>
Oceaneering International, Inc. (OII) - free report >>
|
https://www.zacks.com/stock/news/2216923/equinor-eqnr-taps-kongsberg-for-nok-25m-simulator-project
| 2024-01-30T02:41:39Z
|
blocked_url
|
Shell plc’s (SHEL - Free Report) subsidiary, Shell Deutschland GmbH, announced a final investment decision regarding the transformation of the hydrocracker at its Wesseling site within the Rheinland chemicals complex in Germany. The existing facility, previously dedicated to producing distillate fuels and feedstocks, is set to be transformed into a cutting-edge production unit for base oils — a vital component in the creation of engine and transmission oils. Crude oil processing will be completed at the Wesseling site in 2025, but will keep going at the Godorf site. The implications of this strategic decision extend beyond the borders of Germany, impacting the entire European Union's (EU) demand for base oils.
Understanding Hydrocracking Technology
A hydrocracker, as the core technology behind this transformation, is instrumental in converting heavy, low-quality hydrocarbons into lighter, high-quality products. These products include not only fuels like gasoline, jet fuel and diesel, but also chemical feedstocks and base oil feedstocks. The hydrocracking process involves a high-pressure, high-temperature reaction between hydrocarbons and hydrogen, facilitated by a catalyst.
Shell's Vision: A Shift Toward Sustainable Energy
Shell's forward-thinking approach is not just about a shift in production but also a commitment to environmental sustainability. The new base oil plant, anticipated to commence operations in the second half of the 2020s, boasts an impressive production capacity of 300,000 metric tons per year. This capacity is not merely a numerical figure, it signifies approximately 9% of the current demand for base oils within the EU and a staggering 40% of Germany's internal demand.
Electrification for a Greener Tomorrow
A key aspect of this transformation is the electrification of the newly established base oil plant. Shell envisions a future where traditional crude oil processing for fuels at the Wesseling site is replaced with cleaner, more sustainable practices. This strategic move is not only a testament to Shell's commitment to eco-friendly operations but also a step toward reducing its overall scope 1 and 2 carbon emissions.
Environmental Impact and Net Zero Goals
By shifting focus toward base oil production and terminating crude oil processing for fuels at the Wesseling site, Shell expects to decrease its carbon emissions by 620,000 tons per year. This substantial reduction aligns with Shell's ambitious goal of becoming a net-zero emissions energy business by 2050. It emphasizes the company's determination to play a key role in combating climate change and implementing a sustainable future.
Rheinland Complex: A German Industrial Powerhouse
The Rheinland complex, owned by Shell, is the largest of its kind in Germany and includes the Wesseling and Godorf sites. Currently, the complex can process more than 17 million tons of crude oil annually, with 7.5 million tons processed at the Wesseling site.
The Economic Implications
Beyond its environmental impact, Shell's transformative decision carries significant economic implications. The Rheinland complex, with its expanded focus on base oil production, is poised to become a major player in the European market. The increase in production capacity aligns with the growing demand for high-quality base oils in the region, promising economic growth and job creation.
Conclusion
Shell's commitment to converting the hydrocracker at the Wesseling site into a base oil production unit marks a milestone in the transition toward sustainable energy practices. The electrification of the new plant, coupled with the cessation of crude oil processing for fuels, not only positions Shell as an industry leader but also highlights its dedication to environmental responsibility. The Rheinland complex's role in this transformation highlights its significance as a key player in Germany's industrial landscape.
Zacks Rank and Key Picks
Currently, SHEL carries a Zacks Rank #3 (Hold).
Investors interested in the energy sector might look at some better-ranked stocks like Sunoco LP (SUN - Free Report) and Oceaneering International, Inc. (OII - Free Report) , both sporting a Zacks Rank #1 (Strong Buy), and Enbridge Inc. (ENB - Free Report) , carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Headquartered in Dallas, TX, Sunoco is valued at $5.85 billion. The company currently pays a dividend of $3.37 per share, or 5.78%, on an annual basis.
Sunoco, along with its subsidiaries, distributes and retails motor fuels in the United States. It operates under two segments — Fuel Distribution and Marketing and All Other.
Oceaneering International is worth $2.17 billion. In the past year, its shares have risen 3.7%.
The company provides engineered services and products, and robotic solutions to the offshore energy, defense, aerospace, manufacturing and entertainment industries worldwide.
Enbridge is valued at $76.33 billion. The company currently pays a dividend of $2.6 per share, or 7.24%, on an annual basis.
Enbridge and its subsidiaries are an energy infrastructure company with five segments — Liquids Pipelines, Gas Transmission and Midstream, Gas Distribution and Storage, Renewable Power Generation and Energy Services.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Sunoco LP (SUN) - free report >>
Oceaneering International, Inc. (OII) - free report >>
|
https://www.zacks.com/stock/news/2216924/shells-shel-wesseling-site-shifts-focus-to-base-oils
| 2024-01-30T02:41:45Z
|
blocked_url
|
Petrobras (PBR - Free Report) , a Brazilian state-run oil company, reported a significant surge in its 2023 output. According to a recent securities filing, Petrobras' daily output rose to an impressive 2.78 million barrels of oil equivalent per day (boepd) in the previous year, marking a robust 3.7% increase from the 2022 level.
Production Breakdown
Commercial Production Highlights: Production of oil and natural gas reached a formidable 2.44 million boepd, with oil production alone totaling an impressive 2.24 million barrels per day (bpd). This remarkable achievement is attributed to the successful ramp-up of four offshore platforms, per Petrobras' November projection.
Proven Reserves Growth: PBR has not only boosted its production but also increased its proven oil, condensate and natural gas reserves by 3.8%, reaching 10.9 billion barrels of oil equivalent in 2023, up from 10.5 billion boe in 2022. Of this substantial reserve, 84% comprises oil and condensate, while the remaining 16% constitutes natural gas.
Hydrocarbon Discoveries in Equatorial Margin: A key moment for Petrobras includes the discovery of hydrocarbons in its first Equatorial Margin well, Pitu Oeste. Situated approximately 52 kilometers off the coast of Rio Grande do Norte state, this location is part of a potentially oil-rich region extending along the Brazilian coast from Rio Grande do Norte to Amapa states.
While the discovery is monumental, Petrobras remains cautious about declaring its economic viability conclusively. The company confirmed its findings but did not make firm statements about the project's feasibility.
Strategic Plans and Investments
Upcoming Drilling Endeavors: Undeterred by uncertainties, Petrobras gears up for further exploration. The company is set to drill a second well, approximately 79 kilometers off the coast of Rio Grande do Norte and in proximity to Pitu Oeste. This strategic move aligns with Petrobras' commitment to unlocking the full potential of the Equatorial Margin.
Investment Outlook: Under Petrobras' ambitious 2024-2028 strategic plan, a substantial investment of $3.1 billion is reserved for oil and gas research in the Equatorial Margin. The company envisions drilling a total of 16 wells during this period, signaling a resolute commitment to harnessing the region's energy resources.
Conclusion
Petrobras' notable achievements in production, reserve growth and hydrocarbon discoveries paint a promising future for Brazil's energy sector. The company's strategic plans highlight its commitment to innovation and exploration, setting the stage for sustained growth in the years to come.
Zacks Rank and Key Picks
Currently, PBR carries a Zacks Rank #3 (Hold).
Investors interested in the energy sector might look at some better-ranked stocks like Sunoco LP (SUN - Free Report) and Oceaneering International, Inc. (OII - Free Report) , both sporting a Zacks Rank #1 (Strong Buy), and Enbridge Inc. (ENB - Free Report) , carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Headquartered in Dallas, TX, Sunoco is valued at $5.85 billion. The company currently pays a dividend of $3.37 per share, or 5.78%, on an annual basis.
Sunoco, along with its subsidiaries, distributes and retails motor fuels in the United States. It operates under two segments — Fuel Distribution and Marketing and All Other.
Oceaneering International is worth $2.17 billion. In the past year, its shares have risen 3.7%.
The company provides engineered services and products, and robotic solutions to the offshore energy, defense, aerospace, manufacturing and entertainment industries worldwide.
Enbridge is valued at $76.33 billion. The company currently pays a dividend of $2.6 per share, or 7.24%, on an annual basis.
Enbridge and its subsidiaries are an energy infrastructure company with five segments — Liquids Pipelines, Gas Transmission and Midstream, Gas Distribution and Storage, Renewable Power Generation and Energy Services.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Petroleo Brasileiro S.A.- Petrobras (PBR) - free report >>
Sunoco LP (SUN) - free report >>
|
https://www.zacks.com/stock/news/2216926/petrobras-pbr-increases-oil-and-gas-output-by-37-in-2023
| 2024-01-30T02:41:51Z
|
blocked_url
|
The Boeing Company’s (BA - Free Report) Defense, Space & Security segment is likely to have recorded impressive fourth-quarter 2023 revenues, owing to solid sales from space programs as well as higher deliveries of its defense products.
However, higher estimated costs from the VC-25B program are likely to have had an adverse impact on the BDS segment’s bottom line.
Boeing’s fourth-quarter and full-year 2023 results are scheduled to be released on Jan 31.
Click here to know how the company’s overall performance might have been in the soon-to-be-reported quarter.
Steady Order Flow to Aid Backlog
With the U.S. administration spending significantly on the nation’s defense capabilities for the past few years, Boeing Defense, Space & Security (BDS) unit has been witnessing solid order flow from the Pentagon, NASA and Congress for its varied products. Moreover, the diverse regional threats witnessed across Asia, Europe and the Middle East have also been offering growth opportunities for this unit’s products.
Consequently, Boeing has been witnessing a solid global demand for its major combat programs, which translated into an overall order value of $6 billion for the BDS unit in the third quarter. Such solid order values thereby bolster the BDS segment’s backlog.
We expect the upcoming results to reflect a similar order count for the unit, thereby once again bolstering its backlog figure.
Will Improved Deliveries Aid Q4 Performance?
Boeing’s fourth-quarter defense delivery figures indicate an improvement of 12.5% from the year-ago period’s level.
Its defense deliveries totaled 54 in the quarter, up from 48 in the prior-year quarter. Such improved delivery figures are expected to have bolstered the defense segment’s revenues in the soon-to-be-reported quarter. Moreover, increased sales from space and proprietary programs are also projected to have boosted the BDS unit’s top-line performance.
The Zacks Consensus Estimate for the defense unit’s revenues is pegged at $6,267.7 million, indicating an improvement of 1.4% year over year.
Earnings Prospect
Strong order activities in the previous quarters as well as lower charges from development programs, as BA progresses in these programs, are expected to have favorably contributed to BDS’ earnings performance.
However, higher estimated costs from the VC-25B program are likely to have had an adverse impact on the BDS segment’s bottom line. Moreover, the impact of supply-chain constraints might have hurt its overall fourth-quarter earnings.
Notably, the bottom-line estimate for the company’s defense unit is pegged at a loss of $233.2 million, indicating a deterioration from the year-ago quarter’s reported earnings of $112 million.
What the Zacks Model Unveils
According to the Zacks model, the combination of two key ingredients — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) — increases the odds of an earnings beat. That is the case here.
Boeing has an Earnings ESP of +12.32% and a Zacks Rank #3 at present. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Other Stocks to Consider
Below are two other defense stocks that also have the right combination of elements to post an earnings beat this time around.
CAE Inc. (CAE - Free Report) is slated to release third-quarter fiscal 2024 results on Feb 14. CAE has an Earnings ESP of +7.18% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
CAE delivered a four-quarter average earnings surprise of 15.97%. The consensus estimate for fiscal third-quarter earnings is pegged at 18 cents per share, while that for sales is pinned at $800.7 million.
Leidos (LDOS - Free Report) is scheduled to release fourth-quarter results on Feb 13. LDOS has an Earnings ESP of +1.88% and a Zacks Rank #2 at present.
Leidos delivered a four-quarter average earnings surprise of 11.51%. The Zacks Consensus Estimate for LDOS’ fourth-quarter earnings is pegged at $1.73 per share, while that for sales is pinned at $3.79 billion.
A Recent Defense Release
RTX Corporation’s (RTX - Free Report) fourth-quarter 2023 adjusted earnings per share (EPS) of $1.29 beat the Zacks Consensus Estimate of $1.25 by 3.2%. The bottom line also improved 1.6% from the year-ago quarter’s level of $1.27.
RTX’s fourth-quarter adjusted sales totaled $19,824 million. The company reported GAAP sales of $19,927 million compared with $18,093 million in the fourth quarter of 2022.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
The Boeing Company (BA) - free report >>
CAE Inc (CAE) - free report >>
|
https://www.zacks.com/stock/news/2216928/will-improved-defense-deliveries-boost-boeings-ba-q4-earnings?
| 2024-01-30T02:41:57Z
|
blocked_url
|
Investors are always looking for stocks that are poised to beat at earnings season and Chubb Limited (CB - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Chubb is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for CB in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at $5.13 per share for CB, compared to a broader Zacks Consensus Estimate of $5.07 per share. This suggests that analysts have very recently bumped up their estimates for CB, giving the stock a Zacks Earnings ESP of +1.27% heading into earnings season.
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that CB has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Chubb, and that a beat might be in the cards for the upcoming report.
|
https://www.zacks.com/stock/news/2216929/should-you-buy-chubb-cb-ahead-of-earnings?
| 2024-01-30T02:42:04Z
|
blocked_url
|
Investors are always looking for stocks that are poised to beat at earnings season and Danaher Corporation (DHR - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Danaher is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for DHR in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at $1.96 per share for DHR, compared to a broader Zacks Consensus Estimate of $1.89 per share. This suggests that analysts have very recently bumped up their estimates for DHR, giving the stock a Zacks Earnings ESP of +3.46% heading into earnings season.
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that DHR has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Danaher, and that a beat might be in the cards for the upcoming report.
|
https://www.zacks.com/stock/news/2216930/why-danaher-dhr-might-surprise-this-earnings-season
| 2024-01-30T02:42:10Z
|
blocked_url
|
Tullow Oil plc (TUWOY - Free Report) , an exploration and production company based in Europe, recently released an update on its performance in 2023. The company also released its outlook for 2024. It will declare full-year 2023 results in March.
Operational and Financial Highlights of 2023
In a statement prior to the full-year results, the company declared that its full-year working interest production averaged 63 thousand barrels of oil equivalent per day (kboepd), including 6 kboepd of Jubilee Gas.
The Jubilee facility faced water injection issues in 2023. These issues have been resolved, according to the latest updates. Despite some setbacks, TUWOY reported outstanding drilling performance with four Jubileeproduction wells and three Jubilee water injection wells coming online, and a significant increase in Jubilee production, which surpassed 100 kboepd after the start-up of Jubilee South East.
The company continues its portfolio optimization efforts with the sale of the Orinduik license in Guyana. TUWOY plans to continue focusing on core production assets.
The upstream player generated $1.6 billion in revenues in 2023, 25% higher than $1.28 billion in the previous year. The average realized oil price was $77.5 per barrel (post-hedging). The revenues also include hedging costs of around $140 million.
For 2023, capital expenditures were quoted at $380 million. The company generated free cash flows of $170 million, which surpassed the guidance.
The company reduced net debt by $250 million, ending the year with $1.6 billion net debt. Gross debt was reduced $400 million through tenders of the 2025 and 2026 notes and annual amortizations.
The company secured a $400 million debt facility with Glencore as a part of its refinancing strategy. It was also engaged in the commercialization of Ghana gas through an interim sales agreement generating around $30 million in revenues.
Outlook for 2024
For 2024, the working interest production is expected to be in the range of 62-68 kboepd, including 7 kboepd of gas.
In 2024, five Jubilee wells are expected to come onstream, out of which three are production wells and the rest are water injecting wells. This means that the drilling activity will be completed approximately six months ahead of schedule.
Tullow and its joint venture partners plan to take a drilling break in Ghana, later in 2024. Jubilee’s production during the break will be maintained by the existing wells in production. The company also continues to effectively minimize the decline in production at the TEN fields.
TUWOY has forecasted 2024 capital expenditures of $250 million. Approximately 60% of this figure will be allotted to Jubilee, whereas 25% is earmarked for non-operated assets.
The company has set up the hedge portfolio to protect 60% of the forecasted sales volumes at a price of $58 per barrel on average. Once the legacy hedges expire, it anticipates significant exposure to oil price upside from June. Reflecting on the previous statement, Tullow has fixed 20% of sales volumes at $114 per barrel during June-December.
According to a representative at Tullow, the firm is progressing toward its target of generating $800 million free cash flows over the 2023-2025 period, with more than $600 million free cash flows to be generated between 2024 and 2025 at an estimated price of $80 per barrel. The company also aims to conclude the year with a net debt of less than $1.4 billion.
In conclusion, TUWOY’s 2024 outlook seems positive with its plans to generate increased free cash flows and continued efforts toward reducing debt.
Zacks Rank and Key Picks
Currently, TUWOY carries a Zacks Rank #4 (Sell).
Investors might want to look at some better-ranked stocks in the energy sector, such as Vaalco Energy (EGY - Free Report) , Enbridge (ENB - Free Report) and Harbour Energy (HBRIY - Free Report) . While Vaalco currently sports a Zacks Rank #1 (Strong Buy), Enbridge and Harbour Energy hold a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Vaalco Energy is an independent energy company involved in upstream operation business with a diversified presence in Africa and Canada. Having a large inventory of drilling locations in premium Canadian Acreage, the company’s production outlook seems bright.
Enbridge is an energy infrastructure company with a diversified portfolio of midstream assets. With a huge network of transportation and storage assets, the company derives stable fee-based revenues.
Harbour Energy is a leading independent oil and gas company, primarily involved in upstream operations. Upon completion of the recently announced acquisition of Wintershall Dea asset portfolio, Harbour’s estimated production will increase to 500,000 barrels of oil equivalent per day. The company has also done well in reducing its debt in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Enbridge Inc (ENB) - free report >>
Vaalco Energy Inc (EGY) - free report >>
|
https://www.zacks.com/stock/news/2216931/tullows-tuwoy-free-cash-flows-surpass-2023-guidance
| 2024-01-30T02:42:16Z
|
blocked_url
|
Honeywell International Inc. (HON - Free Report) is likely to witness top-and-bottom-line growth when it reports fourth-quarter 2023 results on Feb 1 before the opening bell. The Zacks Consensus Estimate for revenues is pegged at $9,703 million, which suggests growth of 5.6% from the prior-year quarter’s reported figure.
The consensus mark for earnings is pinned at $2.60 per share, which has improved by a penny in the past 60 days. The figure indicates a jump of 3.2% from the figure reported in the prior-year quarter. The company’s bottom line surpassed the Zacks Consensus Estimate by 2.3% in the last reported quarter. It has a trailing four-quarter earnings surprise of 3%, on average.
Image Source: Zacks Investment Research
In the past three months, HON’s shares have gained 12.3% compared with the industry’s growth of 11.5%.
Let’s see how things have shaped up for Honeywell this earnings season.
Key Factors and Estimates for Q4
Strength across Honeywell’s commercial aviation aftermarket business, supported by stable demand in the air transport market, is likely to have supplemented the top-line performance of its Aerospace segment in the fourth quarter. Also, strength in the company’s commercial aviation original equipment business, backed by solid orders, is likely to have boosted its performance. Solid momentum in the defense and space business is also expected to have been a tailwind for the segment.
For the fourth quarter, we expect the company’s Aerospace segment revenues to increase 18.2% year over year to $3,785.5 million. Our estimate for the segment’s operating profit hints at a year-over-year increase of 17.3%.
The Performance Materials and Technologies (“PMT”) segment is expected to generate a year-over-year increase in revenues, driven by strength in process solutions and UOP operations. The segment’s operations are likely to have performed strongly, driven by solid gas processing and petrochemical catalyst shipments, along with robust demand in the sustainable technology solutions business. However, lower volumes in the advanced materials business due to softness in electronics, chemicals and life science businesses might have been a spoilsport.
Our estimate for PMT revenues in the fourth quarter is pegged at $3,087.4 million, indicating 7.9% growth from the year-ago reported number. We expect the segment’s operating profit to increase 10.4% on a year-over-year basis.
Solid orders for building projects, particularly in the energy space, are likely to have supported the Building Technologies segment in the to-be-reported quarter. Our estimate for Building Technologies revenues is pegged at $1,544.3 million, indicating a 2% improvement from the year-ago reported number. We expect the segment’s operating profit to increase 4.7% on a year-over-year basis.
However, Honeywell’s Safety and Productivity Solutions segment is expected to put up a weak show in the to-be-reported quarter due to lower warehouse, workflow and productivity solutions volumes owing to weakness in the warehouse automation market. We expect the segment’s revenues to decline 21.1% on a year-over-year basis. Our estimate for the segment’s operating profit suggests a 32.1% decline from the year-ago reported figure.
Given HON’s extensive presence in international markets, foreign currency headwinds might have affected its top line in the soon-to-be-reported quarter. Also, the company’s bottom line is expected to reflect the impact of raw material cost inflation.
What the Zacks Model Unveils
Our proven model doesn’t conclusively predict an earnings beat for Honeywell this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as elaborated below.
Earnings ESP: Honeywell has an Earnings ESP of -1.05%, as the Most Accurate Estimate is pegged at $2.57, lower than the Zacks Consensus Estimate of $2.60. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3.
Stocks With the Favorable Combination
Here are three companies that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in the upcoming release:
Griffon Corporation (GFF - Free Report) has an Earnings ESP of +2.08% and sports a Zacks Rank #1. The company is slated to release fourth-quarter results on Jan 30. You can see the complete list of today’s Zacks #1 Rank stocks here.
GFF delivered a trailing four-quarter earnings surprise of 28.6%, on average. The stock has rallied 50.8% in the past three months.
Danaher Corporation (DHR - Free Report) has an Earnings ESP of +3.46% and a Zacks Rank #3. The company is slated to release fourth-quarter results on Jan 30.
Danaher delivered a trailing four-quarter earnings surprise of 8.5%, on average. The stock has rallied 25.9% in the past three months.
Xylem Inc. (XYL - Free Report) has an Earnings ESP of +1.40% and a Zacks Rank #3. The company is slated to release fourth-quarter results on Feb 6.
Xylem delivered a trailing four-quarter earnings surprise of 14.4%, on average. The stock has rallied 25.9% in the past three months.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Honeywell International Inc. (HON) - free report >>
Danaher Corporation (DHR) - free report >>
|
https://www.zacks.com/stock/news/2216933/honeywell-hon-gears-up-to-post-q4-earnings-what-to-expect?
| 2024-01-30T02:42:22Z
|
blocked_url
|
Associated Banc-Corp’s (ASB - Free Report) fourth-quarter 2023 adjusted earnings of 53 cents per share beat the Zacks Consensus Estimate by a penny. However, the bottom line compared unfavorably with the prior-year quarter’s earnings of 70 cents.
Results benefited from higher adjusted non-interest income and a rise in the deposit balance. However, a decline in net interest income (NII), an increase in expenses and provisions and a lower loan balance were headwinds. Hence, because of these concerns, investors turned bearish on the stock, which decreased 1.1% since the release of results last week.
Results excluded certain one-time items. After considering those, the net loss available to common shareholders was $93.7 million against the net income of $105.9 million in the year-ago quarter.
For 2023, adjusted earnings per share of $2.27 met the consensus estimate. Net income available to common shareholders was $171.5 million, down 52% year over year.
Adjusted Revenues Decline, Expenses Rise
Adjusted net revenues (FTE basis) were $322.2 million, down 9% year over year. The top line missed the Zacks Consensus Estimate of $326 million.
NII was $253.4 million, down 12%. Our estimate for NII was $260.1 million.
The net interest margin was 2.69%, down 62 basis points (bps) year over year. We had expected the net interest yield to be 2.71%.
The non-interest loss was $131 million in the reported quarter. Excluding the loss on mortgage portfolio sale and investment securities loss, adjusted non-interest income came in at $64.2 million, up from $61.7 million in the prior-year quarter. Our estimate for the non-interest income was $62.1 million.
Non-interest expenses increased 22% to $239.4 million. These included the FDIC special assessment charge of $39 million. Excluding this, adjusted expenses were $209 million. The rise was due to an increase in all cost components except loan and foreclosure costs, occupancy and equipment. Our estimate for non-interest expenses was $203.1 million and did not include the abovementioned non-recurring charge.
The FTE efficiency ratio was 127.5%, up from 54.08% in the prior-year quarter. A rise in the efficiency ratio indicates a deterioration in profitability.
As of Dec 31, 2023, total loans were $29.2 billion, down 3% from the Sep 30, 2023 level. Total deposits increased 4% to $33.6 billion.
Credit Quality Worsens
In the reported quarter, ASB recorded a provision for credit losses of $21 million, up 5% from the prior-year quarter. Our estimate for the metric was $23.1 million.
As of Dec 31, 2023, total non-performing assets were $160.4 million, up 27%. Total non-accrual loans were $149 million, rising 34%.
Net charge-offs were $21 million, up substantially from $2 million in the prior-year quarter.
Capital Ratios Improve
As of Dec 31, 2023, the Tier 1 risk-based capital ratio was 9.99%, up from the 9.95% recorded in the corresponding period of 2022. The common equity Tier 1 capital ratio was 9.39%, up from 9.35%.
2024 Outlook
Management expects loan growth of 4-6%.
Total core customer deposits are estimated to rise 3-5%.
NII is projected to increase 2-4%. After adjusting to exclude the impact of non-recurring items related to the balance sheet repositioning announced in the fourth quarter of 2023, total non-interest income is expected to remain stable or decrease 2%.
After adjusting to exclude the impact of the FDIC special assessment, total non-interest expenses are anticipated to rise 2-3%.
The effective tax rate is expected to be 19-21%.
Our Take
Associated Banc-Corp’s business-restructuring efforts are likely to keep supporting financials. The company has a solid balance sheet position, making it well-poised for growth. However, elevated expenses and provisions are likely to hurt profits in the near term.
ASB currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance of Other Banks
East West Bancorp’s (EWBC - Free Report) fourth-quarter 2023 adjusted earnings per share of $2.02 surpassed the Zacks Consensus Estimate of $1.89. However, the bottom line declined 14.8% from the prior-year quarter.
Including FDIC special assessment-related expenses and gain on the sale of available-for-sale debt security, EWBC’s earnings per share were $1.69.
Results were primarily aided by an increase in non-interest income. Also, loan balances increased sequentially in the quarter, which was an upside. However, lower NII and higher expenses and provisions were the undermining factors for EWBC.
Webster Financial’s (WBS - Free Report) fourth-quarter 2023 adjusted earnings per share of $1.46 were in line with Zacks Consensus Estimate. This compares favorably with earnings of $1.38 per share a year ago.
Results benefited from lower provisions and solid loans and deposit balances. However, a fall in both NII and non-interest income, along with elevated expenses, was the major headwind for WBS.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Webster Financial Corporation (WBS) - free report >>
|
https://www.zacks.com/stock/news/2216936/associated-banc-corp-asb-down-11-despite-q4-earnings-beat
| 2024-01-30T02:42:30Z
|
blocked_url
|
Investors are always looking for stocks that are poised to beat at earnings season and Alphabet Inc. (GOOGL - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Alphabet is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for GOOGL in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at $1.64 per share for GOOGL, compared to a broader Zacks Consensus Estimate of $1.60 per share. This suggests that analysts have very recently bumped up their estimates for GOOGL, giving the stock a Zacks Earnings ESP of +2.26% heading into earnings season.
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that GOOGL has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Alphabet, and that a beat might be in the cards for the upcoming report.
|
https://www.zacks.com/stock/news/2216937/is-a-surprise-coming-for-alphabet-googl-this-earnings-season?
| 2024-01-30T02:42:36Z
|
blocked_url
|
Investors are always looking for stocks that are poised to beat at earnings season and United Parcel Service, Inc. (UPS - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because United Parcel Service is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for UPS in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at $2.48 per share for UPS, compared to a broader Zacks Consensus Estimate of $2.44 per share. This suggests that analysts have very recently bumped up their estimates for UPS, giving the stock a Zacks Earnings ESP of +1.69% heading into earnings season.
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that UPS has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for United Parcel Service, and that a beat might be in the cards for the upcoming report.
|
https://www.zacks.com/stock/news/2216940/why-united-parcel-service-ups-might-surprise-this-earnings-season
| 2024-01-30T02:42:43Z
|
blocked_url
|
Apellis Pharmaceuticals (APLS - Free Report) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has voted against the approval of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
The negative opinion of the CHMP was expected as the company previously announced a negative trend vote on the marketing authorization application (MAA) for pegcetacoplan following an oral explanation meeting in December 2023.
Per the latest press release, Apellis is currently gearing up to seek immediate re-examination of its application.
The stock fell 3.3% in the last trading session, following the disappointing regulatory update for intravitreal pegcetacoplan. Shares of the company lost 2.4% during the after-market hours. In the past year, shares of APLS have risen 21.4% against the industry’s 14.1% decline.
Image Source: Zacks Investment Research
The MAA submission to the EMA was based on positive 24-month results from the company’s late-stage OAKS and DERBY studies. It was observed that both every-other-month and monthly treatment with pegcetacoplan reduced GA lesion growth with increasing treatment effects over time.
The drug also demonstrated a favorable safety profile. Furthermore, treatment with pegcetacoplan preserved visual function longer in multiple post hoc phase III analyses.
GA is a progressive and irreversible form of vision loss that takes a severe toll on the patient’s quality of life. Per Apellis, more than 2.5 million people in the EU are currently living with GA.
We remind the investors that pegcetacoplan injection is currently approved in the United States under the brand name Syfovre for treating GA secondary to AMD.
Syfovre was approved by the FDA in February 2023 as the first and only treatment for GA secondary to AMD in the United States. Marketing authorization seeking applications for intravitreal pegcetacoplan for the treatment of GA is currently under review in several other countries as well. Approvals from respective regulatory bodies in different countries are expected in the first half of 2024.
Apellis also currently markets pegcetacoplan under the brand name Empaveli as a monotherapy treatment for adult patients suffering from Paroxysmal Nocturnal Hemoglobinuria (PNH).
APLS has seen a strong uptake of Empaveli in recent quarters. Empaveli is currently approved in the EU under the brand name Aspaveli (pegcetacoplan) for the treatment of adult patients with PNH who are anemic after treatment with a C5 inhibitor for at least three months.
Empaveli therapy is also being evaluated for several other rare diseases across hematology and nephrology.
Apellis recently reported strong fourth-quarter 2023 preliminary U.S. revenues, primarily driven by Syfovre’s stellar performance.
Zacks Rank and Other Stocks to Consider
Apellis currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the drug/biotech industry are Puma Biotechnology, Inc. (PBYI - Free Report) , CytomX Therapeutics (CTMX - Free Report) and Journey Medical (DERM - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, the Zacks Consensus Estimate for Puma Biotech’s 2023 earnings per share (EPS) has increased from 72 cents to 73 cents. During the same time frame, the consensus estimate for Puma Biotech’s 2024 EPS has increased from 64 cents to 69 cents. Over the past year, shares of PBYI have risen 14.1%.
PBYI's earnings beat estimates in three of the last four quarters and missed the same in one, delivering an average surprise of 76.55%.
In the past 30 days, the Zacks Consensus Estimate for CytomX’s 2023 EPS has remained constant at 2 cents. The consensus estimate for CytomX’s 2024 loss per share is currently pegged at 6 cents. Over the past year, shares of CTMX have plunged 40.7%.
CTMX's earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 45.44%.
In the past 30 days, the Zacks Consensus Estimate for Journey Medical’s 2023 loss per share has remained constant at 16 cents. During the same period, the consensus estimate for Journey Medical’s 2024 loss per share has remained constant at 69 cents. Over the past year, shares of DERM have skyrocketed 154.5%.
DERM's earnings beat estimates in one of the trailing four quarters and missed in the other three, delivering an average surprise of 118.25%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Puma Biotechnology, Inc. (PBYI) - free report >>
Journey Medical Corporation (DERM) - free report >>
|
https://www.zacks.com/stock/news/2216945/apellis-apls-down-on-negative-chmp-opinion-for-pegcetacoplan
| 2024-01-30T02:42:49Z
|
blocked_url
|
Old Dominion Freight Line (ODFL - Free Report) is scheduled to report fourth-quarter 2023 results on Jan 31 before market open.
The company has an impressive earnings surprise history. Its earnings beat the Zacks Consensus Estimate in three of the preceding four quarters and missed once, the average beat being 3.1%.
Given this backdrop, let’s check out the factors that might have influenced Old Dominion’s performance in the quarter under review.
We expect Old Dominion’s performance to have been hurt by soft revenues due to weak freight demand. The Zacks Consensus Estimate for quarterly revenues is pegged at $1.5 billion, implying a 1% rise from fourth-quarter 2022 actuals.
The bulk of revenues is generated by the Less-Than-Truckload or LTL Service unit. Our estimate for segmental revenues indicates a marginal increase from fourth-quarter 2022 levels. We expect revenues from other sources to be down 13.7% from fourth-quarter 2022 actuals.
On the flip side, lower expenses led by the company’s cost-control initiatives are likely to have aided the bottom-line performance. Due to cost-control exercises, our estimate for salaries, wages and benefits hints at a 1.8% dip from the prior-year quarter’s levels. We predict operating expenses to rise 1.6% from fourth-quarter 2022 actuals.
Despite lower expenses, the top-line weakness, as a result of a lackluster freight-demand scenario, is likely to have led to a deterioration in the operating ratio (operating expenses as a percentage of revenues). Our estimate for this key metric is currently pegged at 72.2%. The operating ratio was 70.6% in fourth-quarter 2022. A lower value of this metric is preferable.
The Zacks Consensus Estimate for quarterly earnings is currently pegged at $2.86 per share, reflecting a 2.1% fall from fourth-quarter 2022 actuals.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for ODFL this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Old Dominion has an Earnings ESP of -1.19% and a Zacks Rank #3.
Highlights of Q3
Old Dominion's third-quarter 2023 earnings per share of $3.09 surpassed the Zacks Consensus Estimate of $2.89 but declined 8% year over year. Revenues of $1,515.27 million beat the Zacks Consensus Estimate of $1,492 million but decreased 5.5% year over year.
Stocks to Consider
Here are a few stocks from the broader Zacks Transportation sector that investors may consider, as our model shows that these have the right combination of elements to beat on their fourth-quarter 2023 earnings.
Allegiant Travel Company (ALGT - Free Report) has an Earnings ESP of +80.07% and carries a Zacks Rank #3. ALGT will release results on Feb 5.
The company has an impressive earnings surprise history. Its earnings beat the Zacks Consensus Estimate in three of the preceding four quarters and missed once, the average beat being 80.8%.
Westinghouse Air Brake Technologies Corporation, operating as Wabtec Corporation (WAB - Free Report) , has an Earnings ESP of +0.85% and sports a Zacks Rank #1. WAB will release results on Feb 14. You can see the complete list of today’s Zacks #1 Rank stocks here.
WAB has an expected earnings growth rate of 20.77% for fourth-quarter 2023. WAB delivered a trailing four-quarter earnings surprise of 7.11%, on average. The Zacks Consensus Estimate for WAB’s fourth-quarter 2023 earnings has improved 3.3% over the past 90 days.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Old Dominion Freight Line, Inc. (ODFL) - free report >>
Allegiant Travel Company (ALGT) - free report >>
Westinghouse Air Brake Technologies Corporation (WAB) - free report >>
|
https://www.zacks.com/stock/news/2216947/old-dominion-odfl-gears-up-for-q4-earnings-whats-in-store?
| 2024-01-30T02:42:55Z
|
blocked_url
|
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.
The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.
Our "Recent Price Strength" screen, which is created on a unique short-term trading strategy, could be pretty useful in this regard. This predefined screen makes it really easy to shortlist the stocks that have enough fundamental strength to maintain their recent uptrend. Also, the screen passes only the stocks that are trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
There are several stocks that passed through the screen and H&E Equipment (HEES - Free Report) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing.
A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. HEES is quite a good fit in this regard, gaining 21.7% over this period.
However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 1.3% over the past four weeks ensures that the trend is still in place for the stock of this construction and industrial equipment service provider.
Moreover, HEES is currently trading at 85.6% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock's near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance.
So, the price trend in HEES may not reverse anytime soon.
In addition to HEES, there are several other stocks that currently pass through our "Recent Price Strength" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
|
https://www.zacks.com/stock/news/2216948/recent-price-trend-in-he-equipment-hees-is-your-friend-heres-why?e-equipment-(hees)-is-your-friend,-here%27s-why
| 2024-01-30T02:43:01Z
|
blocked_url
|
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.
The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.
Our "Recent Price Strength" screen, which is created on a unique short-term trading strategy, could be pretty useful in this regard. This predefined screen makes it really easy to shortlist the stocks that have enough fundamental strength to maintain their recent uptrend. Also, the screen passes only the stocks that are trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
There are several stocks that passed through the screen and Tidewater (TDW - Free Report) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing.
A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. TDW is quite a good fit in this regard, gaining 4.7% over this period.
However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 2.3% over the past four weeks ensures that the trend is still in place for the stock of this offshore energy services provider.
Moreover, TDW is currently trading at 90.5% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock's near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance.
So, the price trend in TDW may not reverse anytime soon.
In addition to TDW, there are several other stocks that currently pass through our "Recent Price Strength" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
|
https://www.zacks.com/stock/news/2216949/what-makes-tidewater-tdw-a-good-fit-for-trend-investing
| 2024-01-30T02:43:08Z
|
blocked_url
|
When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.
Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going.
Investors looking to make a profit from stocks that are currently on the move may find our "Recent Price Strength" screen pretty useful. This predefined screen comes handy in spotting stocks that are on an uptrend backed by strength in their fundamentals, and trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
Oculis Holding AG (OCS - Free Report) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors.
A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. OCS is quite a good fit in this regard, gaining 35.2% over this period.
However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 18% over the past four weeks ensures that the trend is still in place for the stock of this company.
Moreover, OCS is currently trading at 84.8% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock's near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance.
So, the price trend in OCS may not reverse anytime soon.
In addition to OCS, there are several other stocks that currently pass through our "Recent Price Strength" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
|
https://www.zacks.com/stock/news/2216950/what-makes-oculis-holding-ag-ocs-a-good-fit-for-trend-investing
| 2024-01-30T02:43:14Z
|
blocked_url
|
Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.
The earnings figure itself is key, of course, but a beat or miss on the bottom line can sometimes be just as, if not more, important. Therefore, investors should consider paying close attention to these earnings surprises, as a big beat can help a stock climb and vice versa.
The ability to identify stocks that are likely to top quarterly earnings expectations can be profitable, but it's no simple task. Here at Zacks, our Earnings ESP filter helps make things easier.
The Zacks Earnings ESP, Explained
The Zacks Earnings ESP is more formally known as the Expected Surprise Prediction, and it aims to grab the inside track on the latest analyst estimate revisions ahead of a company's report. The idea is relatively intuitive as a newer projection might be based on more complete information.
The core of the ESP model is comparing the Most Accurate Estimate to the Zacks Consensus Estimate, where the resulting percentage difference between the two equals the Expected Surprise Prediction. The Zacks Rank is also factored into the ESP metric to better help find companies that appear poised to top their next bottom-line consensus estimate, which will hopefully help lift the stock price.
When we join a positive earnings ESP with a Zacks Rank #3 (Hold) or stronger, stocks posted a positive bottom-line surprise 70% of the time. Plus, this system saw investors produce roughly 28% annual returns on average, according to our 10 year backtest.
Most stocks, about 60%, fall into the #3 (Hold) category, and they are expected to perform in-line with the broader market. Stocks with a #2 (Buy) and #1 (Strong Buy) rating, or the top 15% and top 5% of stocks, respectively, should outperform the market, with Strong Buy stocks outperforming more than any other rank.
Should You Consider Novartis?
The final step today is to look at a stock that meets our ESP qualifications. Novartis (NVS - Free Report) earns a #3 (Hold) two days from its next quarterly earnings release on January 31, 2024, and its Most Accurate Estimate comes in at $1.73 a share.
By taking the percentage difference between the $1.73 Most Accurate Estimate and the $1.67 Zacks Consensus Estimate, Novartis has an Earnings ESP of +3.39%. Investors should also know that NVS is one of a large group of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
NVS is part of a big group of Medical stocks that boast a positive ESP, and investors may want to take a look at UnitedHealth Group (UNH - Free Report) as well.
UnitedHealth Group is a Zacks Rank #3 (Hold) stock, and is getting ready to report earnings on April 12, 2024. UNH's Most Accurate Estimate sits at $6.74 a share 74 days from its next earnings release.
For UnitedHealth Group, the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $6.57 is +2.71%.
Because both stocks hold a positive Earnings ESP, NVS and UNH could potentially post earnings beats in their next reports.
Find Stocks to Buy or Sell Before They're Reported
Use the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>
|
https://www.zacks.com/stock/news/2216953/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar
| 2024-01-30T02:43:20Z
|
blocked_url
|
When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.
The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.
Investors looking to make a profit from stocks that are currently on the move may find our "Recent Price Strength" screen pretty useful. This predefined screen comes handy in spotting stocks that are on an uptrend backed by strength in their fundamentals, and trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
There are several stocks that passed through the screen and Fujifilm Holdings Corp. (FUJIY - Free Report) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing.
A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. FUJIY is quite a good fit in this regard, gaining 9.5% over this period.
However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 4.8% over the past four weeks ensures that the trend is still in place for the stock of this company.
Moreover, FUJIY is currently trading at 89.6% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock's near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance.
So, the price trend in FUJIY may not reverse anytime soon.
In addition to FUJIY, there are several other stocks that currently pass through our "Recent Price Strength" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
|
https://www.zacks.com/stock/news/2216954/heres-why-momentum-in-fujifilm-holdings-corp-fujiy-should-keep-going
| 2024-01-30T02:43:26Z
|
blocked_url
|
When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.
Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going.
Our "Recent Price Strength" screen, which is created on a unique short-term trading strategy, could be pretty useful in this regard. This predefined screen makes it really easy to shortlist the stocks that have enough fundamental strength to maintain their recent uptrend. Also, the screen passes only the stocks that are trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness.
FinWise Bancorp (FINW - Free Report) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors.
A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. FINW is quite a good fit in this regard, gaining 65.6% over this period.
However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 3% over the past four weeks ensures that the trend is still in place for the stock of this company.
Moreover, FINW is currently trading at 96.7% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout.
Looking at the fundamentals, the stock currently carries a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock's near-term price movements.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance.
So, the price trend in FINW may not reverse anytime soon.
In addition to FINW, there are several other stocks that currently pass through our "Recent Price Strength" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
|
https://www.zacks.com/stock/news/2216955/heres-what-could-help-finwise-bancorp-finw-maintain-its-recent-price-strength
| 2024-01-30T02:43:33Z
|
blocked_url
|
Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.
Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potential fails to justify their swelled-up valuation. In that phase, investors find themselves invested in shares that have limited to no upside or even a downside. So, betting on a stock just by looking at the traditional momentum parameters could be risky at times.
It could be safer to invest in bargain stocks that have been witnessing price momentum recently. While the Zacks Momentum Style Score (part of the Zacks Style Scores system), which pays close attention to trends in a stock's price or earnings, is pretty useful in identifying great momentum stocks, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced.
Carrols Restaurant Group (TAST - Free Report) is one of the several great candidates that made it through the screen. While there are numerous reasons why this stock is a great choice, here are the most vital ones:
Investors' growing interest in a stock is reflected in its recent price increase. A price change of 19.2% over the past four weeks positions the stock of this restaurant operator well in this regard.
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. TAST meets this criterion too, as the stock gained 57.3% over the past 12 weeks.
Moreover, the momentum for TAST is fast paced, as the stock currently has a beta of 2.42. This indicates that the stock moves 142% higher than the market in either direction.
Given this price performance, it is no surprise that TAST has a Momentum Score of A, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
In addition to a favorable Momentum Score, an upward trend in earnings estimate revisions has helped TAST earn a Zacks Rank #1 (Strong Buy). Our research shows that the momentum-effect is quite strong among Zacks Rank #1 and #2 stocks. That's because as covering analysts raise their earnings estimates for a stock, more and more investors take an interest in it, helping its price race to keep up. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Most importantly, despite possessing fast-paced momentum features, TAST is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. TAST is currently trading at 0.28 times its sales. In other words, investors need to pay only 28 cents for each dollar of sales.
So, TAST appears to have plenty of room to run, and that too at a fast pace.
In addition to TAST, there are several other stocks that currently pass through our 'Fast-Paced Momentum at a Bargain' screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
|
https://www.zacks.com/stock/news/2216958/despite-fast-paced-momentum-carrols-restaurant-tast-is-still-a-bargain-stock
| 2024-01-30T02:43:39Z
|
blocked_url
|
Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.
Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ahead of their future growth potential. In such a situation, investors find themselves loaded up on expensive shares with limited to no upside or even a downside. So, going all-in on momentum could be risky at times.
It could be safer to invest in bargain stocks that have been witnessing price momentum recently. While the Zacks Momentum Style Score (part of the Zacks Style Scores system), which pays close attention to trends in a stock's price or earnings, is pretty useful in identifying great momentum stocks, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced.
Goodyear (GT - Free Report) is one of the several great candidates that made it through the screen. While there are numerous reasons why this stock is a great choice, here are the most vital ones:
Investors' growing interest in a stock is reflected in its recent price increase. A price change of 2.4% over the past four weeks positions the stock of this tire maker well in this regard.
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. GT meets this criterion too, as the stock gained 16.7% over the past 12 weeks.
Moreover, the momentum for GT is fast paced, as the stock currently has a beta of 1.84. This indicates that the stock moves 84% higher than the market in either direction.
Given this price performance, it is no surprise that GT has a Momentum Score of A, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
In addition to a favorable Momentum Score, an upward trend in earnings estimate revisions has helped GT earn a Zacks Rank #1 (Strong Buy). Our research shows that the momentum-effect is quite strong among Zacks Rank #1 and #2 stocks. That's because as covering analysts raise their earnings estimates for a stock, more and more investors take an interest in it, helping its price race to keep up. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Most importantly, despite possessing fast-paced momentum features, GT is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. GT is currently trading at 0.20 times its sales. In other words, investors need to pay only 20 cents for each dollar of sales.
So, GT appears to have plenty of room to run, and that too at a fast pace.
In addition to GT, there are several other stocks that currently pass through our 'Fast-Paced Momentum at a Bargain' screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
|
https://www.zacks.com/stock/news/2216959/why-fast-paced-mover-goodyear-gt-is-a-great-choice-for-value-investors
| 2024-01-30T02:43:46Z
|
blocked_url
|
Avidity Biosciences, Inc. (RNA - Free Report) shares ended the last trading session 15% higher at $12.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 12.2% gain over the past four weeks.
The sudden surge in the stock price can be attributed to the positive investor mindset regarding the company's distinguished rare diseases pipeline. Avidity is currently evaluating three investigational candidates in separate early to mid-stage clinical stages for three different muscle disease indications.
This company is expected to post quarterly loss of $0.54 per share in its upcoming report, which represents a year-over-year change of +38.6%. Revenues are expected to be $32.08 million, up 1058.3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Avidity Biosciences, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RNA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Avidity Biosciences, Inc. is part of the Zacks Medical - Biomedical and Genetics industry. HOOKIPA Pharma Inc. (HOOK - Free Report) , another stock in the same industry, closed the last trading session 1.3% lower at $0.70. HOOK has returned -5.3% in the past month.
For HOOKIPA Pharma Inc.
|
https://www.zacks.com/stock/news/2216962/strength-seen-in-avidity-biosciences-inc-rna-can-its-150-jump-turn-into-more-strength?
| 2024-01-30T02:43:52Z
|
blocked_url
|
Olin Corporation (OLN - Free Report) posted fourth-quarter 2023 earnings of 43 cents per share, down from $1.43 per share in the year-ago quarter.
Barring one-time items, adjusted earnings came in at 30 cents per share, topping the Zacks Consensus Estimate of 20 cents.
The chemical maker’s revenues fell roughly 18.3% year over year to $1,614.6 million in the quarter. It beat the Zacks Consensus Estimate of $1,499.2 million.
Segment Review
Chlor Alkali Products and Vinyls: In the fourth quarter, revenues amounted to $906.1 million, down around 22.7% year over year. It surpassed the Zacks Consensus Estimate of $843 million. The decrease in sales was primarily due to lower pricing and a less favorable product mix.
Epoxy: Revenues in the division declined around 35.4% year over year to $313.1 million on lower volumes. It missed the consensus estimate of $323 million. Epoxy sales decreased due to lower product pricing and reduced cumene and bisphenol sales.
Winchester: Revenues rose around 23.6% year over year to $395.4 million. It beat the consensus estimate of $357 million. Winchester revenues grew due to increased commercial ammunition shipments, domestic and international military sales, and White Flyer sales.
Financials
Olin had a cash balance of $170.3 million as of Dec 31, 2023. The company had a net debt of roughly $2.5 billion and a net debt-to-adjusted EBITDA ratio of 1.9x. As of Dec 31, 2023, Olin had around $1.3 billion in available liquidity.
In the fourth quarter, the company repurchased roughly 2.5 million shares of common stock for $116.2 million. In 2023, roughly 13.3 million shares of common stock were repurchased for $711.3 million. Olin had approximately $1 billion available under its share repurchase program as of Dec 31, 2023.
Outlook
Olin expects success with its value accelerator initiative but will limit its market involvement through February 2024. The company anticipates that its initiatives will help to improve adjusted EBITDA in 2024 compared to 2023. Chemical businesses' first-quarter 2024 results are expected to be slightly higher than fourth-quarter 2023 levels, taking into account the challenging global economic situation and the value accelerator initiative. Winchester's first-quarter 2024 results are expected to grow sequentially from the fourth quarter of 2023. Olin expects adjusted EBITDA in the first quarter of 2024 to increase by around 10% from the fourth quarter of 2023.
Price Performance
Shares of Olin have declined 12.1% in the past year compared with the 17.5% decline of the industry.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Olin currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the basic materials space include The Andersons Inc. (ANDE - Free Report) , Carpenter Technology Corporation (CRS - Free Report) and Alpha Metallurgical Resources Inc. (AMR - Free Report) .
Andersons currently sports a Zacks Rank #1 (Strong Buy). ANDE beat the Zacks Consensus Estimate in each of the last four quarters. It delivered a trailing four-quarter earnings surprise of 64.4%, on average. The company’s shares have gained 40.2% in the past year. You can see the complete list of today’s Zacks #1 Rank stocks here.
Carpenter Technology currently sports a Zacks Rank #1. CRS beat the Zacks Consensus Estimate in each of the last four quarters, with the average earnings surprise being 14.3%. The company’s shares have gained 42% in the past year.
The Zacks Consensus Estimate for AMR’s current-year earnings has been revised upward by 69% in the past 60 days. It currently sports a Zacks Rank #1. AMR has a trailing four-quarter earnings surprise of roughly 9.6%, on average. AMR shares have gained around 132.3% in a year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Alpha Metallurgical Resources, Inc. (AMR) - free report >>
The Andersons, Inc. (ANDE) - free report >>
|
https://www.zacks.com/stock/news/2216963/olins-oln-q4-earnings-and-revenues-surpass-estimates
| 2024-01-30T02:43:58Z
|
blocked_url
|
Griffon Corporation (GFF - Free Report) is expected to release first-quarter fiscal 2024 (ended Dec 31, 2023) results on Jan 30.
The company's earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 28.6%. In the last reported quarter, its earnings of $1.19 per share surpassed the Zacks Consensus Estimate of 97 cents by 22.7%.
Image Source: Zacks Investment Research
In the past three months, GFF’s shares have risen 50.8% compared with the industry’s growth of 11.5%.
Let’s see how things might have shaped up prior to the announcement.
Key Factors and Estimates for Q1
Griffon’s fiscal first-quarter performance is likely to have benefited from strength in the Home and Building Products (HBP) segment. The segment is expected to reflect higher revenues on the back of increased commercial and residential volumes and effective pricing.
The company has been trying to improve its performance through operational initiatives. Its increased investment in marketing, along with strong residential and commercial channels, is likely to have boosted its performance in the to-be-reported quarter.
However, the Consumer and Professional Products (CPP) segment is anticipated to have put up a weak show in the quarter due to soft consumer demand, elevated customer inventory levels and customer-supplier diversification in the United States.
Given the company’s substantial international operations, foreign-currency woes might have hurt its top line in the fiscal first quarter. Also, increased labor, advertising and marketing costs are likely to have dented its bottom line. Reduced raw material costs are likely to have offered some respite.
The consensus estimate for Griffon’s fiscal first-quarter total revenues is currently pegged at $597 million, indicating a decrease of 8% from the year-ago quarter's reported number. The consensus estimate for earnings of 78 cents indicates a decline of 9.3% on a year-over-year basis.
Zacks Model
Our proven model predicts an earnings beat for Griffon this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is the case here.
Griffon has an Earnings ESP of +2.08%, as the Most Accurate Estimate is pegged at 79 cents, higher than the Zacks Consensus Estimate of 78 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
The company sports a Zacks Rank #1 at present.
Other Stocks With the Favorable Combination
Here are three other companies that you may want to consider, as our model shows that these too have the right combination of elements to post an earnings beat in the upcoming release.
Danaher Corporation (DHR - Free Report) has an Earnings ESP of +3.46% and a Zacks Rank #3 at present. The company is slated to release fourth-quarter results on Jan 30. You can see the complete list of today’s Zacks #1 Rank stocks here.
Danaher delivered a trailing four-quarter earnings surprise of 8.5%, on average. The stock has rallied 25.9% in the past three months.
Xylem Inc. (XYL - Free Report) has an Earnings ESP of +1.40% and a Zacks Rank #3 at present. The company is slated to release fourth-quarter results on Feb 6.
Xylem delivered a trailing four-quarter earnings surprise of 14.4%, on average. The stock has rallied 25.9% in the past three months.
Eaton Corporation (ETN - Free Report) has an Earnings ESP of +0.20% and a Zacks Rank #2 at present. The company is slated to release fourth-quarter results on Feb 1.
Eaton delivered a trailing four-quarter earnings surprise of 4.2%, on average. The stock has rallied 24.3% in the past three months.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Eaton Corporation, PLC (ETN) - free report >>
Danaher Corporation (DHR) - free report >>
|
https://www.zacks.com/stock/news/2216964/griffon-gff-to-report-q1-earnings-is-a-beat-in-store?
| 2024-01-30T02:44:04Z
|
blocked_url
|
Novo Nordisk (NVO - Free Report) is anticipated to beat estimates when it reports its fourth-quarter and full-year 2023 results on Jan 31 before the opening bell.
Let’s see how things are shaping up for the quarter to be reported.
Factors at Play
Novo Nordisk operates under two segments: Diabetes and Obesity Care and Rare Disease.
The company’s revenues in the last reported quarter were driven by higher sales of Diabetes and Obesity Care products. Diabetes medicines like Ozempic, Rybelsus and fast-acting insulin, Fiasp, are expected to have put up a strong performance in the fourth quarter.
Obesity Care (Saxenda and Wegovy) sales were up significantly year over year in the third quarter of 2023, primarily due to increased Wegovy sales. This was observed after a second contract manufacturer for Wegovy initiated production in April 2023 to meet the increasing demand for the drug. Hence, the strong sales trend of Wegovy is expected to have continued in the to-be-reported quarter, boosting revenues from this segment.
Net sales in the Rare Disease segment were down in the last reported quarter due to a temporary reduction in the manufacturing output of rare endocrine disorder products. This trend is likely to have continued in the fourth quarter.
However, Novo Nordisk’s rare blood disorder products observed a year-over-year increase. Sales of the company’s Hemophilia A and B drugs are expected to have increased and contributed to NVO's revenues in the to-be-reported quarter.
Higher distribution costs, promotional activities related to Ozempic and Rybelsus, and Obesity Care market development activities are likely to have spiked Novo Nordisk’s sales and distribution costs in the fourth quarter of 2023. This, coupled with higher research and development costs driven by clinical activity for late-stage studies, is likely to hurt profits in the quarter to be reported.
Earnings Surprise History
The company has a mixed earnings surprise history. Earnings beat the Zacks Consensus Estimate in two of the trailing four quarters, matched once and missed on another occasion, delivering an average earnings surprise of 0.58%.
In the past year, shares of Novo Nordisk have shot up 55.4% compared with the industry’s 19.8% growth.
Image Source: Zacks Investment Research
What Our Model Predicts
Our proven model predicts an earnings beat for Novo Nordisk this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: NVO has an Earnings ESP of +0.89%.
Zacks Rank: Novo Nordisk currently sports a Zacks Rank #1.
Other Stocks to Consider
Here are some other stocks in the same industry that too have the right combination of elements to beat on earnings this time around:
Novartis (NVS - Free Report) has an Earnings ESP of +3.39% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Novartis’ stock has jumped 19.5% in the past year. The company topped earnings estimates in each of the last four quarters. NVS delivered a four-quarter earnings surprise of 6.99%, on average. Novartis is scheduled to release its fourth-quarter results on Jan 31.
AstraZeneca (AZN - Free Report) has an Earnings ESP of +3.17% and a Zacks Rank #3 at present.
AstraZeneca’s stock has gained 1.9% in the past year. It beat earnings estimates in each of the last four quarters. AZN has a four-quarter earnings surprise of 8.30%, on average. AstraZeneca is scheduled to release its fourth-quarter results on Feb 8.
Sanofi (SNY - Free Report) has an Earnings ESP of +13.01% and a Zacks Rank #3 at present.
Sanofi’s stock has risen 3.2% in the past year. It beat earnings estimates in three of the last four quarters while missing in one. SNY has a four-quarter earnings surprise of 2.88%, on average. Sanofi is scheduled to release its fourth-quarter results on Feb 1.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
AstraZeneca PLC (AZN) - free report >>
|
https://www.zacks.com/stock/news/2216966/novo-nordisk-nvo-to-report-q4-earnings-whats-in-the-cards?
| 2024-01-30T02:44:11Z
|
blocked_url
|
Exxon Mobil Corporation (XOM - Free Report) is set to report fourth-quarter 2023 earnings on Feb 2, before the opening bell.
In the last reported quarter, the integrated energy giant’s earnings per share of $2.27 (excluding identified items) missed the Zacks Consensus Estimate of $2.36 due to lower realizations of crude prices and a decline in oil equivalent production.
ExxonMobil’s earnings beat the Zacks Consensus Estimate in two of the trailing four quarters and missed the same twice, delivering an average surprise of 0.60%.
Estimate Trend
The Zacks Consensus Estimate for ExxonMobil’s fourth-quarter earnings per share of $2.21 witnessed five upward movements and one downward revision over the past 30 days. The estimated figure indicates a 35% decline from the prior-year reported number.
The Zacks Consensus Estimate for fourth-quarter revenues of $91.81 billion indicates a 3.79% decline from the year-ago reported figure.
Factors to Consider
The pricing scenario of oil and natural gas was impressive in the fourth quarter. Per data provided by the U.S. Energy Information Administration, the average West Texas Intermediate crude price per barrel in October, November and December was $85.64, $77.69 and $71.90, respectively. Although the prices were not as high as in the year-ago quarter, the commodity prices were impressive and healthy.
Like oil, natural gas price in the December quarter was healthier than in the third quarter, aiding the exploration and production activities of the company.
ExxonMobil, in its recent SEC filing, expressed optimism over higher oil and natural gas prices aiding its fourth-quarter earnings. We project total refinery throughput at 4000.4 thousand barrels per day (Kbd), indicating an increase from 3,983 Kbd reported a year ago.The solid upstream business is likely to have aided ExxonMobil’s earnings in the December quarter of 2023.
Earnings Whispers
Our proven model conclusively predicts an earnings beat for ExxonMobil this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is the case here, as you will see below.
Earnings ESP: ExxonMobil has an Earnings ESP of +0.47%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: ExxonMobil currently carries a Zacks Rank #3.
Other Stocks to Consider
Here are some other firms that you may want to consider, as these, too, have the right combination of elements to post an earnings beat this reporting cycle.
Marathon Petroleum (MPC - Free Report) currently has an Earnings ESP of +2.21% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
The company is scheduled to release fourth-quarter earnings on Jan 30. The Zacks Consensus Estimate for MPC’s earnings is pegged at $2.36 per share, indicating a 64.5% decline from the year-ago reported figure.
Western Midstream Partners, LP (WES - Free Report) currently has an Earnings ESP of +6.96% and a Zacks Rank #3.
The partnership is scheduled to release fourth-quarter earnings on Feb 21. The Zacks Consensus Estimate for WES’s earnings is pegged at 78 cents per share, indicating a decline from the year-ago quarter’s recorded figure.
Linde plc (LIN - Free Report) has an Earnings ESP of +0.12% and a Zacks Rank #3 at present.
Linde is scheduled to release fourth-quarter results on Feb 6. The Zacks Consensus Estimate for LIN’s earnings is pegged at $3.50 cents per share, indicating a year-over-year improvement of 10.76%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Exxon Mobil Corporation (XOM) - free report >>
Western Midstream Partners, LP (WES) - free report >>
|
https://www.zacks.com/stock/news/2216967/exxonmobil-xom-gears-up-for-q4-earnings-what-to-expect?
| 2024-01-30T02:44:17Z
|
blocked_url
|
Delta Air Lines (DAL - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this airline have returned -1.5%, compared to the Zacks S&P 500 composite's +2.5% change. During this period, the Zacks Transportation - Airline industry, which Delta falls in, has lost 3.5%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Delta is expected to post earnings of $0.35 per share, indicating a change of +40% from the year-ago quarter. The Zacks Consensus Estimate has changed +75.4% over the last 30 days.
The consensus earnings estimate of $6.63 for the current fiscal year indicates a year-over-year change of +6.1%. This estimate has changed -0.8% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $7.39 indicates a change of +11.5% from what Delta is expected to report a year ago. Over the past month, the estimate has changed -1.4%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Delta.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Delta, the consensus sales estimate of $12.87 billion for the current quarter points to a year-over-year change of +0.9%. The $58.22 billion and $60.59 billion estimates for the current and next fiscal years indicate changes of +0.3% and +4.1%, respectively.
Last Reported Results and Surprise History
Delta reported revenues of $14.22 billion in the last reported quarter, representing a year-over-year change of +5.9%. EPS of $1.28 for the same period compares with $1.48 a year ago.
Compared to the Zacks Consensus Estimate of $14.07 billion, the reported revenues represent a surprise of +1.09%. The EPS surprise was +9.4%.
Over the last four quarters, Delta surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Delta is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Delta. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216968/delta-air-lines-inc-dal-is-a-trending-stock-facts-to-know-before-betting-on-it
| 2024-01-30T02:44:23Z
|
blocked_url
|
Tesla (TSLA - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this electric car maker have returned -26.3%, compared to the Zacks S&P 500 composite's +2.5% change. During this period, the Zacks Automotive - Domestic industry, which Tesla falls in, has lost 25%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Earnings Estimate Revisions
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
For the current quarter, Tesla is expected to post earnings of $0.78 per share, indicating a change of -8.2% from the year-ago quarter. The Zacks Consensus Estimate has changed -9.9% over the last 30 days.
The consensus earnings estimate of $3.71 for the current fiscal year indicates a year-over-year change of +18.9%. This estimate has changed -1.4% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $5.05 indicates a change of +36.2% from what Tesla is expected to report a year ago. Over the past month, the estimate has changed +1.4%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Tesla is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Tesla, the consensus sales estimate of $26.05 billion for the current quarter points to a year-over-year change of +11.7%. The $114.36 billion and $142.66 billion estimates for the current and next fiscal years indicate changes of +18.2% and +24.8%, respectively.
Last Reported Results and Surprise History
Tesla reported revenues of $25.17 billion in the last reported quarter, representing a year-over-year change of +3.5%. EPS of $0.71 for the same period compares with $1.19 a year ago.
Compared to the Zacks Consensus Estimate of $25.94 billion, the reported revenues represent a surprise of -2.97%. The EPS surprise was -5.33%.
Over the last four quarters, Tesla surpassed consensus EPS estimates two times. The company topped consensus revenue estimates just once over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Tesla is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Tesla. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216969/tesla-inc-tsla-is-attracting-investor-attention-here-is-what-you-should-know
| 2024-01-30T02:44:29Z
|
blocked_url
|
Verizon Communications (VZ - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this largest U.S. cellphone carrier have returned +12.5% over the past month versus the Zacks S&P 500 composite's +2.5% change. The Zacks Wireless National industry, to which Verizon belongs, has gained 7.9% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate Revisions
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Verizon is expected to post earnings of $1.13 per share for the current quarter, representing a year-over-year change of -5.8%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.4%.
For the current fiscal year, the consensus earnings estimate of $4.58 points to a change of -2.8% from the prior year. Over the last 30 days, this estimate has changed -0.5%.
For the next fiscal year, the consensus earnings estimate of $4.69 indicates a change of +2.3% from what Verizon is expected to report a year ago. Over the past month, the estimate has changed -1.6%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Verizon is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Verizon, the consensus sales estimate of $33.49 billion for the current quarter points to a year-over-year change of +1.8%. The $135.6 billion and $138.09 billion estimates for the current and next fiscal years indicate changes of +1.2% and +1.8%, respectively.
Last Reported Results and Surprise History
Verizon reported revenues of $35.13 billion in the last reported quarter, representing a year-over-year change of -0.3%. EPS of $1.08 for the same period compares with $1.19 a year ago.
Compared to the Zacks Consensus Estimate of $34.82 billion, the reported revenues represent a surprise of +0.9%. The EPS surprise was +0.93%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates just once over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Verizon is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Verizon. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216970/investors-heavily-search-verizon-communications-inc-vz-here-is-what-you-need-to-know
| 2024-01-30T02:44:36Z
|
blocked_url
|
Visa (V - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this global payments processor have returned +2.9% over the past month versus the Zacks S&P 500 composite's +2.5% change. The Zacks Financial Transaction Services industry, to which Visa belongs, has gained 2.5% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate Revisions
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Visa is expected to post earnings of $2.38 per share for the current quarter, representing a year-over-year change of +13.9%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.8%.
For the current fiscal year, the consensus earnings estimate of $9.91 points to a change of +13% from the prior year. Over the last 30 days, this estimate has changed +0.1%.
For the next fiscal year, the consensus earnings estimate of $11.13 indicates a change of +12.3% from what Visa is expected to report a year ago. Over the past month, the estimate has changed -0.2%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Visa is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Visa, the consensus sales estimate of $8.67 billion for the current quarter points to a year-over-year change of +8.6%. The $35.73 billion and $39.22 billion estimates for the current and next fiscal years indicate changes of +9.4% and +9.8%, respectively.
Last Reported Results and Surprise History
Visa reported revenues of $8.63 billion in the last reported quarter, representing a year-over-year change of +8.8%. EPS of $2.41 for the same period compares with $2.18 a year ago.
Compared to the Zacks Consensus Estimate of $8.5 billion, the reported revenues represent a surprise of +1.52%. The EPS surprise was +3.43%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Visa is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Visa. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216971/here-is-what-to-know-beyond-why-visa-inc-v-is-a-trending-stock
| 2024-01-30T02:44:42Z
|
blocked_url
|
Salesforce.com (CRM - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this customer-management software developer have returned +6.4% over the past month versus the Zacks S&P 500 composite's +2.5% change. The Zacks Computer - Software industry, to which Salesforce.com belongs, has gained 6.8% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate Revisions
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Salesforce.com is expected to post earnings of $2.26 per share for the current quarter, representing a year-over-year change of +34.5%. Over the last 30 days, the Zacks Consensus Estimate has changed 0%.
For the current fiscal year, the consensus earnings estimate of $8.20 points to a change of +56.5% from the prior year. Over the last 30 days, this estimate has remained unchanged.
For the next fiscal year, the consensus earnings estimate of $9.51 indicates a change of +16% from what Salesforce.com is expected to report a year ago. Over the past month, the estimate has changed -0.2%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Salesforce.com is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Salesforce.com, the consensus sales estimate of $9.21 billion for the current quarter points to a year-over-year change of +9.9%. The $34.78 billion and $38.59 billion estimates for the current and next fiscal years indicate changes of +10.9% and +11%, respectively.
Last Reported Results and Surprise History
Salesforce.com reported revenues of $8.72 billion in the last reported quarter, representing a year-over-year change of +11.3%. EPS of $2.11 for the same period compares with $1.40 a year ago.
Compared to the Zacks Consensus Estimate of $8.71 billion, the reported revenues represent a surprise of +0.12%. The EPS surprise was +2.43%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Salesforce.com is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Salesforce.com. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216972/is-most-watched-stock-salesforce-inc-crm-worth-betting-on-now?
| 2024-01-30T02:44:48Z
|
blocked_url
|
Uber Technologies (UBER - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this ride-hailing company have returned +6.4%, compared to the Zacks S&P 500 composite's +2.5% change. During this period, the Zacks Internet - Services industry, which Uber falls in, has gained 6.9%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Uber is expected to post earnings of $0.15 per share, indicating a change of -48.3% from the year-ago quarter. The Zacks Consensus Estimate has changed -1.9% over the last 30 days.
The consensus earnings estimate of $0.37 for the current fiscal year indicates a year-over-year change of +108%. This estimate has changed -3.8% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $1.05 indicates a change of +181.4% from what Uber is expected to report a year ago. Over the past month, the estimate has changed -3.8%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Uber.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Uber, the consensus sales estimate of $9.77 billion for the current quarter points to a year-over-year change of +13.5%. The $37.11 billion and $42.92 billion estimates for the current and next fiscal years indicate changes of +16.4% and +15.7%, respectively.
Last Reported Results and Surprise History
Uber reported revenues of $9.29 billion in the last reported quarter, representing a year-over-year change of +11.4%. EPS of $0.10 for the same period compares with -$0.61 a year ago.
Compared to the Zacks Consensus Estimate of $9.47 billion, the reported revenues represent a surprise of -1.84%. The EPS surprise was -23.08%.
Over the last four quarters, Uber surpassed consensus EPS estimates three times. The company topped consensus revenue estimates two times over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Uber is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Uber. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216973/uber-technologies-inc-uber-is-a-trending-stock-facts-to-know-before-betting-on-it
| 2024-01-30T02:44:54Z
|
blocked_url
|
Enterprise Products Partners (EPD - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this provider of midstream energy services have returned +4%, compared to the Zacks S&P 500 composite's +2.5% change. During this period, the Zacks Oil and Gas - Production Pipeline - MLB industry, which Enterprise Products falls in, has gained 3.4%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Enterprise Products is expected to post earnings of $0.66 per share, indicating a change of +1.5% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The consensus earnings estimate of $2.48 for the current fiscal year indicates a year-over-year change of -1.6%. This estimate has changed +0.1% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $2.61 indicates a change of +5.3% from what Enterprise Products is expected to report a year ago. Over the past month, the estimate has changed +0.1%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Enterprise Products.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Enterprise Products, the consensus sales estimate of $12.76 billion for the current quarter points to a year-over-year change of -6.6%. The $47.85 billion and $51.84 billion estimates for the current and next fiscal years indicate changes of -17.8% and +8.3%, respectively.
Last Reported Results and Surprise History
Enterprise Products reported revenues of $12 billion in the last reported quarter, representing a year-over-year change of -22.4%. EPS of $0.60 for the same period compares with $0.63 a year ago.
Compared to the Zacks Consensus Estimate of $12.34 billion, the reported revenues represent a surprise of -2.78%. The EPS surprise was -4.76%.
Over the last four quarters, Enterprise Products surpassed consensus EPS estimates two times. The company could not beat consensus revenue estimates in any of the last four quarters.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Enterprise Products is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Enterprise Products. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216974/enterprise-products-partners-lp-epd-is-a-trending-stock-facts-to-know-before-betting-on-it
| 2024-01-30T02:45:01Z
|
blocked_url
|
Johnson & Johnson (JNJ - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this world's biggest maker of health care products have returned +1.8%, compared to the Zacks S&P 500 composite's +2.5% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Johnson & Johnson falls in, has gained 6.6%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate Revisions
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
For the current quarter, Johnson & Johnson is expected to post earnings of $2.63 per share, indicating a change of -1.9% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.7% over the last 30 days.
The consensus earnings estimate of $10.67 for the current fiscal year indicates a year-over-year change of +7.6%. This estimate has changed +0.2% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $11 indicates a change of +3.1% from what Johnson & Johnson is expected to report a year ago. Over the past month, the estimate has changed -0.8%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Johnson & Johnson is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Johnson & Johnson, the consensus sales estimate for the current quarter of $21.31 billion indicates a year-over-year change of -13.9%. For the current and next fiscal years, $88.36 billion and $90.46 billion estimates indicate -5% and +2.4% changes, respectively.
Last Reported Results and Surprise History
Johnson & Johnson reported revenues of $21.4 billion in the last reported quarter, representing a year-over-year change of -9.8%. EPS of $2.29 for the same period compares with $2.35 a year ago.
Compared to the Zacks Consensus Estimate of $21.11 billion, the reported revenues represent a surprise of +1.34%. The EPS surprise was +0.88%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Johnson & Johnson is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Johnson & Johnson. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216975/johnson-johnson-jnj-is-a-trending-stock-facts-to-know-before-betting-on-it?-johnson-(jnj)-is-a-trending-stock:-facts-to-know-before-betting-on-it
| 2024-01-30T02:45:10Z
|
blocked_url
|
UnitedHealth Group (UNH - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this largest U.S. health insurer have returned -4.4%, compared to the Zacks S&P 500 composite's +2.5% change. During this period, the Zacks Medical - HMOs industry, which UnitedHealth falls in, has lost 4.1%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Earnings Estimate Revisions
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, UnitedHealth is expected to post earnings of $6.57 per share, indicating a change of +5% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.9% over the last 30 days.
The consensus earnings estimate of $27.81 for the current fiscal year indicates a year-over-year change of +10.7%. This estimate has changed -0.3% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $31.27 indicates a change of +12.4% from what UnitedHealth is expected to report a year ago. Over the past month, the estimate has changed -0.2%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for UnitedHealth.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For UnitedHealth, the consensus sales estimate for the current quarter of $99.64 billion indicates a year-over-year change of +8.4%. For the current and next fiscal years, $401.47 billion and $430.41 billion estimates indicate +8% and +7.2% changes, respectively.
Last Reported Results and Surprise History
UnitedHealth reported revenues of $94.43 billion in the last reported quarter, representing a year-over-year change of +14.1%. EPS of $6.16 for the same period compares with $5.34 a year ago.
Compared to the Zacks Consensus Estimate of $92.06 billion, the reported revenues represent a surprise of +2.57%. The EPS surprise was +3.01%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
UnitedHealth is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about UnitedHealth. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216976/here-is-what-to-know-beyond-why-unitedhealth-group-incorporated-unh-is-a-trending-stock
| 2024-01-30T02:45:16Z
|
blocked_url
|
Chevron (CVX - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this oil company have returned 0%, compared to the Zacks S&P 500 composite's +2.5% change. During this period, the Zacks Oil and Gas - Integrated - International industry, which Chevron falls in, has lost 1.6%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Chevron is expected to post earnings of $3.31 per share, indicating a change of -19.1% from the year-ago quarter. The Zacks Consensus Estimate has changed -16.4% over the last 30 days.
For the current fiscal year, the consensus earnings estimate of $12.97 points to a change of -31.1% from the prior year. Over the last 30 days, this estimate has changed -14.4%.
For the next fiscal year, the consensus earnings estimate of $13.08 indicates a change of +0.9% from what Chevron is expected to report a year ago. Over the past month, the estimate has changed -14.4%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Chevron.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Chevron, the consensus sales estimate for the current quarter of $52.59 billion indicates a year-over-year change of -6.9%. For the current and next fiscal years, $206.36 billion and $218.35 billion estimates indicate -16.2% and +5.8% changes, respectively.
Last Reported Results and Surprise History
Chevron reported revenues of $54.08 billion in the last reported quarter, representing a year-over-year change of -18.9%. EPS of $3.05 for the same period compares with $5.56 a year ago.
Compared to the Zacks Consensus Estimate of $54 billion, the reported revenues represent a surprise of +0.15%. The EPS surprise was -17.12%.
Over the last four quarters, Chevron surpassed consensus EPS estimates two times. The company topped consensus revenue estimates three times over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Chevron is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Chevron. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216977/chevron-corporation-cvx-is-a-trending-stock-facts-to-know-before-betting-on-it
| 2024-01-30T02:45:22Z
|
blocked_url
|
Amgen (AMGN - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this world's largest biotech drugmaker have returned +8.3%, compared to the Zacks S&P 500 composite's +2.5% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Amgen falls in, has lost 0.2%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Amgen is expected to post earnings of $4.69 per share, indicating a change of +14.7% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.1% over the last 30 days.
For the current fiscal year, the consensus earnings estimate of $18.64 points to a change of +5.4% from the prior year. Over the last 30 days, this estimate has changed +0.1%.
For the next fiscal year, the consensus earnings estimate of $19.84 indicates a change of +6.4% from what Amgen is expected to report a year ago. Over the past month, the estimate has changed +0.1%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Amgen.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Amgen, the consensus sales estimate for the current quarter of $8.13 billion indicates a year-over-year change of +18.9%. For the current and next fiscal years, $28.13 billion and $32.43 billion estimates indicate +6.9% and +15.3% changes, respectively.
Last Reported Results and Surprise History
Amgen reported revenues of $6.9 billion in the last reported quarter, representing a year-over-year change of +3.8%. EPS of $4.96 for the same period compares with $4.70 a year ago.
Compared to the Zacks Consensus Estimate of $6.96 billion, the reported revenues represent a surprise of -0.8%. The EPS surprise was +6.67%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates two times over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Amgen is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Amgen. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216980/investors-heavily-search-amgen-inc-amgn-here-is-what-you-need-to-know
| 2024-01-30T02:45:28Z
|
blocked_url
|
Abbott (ABT - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this maker of infant formula, medical devices and drugs have returned +1.8% over the past month versus the Zacks S&P 500 composite's +2.5% change. The Zacks Medical - Products industry, to which Abbott belongs, has gained 1.6% over this period. Now the key question is: Where could the stock be headed in the near term?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Earnings Estimate Revisions
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Abbott is expected to post earnings of $0.97 per share for the current quarter, representing a year-over-year change of -5.8%. Over the last 30 days, the Zacks Consensus Estimate has changed -5.5%.
For the current fiscal year, the consensus earnings estimate of $4.62 points to a change of +4.1% from the prior year. Over the last 30 days, this estimate has remained unchanged.
For the next fiscal year, the consensus earnings estimate of $5.10 indicates a change of +10.5% from what Abbott is expected to report a year ago. Over the past month, the estimate has changed +0.2%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Abbott is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Abbott, the consensus sales estimate of $9.83 billion for the current quarter points to a year-over-year change of +0.9%. The $41.75 billion and $44.68 billion estimates for the current and next fiscal years indicate changes of +4.1% and +7%, respectively.
Last Reported Results and Surprise History
Abbott reported revenues of $10.24 billion in the last reported quarter, representing a year-over-year change of +1.5%. EPS of $1.19 for the same period compares with $1.03 a year ago.
Compared to the Zacks Consensus Estimate of $10.17 billion, the reported revenues represent a surprise of +0.71%. The EPS surprise was 0%.
Over the last four quarters, Abbott surpassed consensus EPS estimates three times. The company topped consensus revenue estimates each time over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Abbott is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Abbott. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216981/investors-heavily-search-abbott-laboratories-abt-here-is-what-you-need-to-know
| 2024-01-30T02:45:39Z
|
blocked_url
|
Kimberly-Clark (KMB - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this maker of consumer products such as Huggies diapers and Kleenex tissue have returned -0.3% over the past month versus the Zacks S&P 500 composite's +2.5% change. The Zacks Consumer Products - Staples industry, to which Kimberly-Clark belongs, has lost 2.1% over this period. Now the key question is: Where could the stock be headed in the near term?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
For the current quarter, Kimberly-Clark is expected to post earnings of $1.67 per share, indicating no change from the year-ago quarter. The Zacks Consensus Estimate has changed -11.5% over the last 30 days.
The consensus earnings estimate of $6.83 for the current fiscal year indicates a year-over-year change of +4%. This estimate has changed -2.9% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $7.24 indicates a change of +6% from what Kimberly-Clark is expected to report a year ago. Over the past month, the estimate has changed -2.8%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Kimberly-Clark is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Kimberly-Clark, the consensus sales estimate of $5.1 billion for the current quarter points to a year-over-year change of -1.8%. The $20.48 billion and $21.03 billion estimates for the current and next fiscal years indicate changes of +0.3% and +2.7%, respectively.
Last Reported Results and Surprise History
Kimberly-Clark reported revenues of $4.97 billion in the last reported quarter, representing a year-over-year change of +0.1%. EPS of $1.51 for the same period compares with $1.54 a year ago.
Compared to the Zacks Consensus Estimate of $4.99 billion, the reported revenues represent a surprise of -0.32%. The EPS surprise was -1.31%.
Over the last four quarters, Kimberly-Clark surpassed consensus EPS estimates three times. The company topped consensus revenue estimates two times over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Kimberly-Clark is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom Line
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Kimberly-Clark. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216985/is-trending-stock-kimberly-clark-corporation-kmb-a-buy-now?
| 2024-01-30T02:45:45Z
|
blocked_url
|
Twilio (TWLO - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this company have returned -5.2%, compared to the Zacks S&P 500 composite's +2.5% change. During this period, the Zacks Internet - Software industry, which Twilio falls in, has gained 6.1%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Earnings Estimate Revisions
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Twilio is expected to post earnings of $0.57 per share, indicating a change of +159.1% from the year-ago quarter. The Zacks Consensus Estimate has changed +3.9% over the last 30 days.
The consensus earnings estimate of $2.16 for the current fiscal year indicates a year-over-year change of +1,540%. This estimate has changed +9.3% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $2.38 indicates a change of +10.1% from what Twilio is expected to report a year ago. Over the past month, the estimate has changed +1.3%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Twilio.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Twilio, the consensus sales estimate for the current quarter of $1.04 billion indicates a year-over-year change of +1.5%. For the current and next fiscal years, $4.12 billion and $4.38 billion estimates indicate +7.6% and +6.3% changes, respectively.
Last Reported Results and Surprise History
Twilio reported revenues of $1.03 billion in the last reported quarter, representing a year-over-year change of +5.2%. EPS of $0.58 for the same period compares with -$0.27 a year ago.
Compared to the Zacks Consensus Estimate of $985.03 million, the reported revenues represent a surprise of +4.94%. The EPS surprise was +65.71%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Twilio is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Twilio. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term.
|
https://www.zacks.com/stock/news/2216986/twilio-inc-twlo-is-a-trending-stock-facts-to-know-before-betting-on-it
| 2024-01-30T02:45:52Z
|
blocked_url
|
Freeport-McMoRan (FCX - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this mining company have returned -7%, compared to the Zacks S&P 500 composite's +2.5% change. During this period, the Zacks Mining - Non Ferrous industry, which Freeport-McMoRan falls in, has lost 7.2%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings Estimates
Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Freeport-McMoRan is expected to post earnings of $0.38 per share, indicating a change of -26.9% from the year-ago quarter. The Zacks Consensus Estimate has changed -3.7% over the last 30 days.
For the current fiscal year, the consensus earnings estimate of $1.56 points to a change of +1.3% from the prior year. Over the last 30 days, this estimate has changed -7.4%.
For the next fiscal year, the consensus earnings estimate of $2.34 indicates a change of +49.9% from what Freeport-McMoRan is expected to report a year ago. Over the past month, the estimate has changed -0.9%.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Freeport-McMoRan.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Revenue Growth Forecast
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
For Freeport-McMoRan, the consensus sales estimate for the current quarter of $5.57 billion indicates a year-over-year change of +3.4%. For the current and next fiscal years, $23.02 billion and $23.64 billion estimates indicate +0.7% and +2.7% changes, respectively.
Last Reported Results and Surprise History
Freeport-McMoRan reported revenues of $5.91 billion in the last reported quarter, representing a year-over-year change of +2.6%. EPS of $0.27 for the same period compares with $0.52 a year ago.
Compared to the Zacks Consensus Estimate of $5.82 billion, the reported revenues represent a surprise of +1.45%. The EPS surprise was +28.57%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Freeport-McMoRan is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Freeport-McMoRan. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
|
https://www.zacks.com/stock/news/2216987/investors-heavily-search-freeport-mcmoran-inc-fcx-here-is-what-you-need-to-know
| 2024-01-30T02:45:59Z
|
blocked_url
|
Streaming giant Netflix (NFLX - Free Report) , Inc. has just logged its best weekly performance in over a year, thanks to a better-than-expected earnings report, per Bloomberg, as quoted on Yahoo Finance. Netflix shares recorded an 18% gain for the week. This is the highest the stock has traded in over two years, showing a significant rebound from a volatile 2023 impacted by Hollywood strikes.
Back-to-back solid earnings following the Hollywood strikes have contributed to this optimism. The company provided upbeat guidance. Zacks Rank #1 (Strong Buy) Netflix has an upbeat Momentum score of A.
All these upbeat factors put Netflix-heavy ETFs like MicroSectors FANG+ ETN (FNGS - Free Report) , Invesco Next Gen Media and Gaming ETF (GGME - Free Report) , REX FANG & Innovation Equity Premium Income ETF (FEPI - Free Report) and First Trust S-Network Streaming and Gaming ETF (BNGE - Free Report) .
Inside latest Earnings Results
Although the streaming giant reported fourth-quarter 2023 earnings of $2.11 per share, which missed the Zacks Consensus Estimate by 4.09%, its revenues of $8.83 billion increased 3.4% year over year and beat the consensus mark by 1.33%. Shares jumped as Netflix reported strong subscriber additions which topped 13 million. There was a rise of 1% in average revenue per subscription. Notably, Netflix gained 7.66 million paid subscribers in the year-ago quarter.
This validated the company’s its recent strategic decisions. These include price hikes, a crackdown on password sharing, and the introduction of an advertising-subsidized tier. Additionally, Netflix's venture into live events through acquiring exclusive rights to WWE programming like Raw has been a significant move (read: Netflix Shares Surge Post Earnings: ETFs in Focus).
Guidance
For 2024, the company expects healthy double digit revenue growth on a F/X neutral basis, driven by a rise in membership as well as improvement in F/X neutral ARM. Netflix raised full-year 2024 operating margin forecast from 22%-23% to 24% (based on F/X rates as of Jan 1, 2024). This reflects the weakening of the U.S. dollar compared with other currencies since October as well as stronger-than-forecasted fourth-quarter 2023 performance.
Industry Comparison and Analyst Perspectives
While Netflix thrives, its competitors like Warner Bros. Discovery, Inc., Paramount Global, and Walt Disney Co. have not seen similar success this year. Analysts from Argus Research Co., Citigroup Global Markets Inc., Macquarie Group Ltd., and DZ Bank AG have revised their outlook on Netflix, with many upgrading it to buy-equivalent ratings, pr Bloomberg.
Wall Street's Cautious Optimism
Despite the bullish sentiment, analysts hold a cautious view on the stock's future price. Based on short-term price targets offered by 34 analysts, the average price target for Netflix comes to $532.18. The forecasts range from a low of $333.00 to a high of $700.00. The average price target represents a decline of 5.31% from the last closing price of $562.00.
Netflix currently has an average brokerage recommendation (ABR) of 1.96 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 38 brokerage firms. The current ABR compares to an ABR of 1.90 a month ago based on 36 recommendations.
Of the 38 recommendations deriving the current ABR, 21 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 55.26% and 2.63% of all recommendations. A month ago, Strong Buy made up 58.33%, while Buy represented 2.78%.
Should You Tap Netflix-Heavy ETFs?
Concerns arise as Netflix trades at a premium compared to its peers and the broader market. However, investors seem willing to pay this premium for growth-oriented companies, as observed last year with the Magnificent Seven technology stocks, per Bloomberg. Hence, investors who do not have a strong stomach for risks may play Netflix-heavy ETFs instead of the stock itself as the basket approach minimizes the company-specific risks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Netflix, Inc. (NFLX) - free report >>
MicroSectors FANG+ ETN (FNGS) - free report >>
First Trust S-Network Streaming & Gaming ETF (BNGE) - free report >>
Invesco Next Gen Media and Gaming ETF (GGME) - free report >>
REX FANG & Innovation Equity Premium Income ETF (FEPI) - free report >>
|
https://www.zacks.com/stock/news/2216992/netflix-logs-best-week-since-2022-etfs-to-buy-on-high-momentum?
| 2024-01-30T02:46:06Z
|
blocked_url
|
Canadian Pacific Railway Limited (CP - Free Report) is scheduled to report fourth-quarter 2023 results on Jan 30, after market close.
The company has a disappointing earnings history, having underperformed the Zacks Consensus Estimate in two of the last four quarters and beat twice. CP has a trailing four-quarter negative earnings surprise of 4.04%, on average.
Let’s see how things might have shaped up for Canadian Pacific this reporting cycle.
Factors to Note
The railroad operator’s total operating expenses are likely to have increased in the fourth quarter primarily due to higher fuel costs. This is likely to have hurt the bottom line. Our estimate for total expense has increased 45.3% year over year. The Zacks Consensus Estimate for quarterly earnings is pegged at 83 cents per share, implying a 2.47% increase from the fourth-quarter 2022 actuals.
Canadian Pacific’s high capital expenditures are also expected to have hurt the bottom line in the to-be-reported quarter.
Despite such a backdrop, gradual recovery in freight-market conditions is likely to have boosted the company’s December-quarter performance. Our estimate for freight revenues has jumped 47.8% year over year. The Zacks Consensus Estimate for quarterly revenues is pegged at $2.71 billion, implying a 49.6% improvement from the fourth-quarter 2022 actuals.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for ODFL this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Canadian Pacific has an Earnings ESP of -2.48% and a Zacks Rank #3 at present.
Highlights of Q3 Earnings
Canadian Pacific reported third-quarter 2023 earnings (excluding 6 cents from non-recurring items) per share of 69 cents (C$0.84), which beat the Zacks Consensus Estimate of 68 cents. Nonetheless, the bottom line decreased 10.4% year over year. However, quarterly revenues of $2,489.1 million (C$3,339 million) surpassed the Zacks Consensus Estimate of $2,487.4 million and improved 40.4% year over year.
Stocks to Consider
Here are a few stocks from the broader Zacks Transportation sector that investors may consider, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Allegiant Travel Company (ALGT - Free Report) has an Earnings ESP of +80.07% and a Zacks Rank #3 at present. ALGT is set to release results on Feb 5.
The company has an impressive earnings surprise history. Its earnings beat the Zacks Consensus Estimate in three of the preceding four quarters and missed once, the average beat being 80.8%.
Westinghouse Air Brake Technologies Corporation, operating as Wabtec Corporation (WAB - Free Report) , has an Earnings ESP of +0.85% and a Zacks Rank #1 at present. WAB is set to release results on Feb 14. You can see the complete list of today’s Zacks #1 Rank stocks here.
WAB has an expected earnings growth rate of 20.77% for fourth-quarter 2023. WAB delivered a trailing four-quarter earnings surprise of 7.11%, on average. The Zacks Consensus Estimate for WAB’s fourth-quarter 2023 earnings has improved 3.3% over the past 90 days.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Canadian Pacific Kansas City Limited (CP) - free report >>
Allegiant Travel Company (ALGT) - free report >>
Westinghouse Air Brake Technologies Corporation (WAB) - free report >>
|
https://www.zacks.com/stock/news/2216993/whats-in-store-for-canadian-pacific-cp-in-q4-earnings?
| 2024-01-30T02:46:12Z
|
blocked_url
|
Nextracker Inc. (NXT - Free Report) is slated to report third-quarter fiscal 2024 results on Jan 31, after market close.
In the last reported quarter, the company delivered an earnings surprise of 91.18%. It also delivered a trailing four-quarter average earnings surprise of 43.04%.
Factors to Note
Solid shipment of NX Horizon XTR, the industry's most deployed all-terrain solar tracker, can be expected to have boosted Nextracker’s top line in the fiscal third quarter.
Also, notable demand for its TrueCapture software as well as NX Navigator control systems may have contributed favorably to NXT’s overall revenue performance.
Further, during the fiscal third quarter, the company launched its next-generation technology suite with three new innovations in the United States. The tech suite provides next-generation functionality and value in Hail Protection, undulating terrain and fast-changing atmosphere conditions. Consecutive sales of this product, following the launch, might have also added impetus to NXT’s fiscal third-quarter top line.
The Zacks Consensus Estimate for revenues is pegged at $615.5 million, indicating a 7.4% improvement from the prior quarter’s reported number.
In November 2023, the company opened its new factory in Las Vegas for manufacturing critical steel components exclusively for Nextracker. The components will be used in ground-mount solar power generation plants to primarily serve projects in Nevada and southwestern states. This must have facilitated production ramp-up for NXT, which can be projected to be reflected in the upcoming results.
The separation of Nextracker from its contract manufacturer Flex Ltd., announced in October 2023, might have had some adverse impact on NXT’s overall earnings performance in the fiscal third quarter. Moreover, higher operating expenses, as the company keeps on enhancing its manufacturing capability to meet the growing demand for its products, can be anticipated to have hurt NXT’s quarterly bottom-line performance amid its cost-saving initiatives. Higher research and development expenses might have also impacted earnings.
The Zacks Consensus Estimate for fiscal third-quarter earnings is pegged at 49 cents per share, implying a decline of 24.6% from the earlier quarter’s reported figure.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Nextracker this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is not the case here.
Earnings ESP: NXT’s Earnings ESP is 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Nextracker currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Here are three companies from the same sector you may want to consider, as these have the right combination of elements to post an earnings beat this reporting cycle.
SolarEdge Technologies (SEDG - Free Report) currently has an Earnings ESP of +11.80% and a Zacks Rank #3. The Zacks Consensus Estimate for SolarEdge’s fourth-quarter sales is pegged at $321.5 million, indicating a 63.9% decline from the prior-year quarter’s level.
The consensus estimate for fourth-quarter earnings is pegged at a loss of $1.34 per share. SEDG has a trailing four-quarter average negative earnings surprise of 13.23%.
Energy Transfer (ET - Free Report) currently has an Earnings ESP of +15.39% and a Zacks Rank #2. The Zacks Consensus Estimate for Energy Transfer’s fourth-quarter sales is pegged at $23.59 billion, implying an improvement of 15% from the prior-year reported figure.
ET delivered a trailing four-quarter average negative earnings surprise of 5.23%. The consensus estimate for fourth-quarter earnings is pegged at 29 cents per share.
ONEOK (OKE - Free Report) currently has an Earnings ESP of +12.04% and a Zacks Rank #3. The Zacks Consensus Estimate for fourth-quarter sales is pegged at $5.55 billion, indicating a rise of 10.3% from the year-ago quarter’s reported number.
The consensus mark for fourth-quarter earnings is pegged at $1.25 per share. The company delivered a trailing four-quarter average earnings surprise of 5.99%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
ONEOK, Inc. (OKE) - free report >>
Energy Transfer LP (ET) - free report >>
|
https://www.zacks.com/stock/news/2216994/nextracker-nxt-to-report-q3-earnings-whats-in-the-cards?
| 2024-01-30T02:46:18Z
|
blocked_url
|
Profound Medical (PROF - Free Report) shares ended the last trading session 9.4% higher at $9.06. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.5% gain over the past four weeks.
The sudden surge in share price can be attributed to positive investor expectation from the company's lead marketed product Tulsa-Pro system which is approved for the ablation of prostate tissue. Earlier this month, the company reported preliminary fourth quarter total revenues to be in the approximate range of $1.9 million to $2.0 million, with the full amount coming from recurring revenue, which consists of the sale of Tulsa-Pro consumables, lease of medical devices, procedures and services associated with extended warranties. The preliminary total revenue figures represents a recurring revenue growth of between 51% and 59% year-over-year.
This company is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents a year-over-year change of +45.7%. Revenues are expected to be $1.9 million, up 50.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Profound Medical, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on PROF going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Profound Medical is part of the Zacks Medical - Drugs industry. Lyell Immunopharma (LYEL - Free Report) , another stock in the same industry, closed the last trading session 0.5% lower at $2.08. LYEL has returned -1% in the past month.
For Lyell Immunopharma
|
https://www.zacks.com/stock/news/2216995/profound-medical-prof-soars-94-is-further-upside-left-in-the-stock?
| 2024-01-30T02:46:24Z
|
blocked_url
|
Altria Group, Inc. (MO - Free Report) is likely to register a bottom-line decline when it reports fourth-quarter 2023 earnings on Feb 1. The consensus mark for quarterly earnings has remained unchanged in the past 30 days at $1.17 per share. This indicates a decline of 0.9% from the year-ago quarter’s reported figure. MO has a trailing four-quarter negative earnings surprise of 0.4%, on average.
The Zacks Consensus Estimate for revenues is pegged at $5.1 billion, suggesting a slight increase from the prior-year quarter’s reported figure of $5.08 billion.
Factors to Consider
The overall cigarette industry has been bearing the brunt of the inflationary environment, which has affected Adult Tobacco Consumers’ (“ATC”) spending patterns. This has been affecting cigarette consumption and volumes. We note that Altria has been witnessing a decline in its Smokeable Product segment revenues for the past few quarters. In the third quarter of 2023, the company’s Smokeable Products segment revenues were hurt by soft domestic cigarette shipment volumes, which tumbled 11.6%, mainly due to the industry’s decline rate and retail share losses, trade inventory movements and calendar differences.
Though Altria’s third-quarter results reflect its resilience in a tough macroeconomic landscape, the impact of overall inflation on ATC spending patterns remains a concern. The Zacks Consensus Estimate for fourth-quarter revenues for the Smokeable Products segment is pegged at $5,296 million, suggesting a drop from $5,456 million reported in the year-ago period.
Management narrowed its guidance range for the full year 2023 in its third-quarter earnings release. It now envisions the adjusted EPS in the range of $4.91-$4.98, indicating growth of 1.5-3% from the $4.84 recorded in 2022. The bottom-line view for 2023 considers planned investments associated with costs to improve the digital consumer engagement system and enhanced smoke-free product research, development and marketplace activities to support the company’s smoke-free products (including investments related to the commercialization of ACE in the United States).
However, Altria has been benefiting from its strong pricing power. Though higher pricing might lead to a possible decline in cigarette consumption, it is seen that smokers tend to absorb price increases due to the addictive quality of cigarettes. Additionally, the company’s focus on oral tobacco, e-vapor and heated tobacco offerings has been helping as consumers are increasingly gravitating toward reduced-risk products or smoke-free alternatives. on! has been a valuable addition to the company's smoke-free product portfolio.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for Altria this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here.
Altria has an Earnings ESP of -1.75%, and it carries a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks With the Favorable Combination
Here are three companies worth considering as our model shows that these have the correct combination to beat on earnings this time:
Inter Parfums (IPAR - Free Report) currently has an Earnings ESP of +11.27% and a Zacks Rank of 2. The company is likely to register a top-line increase when it reports fourth-quarter 2023 numbers. The Zacks Consensus Estimate for Inter Parfums’ quarterly revenues is pegged at $329.1 million, indicating a rise of 5.9% from the figure reported in the prior-year quarter. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Inter Parfums’ quarterly earnings of 35 cents suggests a decrease of 50.7% from the year-ago quarter’s levels. IPAR has a trailing four-quarter earnings surprise of 45.7%, on average.
Mondelez International (MDLZ - Free Report) currently has an Earnings ESP of +0.62% and a Zacks Rank #3. The company is likely to register top-and-bottom-line growth when it reports fourth-quarter 2023 numbers. The Zacks Consensus Estimate for Mondelez’s quarterly revenues is pegged at $9.3 billion, indicating a rise of roughly 7% from the figure reported in the prior-year quarter.
The Zacks Consensus Estimate for Mondelez’s quarterly earnings of 78 cents suggests an increase of 6.9% from the year-ago quarter’s levels. MDLZ has a trailing four-quarter earnings surprise of 7.3%, on average.
The Estee Lauder Companies (EL - Free Report) has an Earnings ESP of +3.55% and a Zacks Rank #3. The company is likely to witness top-and-bottom-line decline when it reports second-quarter fiscal 2024 results. The Zacks Consensus Estimate for Estee Lauder’s quarterly revenues is pegged at $4.2 billion, which suggests a drop of 9.2% from the figure reported in the prior-year quarter.
The Zacks Consensus Estimate for Estee Lauder’s quarterly EPS has remained unchanged in the past 30 days at 55 cents, which suggests a decrease of 64.3% from the year-ago quarter’s level. EL has a trailing four-quarter earnings surprise of 110.1%, on average.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Altria Group, Inc. (MO) - free report >>
The Estee Lauder Companies Inc. (EL) - free report >>
|
https://www.zacks.com/stock/news/2216998/altrias-mo-q4-earnings-coming-up-factors-worth-noting
| 2024-01-30T02:46:31Z
|
blocked_url
|
Analysts on Wall Street project that Trane Technologies (TT - Free Report) will announce quarterly earnings of $2.13 per share in its forthcoming report, representing an increase of 17% year over year. Revenues are projected to reach $4.42 billion, increasing 8.6% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain Trane Technologies metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Revenues- Americas' will reach $3.39 billion. The estimate suggests a change of +8.1% year over year.
The consensus estimate for 'Revenues- EMEA' stands at $635.32 million. The estimate suggests a change of +13.8% year over year.
Based on the collective assessment of analysts, 'Revenues- Asia Pacific' should arrive at $392.21 million. The estimate indicates a year-over-year change of +4.5%.
The combined assessment of analysts suggests that 'Adjusted EBITDA- Americas' will likely reach $607.14 million. The estimate is in contrast to the year-ago figure of $520.80 million.
Analysts forecast 'Adjusted EBITDA- EMEA' to reach $116.51 million. Compared to the current estimate, the company reported $91.90 million in the same quarter of the previous year.
Analysts' assessment points toward 'Adjusted EBITDA- Asia Pacific' reaching $81.70 million. The estimate is in contrast to the year-ago figure of $79.70 million.
View all Key Company Metrics for Trane Technologies here>>>
Shares of Trane Technologies have experienced a change of +3.1% in the past month compared to the +2.5% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), TT is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217002/unveiling-trane-technologies-tt-q4-outlook-wall-street-estimates-for-key-metrics
| 2024-01-30T02:46:37Z
|
blocked_url
|
The upcoming report from Avnet (AVT - Free Report) is expected to reveal quarterly earnings of $1.39 per share, indicating a decline of 30.5% compared to the year-ago period. Analysts forecast revenues of $6.15 billion, representing a decrease of 8.4% year over year.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 1.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Avnet metrics that Wall Street analysts commonly model and monitor.
The average prediction of analysts places 'Sales- Farnell' at $398.96 million. The estimate points to a change of -2.2% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Sales- Electronic Components' of $5.75 billion. The estimate points to a change of -8.8% from the year-ago quarter.
Analysts' assessment points toward 'Operating Income (loss)- Electronic Components' reaching $248.26 million. Compared to the current estimate, the company reported $296.70 million in the same quarter of the previous year.
Analysts predict that the 'Operating Income (loss)- Farnell' will reach $20.01 million. Compared to the current estimate, the company reported $36.90 million in the same quarter of the previous year.
View all Key Company Metrics for Avnet here>>>
Over the past month, shares of Avnet have returned -6.2% versus the Zacks S&P 500 composite's +2.5% change. Currently, AVT carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217003/avnet-avt-q2-earnings-preview-what-you-should-know-beyond-the-headline-estimates
| 2024-01-30T02:46:43Z
|
blocked_url
|
Wall Street analysts forecast that Nov Inc. (NOV - Free Report) will report quarterly earnings of $0.41 per share in its upcoming release, pointing to a year-over-year increase of 57.7%. It is anticipated that revenues will amount to $2.26 billion, exhibiting an increase of 9.2% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 2.5% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific Nov Inc. metrics that are commonly monitored and projected by Wall Street analysts.
According to the collective judgment of analysts, 'Revenue- Rig Technologies' should come in at $700.46 million. The estimate indicates a change of +13% from the prior-year quarter.
The consensus estimate for 'Revenue- Completion & Production Solutions' stands at $785.41 million. The estimate points to a change of +6.4% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenue- Wellbore Technologies' of $839.39 million. The estimate indicates a year-over-year change of +10.2%.
Analysts' assessment points toward 'Rig Technologies - New Orders Booked' reaching $239.94 million. The estimate compares to the year-ago value of $254 million.
The average prediction of analysts places 'Completion & Production Solutions - New Orders Booked' at $531.04 million. Compared to the present estimate, the company reported $557 million in the same quarter last year.
The consensus among analysts is that 'Completion & Production Solutions - Orders Shipped' will reach $496.76 million. The estimate compares to the year-ago value of $472 million.
Analysts expect 'Rig Technologies - Orders Shipped' to come in at $234.99 million. Compared to the present estimate, the company reported $257 million in the same quarter last year.
Based on the collective assessment of analysts, 'Completion & Production Solutions - Book-to-Bill' should arrive at 101.3%. The estimate is in contrast to the year-ago figure of 118%.
The combined assessment of analysts suggests that 'Adjusted EBITDA- Wellbore Technologies' will likely reach $175.66 million. The estimate compares to the year-ago value of $146 million.
Analysts forecast 'Adjusted EBITDA- Rig Technologies' to reach $105.24 million. Compared to the current estimate, the company reported $88 million in the same quarter of the previous year.
It is projected by analysts that the 'Adjusted EBITDA- Completion & Production Solutions' will reach $86.97 million. The estimate compares to the year-ago value of $66 million.
View all Key Company Metrics for Nov Inc. here>>>
Over the past month, Nov Inc. shares have recorded returns of +3.5% versus the Zacks S&P 500 composite's +2.5% change. Based on its Zacks Rank #3 (Hold), NOV will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217004/unveiling-nov-inc-nov-q4-outlook-wall-street-estimates-for-key-metrics
| 2024-01-30T02:46:50Z
|
blocked_url
|
Analysts on Wall Street project that Deckers (DECK - Free Report) will announce quarterly earnings of $11.36 per share in its forthcoming report, representing an increase of 8.4% year over year. Revenues are projected to reach $1.43 billion, increasing 6.6% from the same quarter last year.
The consensus EPS estimate for the quarter has undergone a downward revision of 1.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Deckers metrics that are routinely monitored and predicted by Wall Street analysts.
According to the collective judgment of analysts, 'Net sales by brand and channel- UGG brand- Total' should come in at $947.57 million. The estimate suggests a change of +1.9% year over year.
The average prediction of analysts places 'Net sales by brand and channel- Teva brands- Total' at $25.44 million. The estimate indicates a year-over-year change of -16.6%.
Based on the collective assessment of analysts, 'Net sales by brand and channel- Sanuk brands- Total' should arrive at $4.66 million. The estimate points to a change of -16.8% from the year-ago quarter.
Analysts' assessment points toward 'Net sales by brand and channel- HOKA brand- Total' reaching $409.45 million. The estimate points to a change of +16.3% from the year-ago quarter.
Analysts expect 'Net sales by brand and channel- Other brands- Total' to come in at $26.97 million. The estimate indicates a year-over-year change of +0.3%.
The collective assessment of analysts points to an estimated 'Net sales by brand and channel- Other brands- Wholesale' of $20.60 million. The estimate indicates a year-over-year change of +2.1%.
Analysts forecast 'Net sales by brand and channel- Sanuk brands- Wholesale' to reach $2.03 million. The estimate indicates a year-over-year change of -33.2%.
It is projected by analysts that the 'Net sales by brand and channel- Teva brands- Wholesale' will reach $20.09 million. The estimate points to a change of -20.2% from the year-ago quarter.
The consensus among analysts is that 'Net sales by brand and channel- UGG brand- Wholesale' will reach $372.45 million. The estimate suggests a change of -0.4% year over year.
The combined assessment of analysts suggests that 'Net sales by brand and channel- HOKA brand- Direct-to-Consumer' will likely reach $167.76 million. The estimate points to a change of +30.8% from the year-ago quarter.
Analysts predict that the 'Net sales by brand and channel- HOKA brand- Wholesale' will reach $244.64 million. The estimate indicates a change of +9.3% from the prior-year quarter.
The consensus estimate for 'Net sales by brand and channel- Other brands- Direct-to-Consumer' stands at $6.90 million. The estimate indicates a change of +2.6% from the prior-year quarter.
View all Key Company Metrics for Deckers here>>>
Shares of Deckers have demonstrated returns of +14.9% over the past month compared to the Zacks S&P 500 composite's +2.5% change. With a Zacks Rank #2 (Buy), DECK is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217005/unveiling-deckers-deck-q3-outlook-wall-street-estimates-for-key-metrics
| 2024-01-30T02:46:56Z
|
blocked_url
|
Analysts on Wall Street project that Cardinal Health (CAH - Free Report) will announce quarterly earnings of $1.57 per share in its forthcoming report, representing an increase of 18.9% year over year. Revenues are projected to reach $56.82 billion, increasing 10.4% from the same quarter last year.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.9% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Cardinal metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts' assessment points toward 'Revenue- Pharmaceutical' reaching $52.95 billion. The estimate suggests a change of +11.1% year over year.
It is projected by analysts that the 'Revenue- Medical' will reach $3.85 billion. The estimate indicates a year-over-year change of +1.5%.
The combined assessment of analysts suggests that 'Operating earnings- Medical' will likely reach $82.78 million. The estimate is in contrast to the year-ago figure of $17 million.
The consensus among analysts is that 'Operating earnings- Pharmaceutical' will reach $502.68 million. The estimate is in contrast to the year-ago figure of $464 million.
View all Key Company Metrics for Cardinal here>>>
Over the past month, shares of Cardinal have returned +4.9% versus the Zacks S&P 500 composite's +2.5% change. Currently, CAH carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217006/ahead-of-cardinal-cah-q2-earnings-get-ready-with-wall-street-estimates-for-key-metrics
| 2024-01-30T02:47:00Z
|
blocked_url
|
The upcoming report from Peloton (PTON - Free Report) is expected to reveal quarterly loss of $0.55 per share, indicating an increase of 43.9% compared to the year-ago period. Analysts forecast revenues of $740.82 million, representing a decrease of 6.6% year over year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Bearing this in mind, let's now explore the average estimates of specific Peloton metrics that are commonly monitored and projected by Wall Street analysts.
The consensus among analysts is that 'Revenues- Subscription' will reach $417.72 million. The estimate points to a change of +1.6% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Connected Fitness Products' will likely reach $323.62 million. The estimate indicates a change of -15.2% from the prior-year quarter.
Analysts forecast 'Ending Connected Fitness Subscriptions' to reach 2,985. The estimate is in contrast to the year-ago figure of 3,033.
According to the collective judgment of analysts, 'Gross profit- Subscription' should come in at $286.30 million. Compared to the present estimate, the company reported $277.90 million in the same quarter last year.
View all Key Company Metrics for Peloton here>>>
Peloton shares have witnessed a change of -4.8% in the past month, in contrast to the Zacks S&P 500 composite's +2.5% move. With a Zacks Rank #3 (Hold), PTON is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217007/unveiling-peloton-pton-q2-outlook-wall-street-estimates-for-key-metrics
| 2024-01-30T02:47:06Z
|
blocked_url
|
In its upcoming report, Axis Capital (AXS - Free Report) is predicted by Wall Street analysts to post quarterly loss of $1.25 per share, reflecting a decline of 164.1% compared to the same period last year. Revenues are forecasted to be $1.42 billion, representing a year-over-year decrease of 4.7%.
Over the last 30 days, there has been an upward revision of 9.8% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Axis Capital metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Net investment income' at $168.00 million. The estimate indicates a year-over-year change of +14.2%.
It is projected by analysts that the 'Net premiums earned' will reach $1.31 billion. The estimate points to a change of -2.1% from the year-ago quarter.
Analysts forecast 'Other insurance related income (loss)' to reach $11.68 million. The estimate indicates a year-over-year change of +279.6%.
The consensus estimate for 'Net loss and loss expense ratio - Total' stands at 80.8%. The estimate is in contrast to the year-ago figure of 59.6%.
Analysts' assessment points toward 'Combined Ratio - Total' reaching 114.5%. The estimate is in contrast to the year-ago figure of 94.1%.
Analysts predict that the 'Acquisition Cost Ratio - Total' will reach 20.2%. Compared to the present estimate, the company reported 20.6% in the same quarter last year.
View all Key Company Metrics for Axis Capital here>>>
Axis Capital shares have witnessed a change of +7.4% in the past month, in contrast to the Zacks S&P 500 composite's +2.5% move. With a Zacks Rank #3 (Hold), AXS is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217008/gear-up-for-axis-capital-axs-q4-earnings-wall-street-estimates-for-key-metrics
| 2024-01-30T02:47:13Z
|
blocked_url
|
In its upcoming report, Apple (AAPL - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $2.09 per share, reflecting an increase of 11.2% compared to the same period last year. Revenues are forecasted to be $117.62 billion, representing a year-over-year increase of 0.4%.
Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Apple metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts expect 'Revenue- Wearables, Home and Accessories' to come in at $11.27 billion. The estimate indicates a year-over-year change of -16.4%.
The consensus among analysts is that 'Revenue- iPhone' will reach $68.64 billion. The estimate points to a change of +4.4% from the year-ago quarter.
The average prediction of analysts places 'Net Sales- Services' at $23.40 billion. The estimate indicates a year-over-year change of +12.7%.
Analysts forecast 'Revenue- Mac' to reach $7.77 billion. The estimate points to a change of +0.4% from the year-ago quarter.
Analysts predict that the 'Net Sales- Products' will reach $94.45 billion. The estimate points to a change of -2% from the year-ago quarter.
Analysts' assessment points toward 'Revenue- iPad' reaching $6.77 billion. The estimate indicates a change of -28% from the prior-year quarter.
The consensus estimate for 'Geographic Revenue- Greater China' stands at $23.32 billion. The estimate points to a change of -2.5% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Geographic Revenue- Europe' of $28.66 billion. The estimate indicates a change of +3.5% from the prior-year quarter.
It is projected by analysts that the 'Geographic Revenue- Rest of Asia Pacific' will reach $9.28 billion. The estimate indicates a year-over-year change of -2.7%.
Based on the collective assessment of analysts, 'Geographic Revenue- Japan' should arrive at $7.15 billion. The estimate suggests a change of +5.8% year over year.
According to the collective judgment of analysts, 'Geographic Revenue- Americas' should come in at $49.83 billion. The estimate points to a change of +1.1% from the year-ago quarter.
The combined assessment of analysts suggests that 'Gross margin- Services' will likely reach $16.79 billion. Compared to the present estimate, the company reported $14.71 billion in the same quarter last year.
View all Key Company Metrics for Apple here>>>
Shares of Apple have experienced a change of -0.1% in the past month compared to the +2.5% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), AAPL is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217009/seeking-clues-to-apple-aapl-q1-earnings-a-peek-into-wall-street-projections-for-key-metrics?-a-peek-into-wall-street-projections-for-key-metrics
| 2024-01-30T02:47:19Z
|
blocked_url
|
The upcoming report from Microchip Technology (MCHP - Free Report) is expected to reveal quarterly earnings of $1.06 per share, indicating a decline of 32.1% compared to the year-ago period. Analysts forecast revenues of $1.79 billion, representing a decrease of 17.4% year over year.
Over the last 30 days, there has been a downward revision of 5.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Microchip Tech metrics that Wall Street analysts commonly model and monitor.
Analysts expect 'Net Sales- Mixed-signal Microcontrollers' to come in at $994.82 million. The estimate points to a change of -18.5% from the year-ago quarter.
It is projected by analysts that the 'Net Sales- Other' will reach $284.35 million. The estimate indicates a change of -16.7% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Net Sales- Analog' of $499.55 million. The estimate indicates a year-over-year change of -17.6%.
View all Key Company Metrics for Microchip Tech here>>>
Over the past month, Microchip Tech shares have recorded returns of -3.6% versus the Zacks S&P 500 composite's +2.5% change. Based on its Zacks Rank #5 (Strong Sell), MCHP will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217010/countdown-to-microchip-tech-mchp-q3-earnings-wall-street-forecasts-for-key-metrics
| 2024-01-30T02:47:25Z
|
blocked_url
|
The upcoming report from Illinois Tool Works (ITW - Free Report) is expected to reveal quarterly earnings of $2.39 per share, indicating an increase of 2.1% compared to the year-ago period. Analysts forecast revenues of $4.01 billion, representing an increase of 1% year over year.
The current level reflects a downward revision of 1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Illinois Tool Works metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts forecast 'Operating Revenues- Test & Measurement and Electronics' to reach $735.36 million. The estimate suggests a change of +0.5% year over year.
Analysts expect 'Operating Revenues- Construction Products' to come in at $468.27 million. The estimate indicates a change of -0.4% from the prior-year quarter.
The average prediction of analysts places 'Operating Revenues- Food Equipment' at $678.89 million. The estimate points to a change of +7.6% from the year-ago quarter.
Analysts' assessment points toward 'Operating Revenues- Specialty Products' reaching $444.50 million. The estimate indicates a year-over-year change of -3.8%.
Analysts predict that the 'Operating Revenues- Automotive OEM' will reach $741.75 million. The estimate indicates a change of -0.4% from the prior-year quarter.
It is projected by analysts that the 'Operating Revenue - Organic growth - Total ITW' will reach 0.5%. The estimate is in contrast to the year-ago figure of 11.9%.
The consensus among analysts is that 'Operating Revenue - Test & Measurement and Electronics - Organic growth' will reach 0.8%. Compared to the present estimate, the company reported 10.4% in the same quarter last year.
Based on the collective assessment of analysts, 'Operating Revenue - Automotive OEM - Organic growth' should arrive at -0.4%. Compared to the current estimate, the company reported 19.6% in the same quarter of the previous year.
The combined assessment of analysts suggests that 'Operating Revenue - Food Equipment - Organic growth' will likely reach 6.5%. Compared to the present estimate, the company reported 16.8% in the same quarter last year.
According to the collective judgment of analysts, 'Operating Revenue - Polymers & Fluids - Organic growth' should come in at 3.0%. Compared to the present estimate, the company reported 10.8% in the same quarter last year.
The collective assessment of analysts points to an estimated 'Operating Revenue - Welding - Organic growth' of -0.3%. Compared to the current estimate, the company reported 15.4% in the same quarter of the previous year.
The consensus estimate for 'Operating Revenue - Construction Products - Organic growth' stands at -2.8%. Compared to the present estimate, the company reported 4.2% in the same quarter last year.
View all Key Company Metrics for Illinois Tool Works here>>>
Shares of Illinois Tool Works have demonstrated returns of +0.2% over the past month compared to the Zacks S&P 500 composite's +2.5% change. With a Zacks Rank #3 (Hold), ITW is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217011/illinois-tool-works-itw-q4-earnings-on-the-horizon-analysts-insights-on-key-performance-measures
| 2024-01-30T02:47:31Z
|
blocked_url
|
Analysts on Wall Street project that Merck (MRK - Free Report) will announce quarterly loss of $0.09 per share in its forthcoming report, representing a decline of 105.6% year over year. Revenues are projected to reach $14.68 billion, increasing 6.2% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain Merck metrics that are commonly tracked and forecasted by Wall Street analysts.
According to the collective judgment of analysts, 'Sales- Alliance Revenue- Lynparza' should come in at $348.06 million. The estimate suggests a change of +19.2% year over year.
The combined assessment of analysts suggests that 'Sales- Bridion' will likely reach $446.03 million. The estimate suggests a change of +1.1% year over year.
Analysts predict that the 'Sales- Alliance revenue- Lenvima' will reach $240.51 million. The estimate indicates a year-over-year change of +11.4%.
The average prediction of analysts places 'Segment revenues- Animal health' at $1.28 billion. The estimate points to a change of +4.3% from the year-ago quarter.
Based on the collective assessment of analysts, 'Sales- Hospital Acute Care- Bridion- U.S' should arrive at $307.89 million. The estimate suggests a change of +19.8% year over year.
The collective assessment of analysts points to an estimated 'Sales- Keytruda-International' of $2.55 billion. The estimate points to a change of +23% from the year-ago quarter.
Analysts' assessment points toward 'Sales- Diabetes- Janumet- U.S' reaching $85.34 million. The estimate indicates a year-over-year change of -12%.
Analysts expect 'Sales- Oncology- Alliance revenue- Lynparza- US' to come in at $182.30 million. The estimate points to a change of +16.1% from the year-ago quarter.
The consensus among analysts is that 'Sales- Oncology- Alliance revenue- Lynparza- International' will reach $165.77 million. The estimate points to a change of +22.8% from the year-ago quarter.
Analysts forecast 'Sales- Oncology- Alliance revenue- Lenvima - U.S' to reach $163.73 million. The estimate points to a change of +6.3% from the year-ago quarter.
It is projected by analysts that the 'Sales- Oncology- Alliance revenue- Lenvima - International' will reach $76.77 million. The estimate indicates a year-over-year change of +23.8%.
The consensus estimate for 'Sales- Diabetes- Januvia- U.S' stands at $271.46 million. The estimate points to a change of -6.4% from the year-ago quarter.
View all Key Company Metrics for Merck here>>>
Merck shares have witnessed a change of +10.8% in the past month, in contrast to the Zacks S&P 500 composite's +2.5% move. With a Zacks Rank #3 (Hold), MRK is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217012/countdown-to-merck-mrk-q4-earnings-wall-street-forecasts-for-key-metrics
| 2024-01-30T02:47:38Z
|
blocked_url
|
Analysts on Wall Street project that Techne (TECH - Free Report) will announce quarterly earnings of $0.42 per share in its forthcoming report, representing a decline of 10.6% year over year. Revenues are projected to reach $277.48 million, increasing 2.2% from the same quarter last year.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.9% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Techne metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Net Sales- Diagnostics and Genomics' will likely reach $74.28 million. The estimate points to a change of +9.2% from the year-ago quarter.
The average prediction of analysts places 'Net Sales- Protein Sciences' at $204.36 million. The estimate indicates a year-over-year change of +0.2%.
Based on the collective assessment of analysts, 'Organic Growth' should arrive at -0.7%. Compared to the present estimate, the company reported 4% in the same quarter last year.
According to the collective judgment of analysts, 'Organic Growth - Diagnostics and Genomics' should come in at 3.2%. Compared to the current estimate, the company reported 7% in the same quarter of the previous year.
View all Key Company Metrics for Techne here>>>
Over the past month, Techne shares have recorded returns of -5.9% versus the Zacks S&P 500 composite's +2.5% change. Based on its Zacks Rank #3 (Hold), TECH will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217013/what-analyst-projections-for-key-metrics-reveal-about-techne-tech-q2-earnings
| 2024-01-30T02:47:44Z
|
blocked_url
|
Wall Street analysts forecast that Becton Dickinson (BDX - Free Report) will report quarterly earnings of $2.39 per share in its upcoming release, pointing to a year-over-year decline of 19.8%. It is anticipated that revenues will amount to $4.74 billion, exhibiting an increase of 3.3% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Becton Dickinson metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts expect 'Revenues- BD Medical' to come in at $2.27 billion. The estimate indicates a year-over-year change of +5.4%.
Analysts forecast 'Revenues- BD Interventional' to reach $1.17 billion. The estimate suggests a change of +3.5% year over year.
Based on the collective assessment of analysts, 'Revenues- BD Life Sciences' should arrive at $1.30 billion. The estimate points to a change of -0.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- BD Life Sciences- Biosciences' should come in at $371.22 million. The estimate indicates a year-over-year change of +6.4%.
The combined assessment of analysts suggests that 'Revenues- BD Medical- Medication Management Solutions- International' will likely reach $158.43 million. The estimate suggests a change of +11.6% year over year.
The consensus among analysts is that 'Revenues- BD Life Sciences- Biosciences- International' will reach $226.47 million. The estimate indicates a year-over-year change of +6.8%.
The average prediction of analysts places 'Revenues- BD Interventional- Peripheral Intervention- United States' at $249.96 million. The estimate points to a change of +5.9% from the year-ago quarter.
Analysts predict that the 'Revenues- BD Interventional- Urology and Critical Care- United States' will reach $275.93 million. The estimate indicates a year-over-year change of +6.5%.
The collective assessment of analysts points to an estimated 'Revenues- BD Interventional- United States' of $801.47 million. The estimate points to a change of +2.5% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- BD Interventional- Surgery- International' reaching $80.19 million. The estimate indicates a change of +5.5% from the prior-year quarter.
The consensus estimate for 'Revenues- BD Interventional- Peripheral Intervention- International' stands at $212.77 million. The estimate suggests a change of +8% year over year.
It is projected by analysts that the 'Revenues- BD Interventional- Urology and Critical Care- International' will reach $77.50 million. The estimate points to a change of +4.7% from the year-ago quarter.
View all Key Company Metrics for Becton Dickinson here>>>
Shares of Becton Dickinson have experienced a change of -2.9% in the past month compared to the +2.5% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), BDX is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217014/becton-dickinson-bdx-q1-earnings-preview-what-you-should-know-beyond-the-headline-estimates
| 2024-01-30T02:47:54Z
|
blocked_url
|
Analysts on Wall Street project that LPL Financial Holdings Inc. (LPLA - Free Report) will announce quarterly earnings of $3.33 per share in its forthcoming report, representing a decline of 20.9% year over year. Revenues are projected to reach $2.54 billion, increasing 9.1% from the same quarter last year.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some LPL Financial Holdings Inc. metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts expect 'Advisory fees' to come in at $1.08 billion. The estimate indicates a change of +20% from the prior-year quarter.
It is projected by analysts that the 'Commissions' will reach $640.80 million. The estimate indicates a year-over-year change of +10.1%.
The collective assessment of analysts points to an estimated 'Service and fee' of $125.80 million. The estimate points to a change of +4.8% from the year-ago quarter.
The average prediction of analysts places 'Transaction and other fees' at $52.65 million. The estimate indicates a year-over-year change of +12.5%.
According to the collective judgment of analysts, 'Total Advisory and Brokerage Assets' should come in at $1,327.81 billion. The estimate is in contrast to the year-ago figure of $1,110.8 billion.
Analysts forecast 'Total Advisory and Brokerage Assets - Brokerage Assets' to reach $614.25 billion. Compared to the current estimate, the company reported $527.7 billion in the same quarter of the previous year.
The consensus estimate for 'Number of advisors' stands at 22,715. The estimate is in contrast to the year-ago figure of 21,275.
Analysts' assessment points toward 'Net New Assets (NNA)- Net new advisory assets' reaching $19.53 billion. Compared to the present estimate, the company reported $12.6 billion in the same quarter last year.
The consensus among analysts is that 'Total Net New Assets' will reach $30.12 billion. The estimate compares to the year-ago value of $21.3 billion.
The combined assessment of analysts suggests that 'Total Advisory and Brokerage Assets - Advisory Assets' will likely reach $709.15 billion. The estimate compares to the year-ago value of $583.1 billion.
Based on the collective assessment of analysts, 'Net New Assets (NNA) - Net New Brokerage Assets' should arrive at $10.59 billion. The estimate is in contrast to the year-ago figure of $8.6 billion.
View all Key Company Metrics for LPL Financial Holdings Inc. here>>>
Over the past month, shares of LPL Financial Holdings Inc. have returned +6.8% versus the Zacks S&P 500 composite's +2.5% change. Currently, LPLA carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217015/ahead-of-lpl-financial-holdings-inc-lpla-q4-earnings-get-ready-with-wall-street-estimates-for-key-metrics
| 2024-01-30T02:48:00Z
|
blocked_url
|
Wall Street analysts expect Kirby (KEX - Free Report) to post quarterly earnings of $1.03 per share in its upcoming report, which indicates a year-over-year increase of 53.7%. Revenues are expected to be $780.96 million, up 7% from the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Kirby metrics that are routinely monitored and predicted by Wall Street analysts.
The average prediction of analysts places 'Revenues- Marine transportation- Inland transportation' at $353.46 million. The estimate points to a change of +4.9% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Distribution and services' reaching $345.62 million. The estimate indicates a change of +12.4% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Marine transportation' will reach $435.34 million. The estimate indicates a change of +3% from the prior-year quarter.
Analysts forecast 'Revenues- Marine transportation- Coastal transportation' to reach $81.83 million. The estimate indicates a year-over-year change of -4.4%.
The combined assessment of analysts suggests that 'Operating income- Distribution and services' will likely reach $24.91 million. The estimate is in contrast to the year-ago figure of $17.06 million.
The collective assessment of analysts points to an estimated 'Operating income- Marine transportation' of $71.86 million. Compared to the current estimate, the company reported $46.72 million in the same quarter of the previous year.
View all Key Company Metrics for Kirby here>>>
Shares of Kirby have demonstrated returns of +1.7% over the past month compared to the Zacks S&P 500 composite's +2.5% change. With a Zacks Rank #4 (Sell), KEX is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217016/unlocking-q4-potential-of-kirby-kex-exploring-wall-street-estimates-for-key-metrics
| 2024-01-30T02:48:01Z
|
blocked_url
|
Wall Street analysts expect Allegheny Technologies (ATI - Free Report) to post quarterly earnings of $0.62 per share in its upcoming report, which indicates a year-over-year increase of 17%. Revenues are expected to be $1.03 billion, up 1.9% from the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Allegheny Technologies metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts expect 'Sales- High Performance Materials & Components' to come in at $549.82 million. The estimate points to a change of +23.3% from the year-ago quarter.
It is projected by analysts that the 'Sales- Advanced Alloys & Solutions' will reach $509.45 million. The estimate indicates a change of -9.8% from the prior-year quarter.
According to the collective judgment of analysts, 'EBITDA- Advanced Alloys & Solutions' should come in at $61.57 million. Compared to the present estimate, the company reported $72.10 million in the same quarter last year.
The collective assessment of analysts points to an estimated 'EBITDA- High Performance Materials & Components' of $116.28 million. The estimate compares to the year-ago value of $81.80 million.
View all Key Company Metrics for Allegheny Technologies here>>>
Allegheny Technologies shares have witnessed a change of -9.5% in the past month, in contrast to the Zacks S&P 500 composite's +2.5% move. With a Zacks Rank #5 (Strong Sell), ATI is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217017/what-analyst-projections-for-key-metrics-reveal-about-allegheny-technologies-ati-q4-earnings
| 2024-01-30T02:48:07Z
|
blocked_url
|
In its upcoming report, Flex (FLEX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.62 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $6.73 billion, representing a year-over-year decrease of 13.2%.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Flex metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Revenue- Flex Agility Solutions' should arrive at $3.24 billion. The estimate indicates a change of -19.5% from the prior-year quarter.
Analysts predict that the 'Revenue- Nextracker' will reach $612.09 million. The estimate indicates a change of +18.6% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Revenue- Flex Reliability Solutions' of $2.87 billion. The estimate indicates a year-over-year change of -11%.
Analysts' assessment points toward 'Segment income- Nextracker' reaching $114.58 million. The estimate compares to the year-ago value of $60 million.
The combined assessment of analysts suggests that 'Segment income- Flex Reliability Solutions' will likely reach $153.53 million. The estimate compares to the year-ago value of $143 million.
The consensus estimate for 'Segment income- Flex Agility Solutions' stands at $154.04 million. The estimate compares to the year-ago value of $181 million.
View all Key Company Metrics for Flex here>>>
Shares of Flex have experienced a change of -24.5% in the past month compared to the +2.5% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), FLEX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217018/flex-flex-q3-earnings-preview-what-you-should-know-beyond-the-headline-estimates
| 2024-01-30T02:48:13Z
|
blocked_url
|
In its upcoming report, Evercore (EVR - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.63 per share, reflecting a decline of 53.4% compared to the same period last year. Revenues are forecasted to be $700.37 million, representing a year-over-year decrease of 15.8%.
The consensus EPS estimate for the quarter has undergone a downward revision of 2.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Evercore metrics that Wall Street analysts commonly model and monitor.
The average prediction of analysts places 'Net Revenues- Other Revenue, net' at $22.89 million. The estimate points to a change of +64.4% from the year-ago quarter.
According to the collective judgment of analysts, 'Adjusted Net Revenues- Investment Management- Asset Management and Administration Fees' should come in at $19.46 million. The estimate points to a change of +16.4% from the year-ago quarter.
The consensus among analysts is that 'Adjusted Net Revenues- Investment Banking & Equities-Total' will reach $670.41 million. The estimate indicates a year-over-year change of -18.3%.
View all Key Company Metrics for Evercore here>>>
Shares of Evercore have demonstrated returns of +1.7% over the past month compared to the Zacks S&P 500 composite's +2.5% change. With a Zacks Rank #4 (Sell), EVR is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217019/ahead-of-evercore-evr-q4-earnings-get-ready-with-wall-street-estimates-for-key-metrics
| 2024-01-30T02:48:19Z
|
blocked_url
|
Wall Street analysts forecast that Huntington Ingalls (HII - Free Report) will report quarterly earnings of $4.27 per share in its upcoming release, pointing to a year-over-year increase of 39.1%. It is anticipated that revenues will amount to $2.76 billion, exhibiting a decline of 1.9% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 6.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Huntington Ingalls metrics that Wall Street analysts commonly model and monitor.
Analysts forecast 'Sales and Service Revenues- Mission Technologies' to reach $631.44 million. The estimate indicates a change of +4.9% from the prior-year quarter.
The consensus among analysts is that 'Sales and Service Revenues- Newport News' will reach $1.54 billion. The estimate indicates a year-over-year change of -2.6%.
The combined assessment of analysts suggests that 'Sales and Service Revenues- Ingalls' will likely reach $646.99 million. The estimate points to a change of -1.7% from the year-ago quarter.
According to the collective judgment of analysts, 'Segment operating income (loss)- Ingalls' should come in at $73.75 million. The estimate is in contrast to the year-ago figure of $50 million.
It is projected by analysts that the 'Segment operating income (loss)- Mission Technologies' will reach $19.65 million. Compared to the current estimate, the company reported $15 million in the same quarter of the previous year.
Analysts predict that the 'Segment operating income (loss)- Newport News' will reach $131.55 million. Compared to the current estimate, the company reported $80 million in the same quarter of the previous year.
View all Key Company Metrics for Huntington Ingalls here>>>
Shares of Huntington Ingalls have demonstrated returns of -1.5% over the past month compared to the Zacks S&P 500 composite's +2.5% change. With a Zacks Rank #3 (Hold), HII is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217020/curious-about-huntington-ingalls-hii-q4-performance-explore-wall-street-estimates-for-key-metrics?-explore-wall-street-estimates-for-key-metrics
| 2024-01-30T02:48:21Z
|
blocked_url
|
In its upcoming report, Brandywine Realty Trust (BDN - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.29 per share, reflecting a decline of 9.4% compared to the same period last year. Revenues are forecasted to be $134.08 million, representing a year-over-year increase of 4%.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Brandywine Realty Trust metrics that Wall Street analysts commonly model and monitor.
Analysts expect 'Revenue- Rents' to come in at $123.30 million. The estimate suggests a change of +2.3% year over year.
The combined assessment of analysts suggests that 'Revenue- Third party management fees, labor reimbursement and leasing' will likely reach $5.64 million. The estimate indicates a year-over-year change of -9.4%.
The average prediction of analysts places 'Depreciation and amortization' at $53.33 million. The estimate is in contrast to the year-ago figure of $45.11 million.
View all Key Company Metrics for Brandywine Realty Trust here>>>
Over the past month, shares of Brandywine Realty Trust have returned -5.6% versus the Zacks S&P 500 composite's +2.5% change. Currently, BDN carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217021/unlocking-q4-potential-of-brandywine-realty-trust-bdn-exploring-wall-street-estimates-for-key-metrics
| 2024-01-30T02:48:27Z
|
blocked_url
|
In its upcoming report, MarketAxess (MKTX - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.72 per share, reflecting an increase of 8.9% compared to the same period last year. Revenues are forecasted to be $195.85 million, representing a year-over-year increase of 10.1%.
The current level reflects an upward revision of 1.8% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some MarketAxess metrics that Wall Street analysts commonly model and monitor.
The collective assessment of analysts points to an estimated 'Revenues- Commissions' of $170.78 million. The estimate suggests a change of +7.8% year over year.
According to the collective judgment of analysts, 'Revenues- Information services' should come in at $11.91 million. The estimate indicates a year-over-year change of +14.5%.
Analysts' assessment points toward 'Revenues- Post-trade services' reaching $9.71 million. The estimate points to a change of +10.1% from the year-ago quarter.
It is projected by analysts that the 'Total commission revenue- Total fixed distribution fees' will reach $37.64 million. The estimate suggests a change of +14.5% year over year.
Based on the collective assessment of analysts, 'Total commission revenue- Total variable transaction fees' should arrive at $134.05 million. The estimate indicates a year-over-year change of +6.8%.
Analysts forecast 'Average Variable Transaction Fee Per Million - Rates' to reach $4.39. The estimate is in contrast to the year-ago figure of $4.16.
Analysts predict that the 'Average Daily Volume - Total rates trading' will reach $16.75 billion. The estimate compares to the year-ago value of $18.38 billion.
Analysts expect 'Average Daily Volume - High-grade' to come in at $6.14 billion. Compared to the current estimate, the company reported $5.49 billion in the same quarter of the previous year.
The consensus estimate for 'Total Trading Volume' stands at $1,841.61 billion. Compared to the present estimate, the company reported $1,859.41 billion in the same quarter last year.
View all Key Company Metrics for MarketAxess here>>>
Shares of MarketAxess have demonstrated returns of -5.6% over the past month compared to the Zacks S&P 500 composite's +2.5% change. With a Zacks Rank #3 (Hold), MKTX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217022/seeking-clues-to-marketaxess-mktx-q4-earnings-a-peek-into-wall-street-projections-for-key-metrics?-a-peek-into-wall-street-projections-for-key-metrics
| 2024-01-30T02:48:33Z
|
blocked_url
|
Wall Street analysts expect Beazer Homes (BZH - Free Report) to post quarterly earnings of $0.71 per share in its upcoming report, which indicates a year-over-year decline of 11.3%. Revenues are expected to be $426.07 million, down 4.2% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 1.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Beazer metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts expect 'Revenue- Homebuilding' to come in at $423.32 million. The estimate points to a change of -4.7% from the year-ago quarter.
Analysts' assessment points toward 'Total home closings' reaching 830. Compared to the current estimate, the company reported 833 in the same quarter of the previous year.
According to the collective judgment of analysts, 'Average Closing Price - Continuing Operations (ASP from closing)' should come in at $510.12. The estimate compares to the year-ago value of $533.10.
The collective assessment of analysts points to an estimated 'New home orders, net of cancellations' of 640. The estimate is in contrast to the year-ago figure of 482.
Analysts predict that the 'Units in Backlog - Continuing Operations (Backlog units)' will reach 1,521. Compared to the current estimate, the company reported 1,740 in the same quarter of the previous year.
It is projected by analysts that the 'Actual Community Count at quarter-end' will reach 132. The estimate compares to the year-ago value of 119.
The combined assessment of analysts suggests that 'Gross profit (loss)- Homebuilding' will likely reach $84.67 million. Compared to the current estimate, the company reported $85.11 million in the same quarter of the previous year.
View all Key Company Metrics for Beazer here>>>
Shares of Beazer have demonstrated returns of -5.8% over the past month compared to the Zacks S&P 500 composite's +2.5% change. With a Zacks Rank #4 (Sell), BZH is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217023/exploring-analyst-estimates-for-beazer-bzh-q1-earnings-beyond-revenue-and-eps
| 2024-01-30T02:48:40Z
|
blocked_url
|
Analysts on Wall Street project that Honeywell International Inc. (HON - Free Report) will announce quarterly earnings of $2.60 per share in its forthcoming report, representing an increase of 3.2% year over year. Revenues are projected to reach $9.7 billion, increasing 5.6% from the same quarter last year.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Honeywell International Inc. metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts expect 'Net Sales- Safety and Productivity Solutions' to come in at $1.31 billion. The estimate points to a change of -18.2% from the year-ago quarter.
The combined assessment of analysts suggests that 'Net Sales- Performance Materials and Technologies' will likely reach $3.12 billion. The estimate indicates a year-over-year change of +9.1%.
The average prediction of analysts places 'Net Sales- Aerospace' at $3.71 billion. The estimate indicates a change of +16% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Honeywell Building Technologies' will reach $1.54 billion. The estimate suggests a change of +1.8% year over year.
Analysts' assessment points toward 'Safety and Productivity Solutions Sales- Warehouse and Workflow Solutions' reaching $323.82 million. The estimate indicates a year-over-year change of -36.1%.
Based on the collective assessment of analysts, 'Aerospace Sales- Commercial Aviation Aftermarket' should arrive at $1.59 billion. The estimate indicates a change of +13.9% from the prior-year quarter.
It is projected by analysts that the 'Aerospace Sales- Defense and Space' will reach $1.47 billion. The estimate suggests a change of +16.2% year over year.
The consensus estimate for 'Performance Materials and Technologies Sales- UOP' stands at $779.72 million. The estimate points to a change of +7.3% from the year-ago quarter.
Analysts predict that the 'Performance Materials and Technologies Sales- Advanced Materials' will reach $925.29 million. The estimate indicates a change of +5.9% from the prior-year quarter.
Analysts forecast 'Aerospace Sales- Commercial Aviation Original Equipment' to reach $660.61 million. The estimate indicates a year-over-year change of +21%.
The collective assessment of analysts points to an estimated 'Performance Materials and Technologies Sales- Process Solutions' of $1.42 billion. The estimate points to a change of +12.7% from the year-ago quarter.
According to the collective judgment of analysts, 'Honeywell Building Technologies Sales- Products' should come in at $898.39 million. The estimate indicates a year-over-year change of -1.1%.
View all Key Company Metrics for Honeywell International Inc. here>>>
Honeywell International Inc. shares have witnessed a change of -3.8% in the past month, in contrast to the Zacks S&P 500 composite's +2.5% move. With a Zacks Rank #3 (Hold), HON is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217024/exploring-analyst-estimates-for-honeywell-international-inc-hon-q4-earnings-beyond-revenue-and-eps
| 2024-01-30T02:48:41Z
|
blocked_url
|
Wall Street analysts forecast that Rayonier (RYN - Free Report) will report quarterly earnings of $0.17 per share in its upcoming release, pointing to a year-over-year increase of 54.6%. It is anticipated that revenues will amount to $235.94 million, exhibiting a decline of 3.9% compared to the year-ago quarter.
The current level reflects a downward revision of 22.6% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Rayonier metrics that are routinely monitored and predicted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Sales- Real Estate' of $67.17 million. The estimate suggests a change of +17.8% year over year.
The consensus among analysts is that 'Sales- Southern Timber' will reach $56.66 million. The estimate indicates a year-over-year change of +0.1%.
According to the collective judgment of analysts, 'Sales- Trading' should come in at $13.76 million. The estimate indicates a change of -24.4% from the prior-year quarter.
It is projected by analysts that the 'Sales- New Zealand Timber' will reach $59.25 million. The estimate points to a change of -17% from the year-ago quarter.
Analysts predict that the 'Sales- Pacific Northwest Timber' will reach $36.08 million. The estimate points to a change of -14.9% from the year-ago quarter.
Analysts expect 'Total Harvest Volume - Pacific Northwest Timber' to come in at 395.69 KTons. Compared to the current estimate, the company reported 397 KTons in the same quarter of the previous year.
The consensus estimate for 'Operating Income (Loss)- Southern Timber' stands at $12.00 million. The estimate is in contrast to the year-ago figure of $19.70 million.
Based on the collective assessment of analysts, 'Operating Income (Loss)- Pacific Northwest Timber' should arrive at -$1.39 million. The estimate compares to the year-ago value of $3.50 million.
Analysts forecast 'Operating income (loss)- Real estate' to reach $33.96 million. The estimate compares to the year-ago value of $21.50 million.
The average prediction of analysts places 'Operating Income (Loss)- New Zealand Timber' at $2.81 million. Compared to the present estimate, the company reported $8 million in the same quarter last year.
View all Key Company Metrics for Rayonier here>>>
Rayonier shares have witnessed a change of -7.5% in the past month, in contrast to the Zacks S&P 500 composite's +2.5% move. With a Zacks Rank #4 (Sell), RYN is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217025/countdown-to-rayonier-ryn-q4-earnings-a-look-at-estimates-beyond-revenue-and-eps
| 2024-01-30T02:48:47Z
|
blocked_url
|
Analysts on Wall Street project that SEI Investments (SEIC - Free Report) will announce quarterly earnings of $0.91 per share in its forthcoming report, representing an increase of 9.6% year over year. Revenues are projected to reach $481.24 million, increasing 5.4% from the same quarter last year.
The consensus EPS estimate for the quarter has undergone an upward revision of 4.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain SEI metrics that are commonly tracked and forecasted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Revenue- Private Banks' of $121.65 million. The estimate points to a change of +5.6% from the year-ago quarter.
It is projected by analysts that the 'Revenue- Investments in New Business' will reach $5.06 million. The estimate suggests a change of +6.8% year over year.
Analysts expect 'Revenue- Investment Managers' to come in at $170.98 million. The estimate indicates a change of +9.6% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- Asset management, administration and distribution fees' should come in at $382.96 million. The estimate suggests a change of +4.9% year over year.
Analysts forecast 'Revenue- Information processing and software servicing fees' to reach $96.61 million. The estimate points to a change of +5.8% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Investment Advisors' will likely reach $110.67 million. The estimate indicates a change of +4.6% from the prior-year quarter.
The average prediction of analysts places 'Assets under management - Institutional Investors' at $78.25 billion. Compared to the present estimate, the company reported $74.74 billion in the same quarter last year.
Based on the collective assessment of analysts, 'Assets under management - LSV - Equity and Fixed Income programs' should arrive at $87.86 billion. Compared to the present estimate, the company reported $83.75 billion in the same quarter last year.
The consensus estimate for 'Assets under management - Investments in New Business' stands at $2.29 billion. The estimate compares to the year-ago value of $2.13 billion.
Analysts' assessment points toward 'Assets under management - Investment Advisors' reaching $76.56 billion. The estimate compares to the year-ago value of $71.68 billion.
The consensus among analysts is that 'Assets under management - Private Banks' will reach $28.22 billion. The estimate compares to the year-ago value of $25.59 billion.
Analysts predict that the 'Assets under management - Investment Managers' will reach $154.15 billion. Compared to the present estimate, the company reported $141.48 billion in the same quarter last year.
View all Key Company Metrics for SEI here>>>
Over the past month, SEI shares have recorded returns of +0.6% versus the Zacks S&P 500 composite's +2.5% change. Based on its Zacks Rank #2 (Buy), SEIC will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217026/ahead-of-sei-seic-q4-earnings-get-ready-with-wall-street-estimates-for-key-metrics
| 2024-01-30T02:48:54Z
|
blocked_url
|
Wall Street analysts expect Hologic (HOLX - Free Report) to post quarterly earnings of $0.94 per share in its upcoming report, which indicates a year-over-year decline of 12.2%. Revenues are expected to be $983.25 million, down 8.5% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
That said, let's delve into the average estimates of some Hologic metrics that Wall Street analysts commonly model and monitor.
Analysts expect 'Revenue- GYN Surgical' to come in at $150.00 million. The estimate indicates a year-over-year change of -2.7%.
The average prediction of analysts places 'Revenues- Diagnostics- Molecular Diagnostics' at $323.41 million. The estimate indicates a year-over-year change of -23.9%.
The consensus estimate for 'Revenues- Diagnostics- Blood Screening' stands at $9.38 million. The estimate points to a change of +28.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Breast Health- Breast Imaging' should come in at $280.17 million. The estimate points to a change of +6% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Total Diagnostics' will likely reach $447.49 million. The estimate indicates a change of -20% from the prior-year quarter.
The consensus among analysts is that 'Revenue- Skeletal Health' will reach $26.97 million. The estimate indicates a year-over-year change of +1.4%.
Analysts predict that the 'Revenues- Diagnostics- Cytology & Perinatal' will reach $116.71 million. The estimate indicates a year-over-year change of -8%.
It is projected by analysts that the 'Revenue- Total Breast Health' will reach $352.90 million. The estimate suggests a change of +5.6% year over year.
Analysts' assessment points toward 'Revenues- Breast Health- Interventional Breast Solutions' reaching $72.73 million. The estimate suggests a change of +4.2% year over year.
The collective assessment of analysts points to an estimated 'Service and other revenue' of $178.29 million. The estimate indicates a year-over-year change of -5.1%.
Analysts forecast 'Product Sales' to reach $801.50 million. The estimate indicates a change of -9.6% from the prior-year quarter.
View all Key Company Metrics for Hologic here>>>
Shares of Hologic have experienced a change of +4.1% in the past month compared to the +2.5% move of the Zacks S&P 500 composite. With a Zacks Rank #2 (Buy), HOLX is expected to outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
|
https://www.zacks.com/stock/news/2217027/what-analyst-projections-for-key-metrics-reveal-about-hologic-holx-q1-earnings
| 2024-01-30T02:49:00Z
|
blocked_url
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.